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with a 0.3 Capillary Dose Factor are very similar and thus not shown.

Figure 11.1. Advantage Depth as a function of D20 replacement in the elliptical
skull/brain model for the 0.025eV thermal neutron beam. Curves depicting tumour to
blood

10

B ratios of 1, 2, 3, 4, 5, and 10 are shown, all for 10jj.g/g blood

10

B

concentration.

Figure 11.2 Therapeutic Depth as a function of D20 replacement in the elliptical
skull/brain model for the 0.025eV thermal neutron beam. Curves depicting tumour to
blood 1 0 B ratios of 3, 4, 5, and 10 are shown, all for 10p.g/g blood 1 0 B concentration.

Figure 11.3 Advantage Depth as a function of D20 replacement in the elliptical
skull/brain model for the 2-7keV epithermal neutron beam. Curves depicting tumour to
blood

10

B ratios of 1, 2, 3, 4, 5, and 10 are shown, all for 10|j.g/g blood

10

B

concentration.

Figure 11.4 Therapeutic Depth as a function of D20 replacement in the elliptical
skull/brain model for the 2-7keV epithermal neutron beam. Curves depicting tumour to
blood 1 0 B ratios of 3, 4, 5, and 10 are shown, all for 10|ig/g blood 1 0 B concentration.

Figure 11.5 Effective 10B tumour to blood ratio required for the Therapeutic Depth to
reach the brain midline (6cm from brain surface) using 2-7keV epithermal neutrons as a
function of heavy water replacement.

Figure 11.6 Dose (RBE Gy/source neutron) along beam axis vs. depth for 10(ig/g blood
10

B and 43fig/g tumour 1 0 B (T/B = 4.3) - tumour site 5.25 to 6.25cm from brain surface.

Dose profiles for the 2-7keV epithermal b e a m are shown for 0 % and 2 0 % heavy water
replacement. The boron dose component to the tumour is increased with heavy water
present due to improved neutron flux penetration. Healthy tissue dose is also reduced
as a result of less induced g a m m a s . This study has only 0.5cm resolution. The
transition from tumour to healthy tissue dose is expected to be much sharper.
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Figure 11.7 Calculated thermal neutron fluence as a function of depth for the Petten
H F R epithermal neutron beam. Heavy water replacement improves neutron penetration.

Figure 11.8 For bilateral irradiation, the improved neutron penetration as a result of
heavy water replacement promotes a homogeneous thermal neutron flux distribution.

Figure 11.9 Heavy water replacement significantly lowers induced gamma dose to
healthy tissue. For unilateral irradiation, the reduction in peak dose is over 3 0 % .

Figure 11.10 Induced gamma dose distribution for bilateral irradiation using the Petten
HFR

epithermal neutron beam. Heavy water replacement not only allows a

homogeneous thermal neutron flux throughout the brain for widespread cancer cell kill,
but also substantially reduces healthy tissue induced g a m m a dose.

Figure 11.11 Dose profiles using unilateral irradiation with the Petten HFR beam for a
tumour of approximately 1cm diameter situated near the midline of the brain. 0 % and
2 0 % heavy water profiles are shown.

Figure 11.12 Dose profiles using bilateral irradiation with the Petten HFR beam for a
tumour of approximately 1cm diameter situated near the midline of the brain. 0 % and
2 0 % heavy water profiles are shown.

Figure 11.13 Unilateral therapeutic ratio as a function of depth for 0% and 20% heavy
water replacement.

Figure 11.14 Unilateral 20% heavy water therapeutic ratio divided by 0% heavy water
therapeutic ratio. U p to 4 0 % enhancement from a low base is observed.

Figure 11.15 Bilateral therapeutic ratio as a function of depth for 0% and 20% heavy
water replacement. The T R throughout the midbrain is significantly improved with 2 0 %
D 2 0.

Figure 11.16 Bilateral 20% heavy water therapeutic ratio divided by 0% heavy water
therapeutic ratio. 2 0 % enhancement for 4 c m throughout the mid brain region can be
seen.
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ABSTRACT

Over the past 40 years, tremendous advances in science and technology
have been reflected in the techniques for diagnosis and therapy of cancer.
With such an enormous use of resources, w e should realistically expect a
reduction in incidence and mortality rates. While this is true for s o m e types
of cancers, the s a m e cannot be said for the overall profile of mortality due
to cancer. Indeed an increase in incidence and mortality from primary brain
cancer in the elderly has been reported in the U S A and Europe. Clearly
what must be recognised is that a significant shift in the research of today
must be undertaken if these trends are to be altered in the future. From a
fundamental level, conventional radiotherapy cannot effectively treat high
grade brain tumours. Dose is preferentially delivered to the clinical tumour
region via geometrically overlapping x-ray beams. This extrinsic selectivity
relies on prior identification of the tumour site. This simply is not possible
for sub-clinical metastases commonly associated with high grade brain
tumours. W h a t is required is a treatment technique with intrinsic selectivity
that requires no prior identification of cancerous regions. T h e binary
treatment modality Boron Neutron Capture Therapy ( B N C T ) currently offers
the best prospects for intrinsic selectivity. This has been reinforced with
recent research showing selective boron compound uptake in nests of as
few as three cancer cells.

This project first details the construction of anthropomorphic head and torso
phantoms suitable for use with neutron radiation. Tissues simulated include
brain, liver, muscle, heart, lungs, stomach, intestines, pancreas, spleen,
kidney and adipose. These phantoms were used to validate

MCNP

treatment planning calculations targeting the brain and liver using a
variable voxel geometric reconstruction directly from "patient" C T scans.
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The user m a y specify "regions of interest" where small voxels m a y be
applied giving detailed geometrical modelling and dose planning. Larger
voxels m a y be applied to surrounding regions where detailed modelling is
not required. Body tissues are discriminated on the C T scan on the basis of
grayscale number. Programs are presented to enable the discrimination of
spatially isolated tissues with c o m m o n grayscale numbers.

MCNP calculations were initially benchmarked against the Petten HFR
epithermal neutron beam

using the geometrically simple cylindrical

phantom. Epithermal neutron beam facilities are not available in Australia
and the Petten facility is unique to Europe and one of the few in the world.
Gold and copper foil activation measurements generally show agreement to
within 1 0 % of the calculations. Larger discrepancies with the cadmium
covered manganese foils are possibly the result of a number of causes.
The results of the experimental Positive Intrinsic Negative (PIN) diode
(responding dominanfly to fast neutrons) showed good agreement with the
calculated response. Similarly Metal Oxide Semiconductor Field Effect
Transistor ( M O S F E T ) g a m m a detectors showed excellent correlation with
the induced g a m m a dose. (The author's role in the PIN and M O S F E T
detectors is limited to calculations of predicted response)

The prototype "patients" modelled from CT scans using the variable voxel
technique include: i) the head phantom, ii) the torso phantom, and iii) the
cervical region using C T scans of a cervical cancer patient. For the head
and torso phantoms, M C N P calculations show agreement generally to
within 1 0 % of bare and cadmium covered gold foil measurements in the
brain, liver, lungs and pancreas irradiated in the Petten H F R epithermal
neutron beam. PIN diode measurements are aJso well correlated to M C N P
predicted resuKs, however there is evidence of increasing discrepancy with
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depth from the b e a m entrance surface of the phantoms. M O S F E T response
also appears to be well correlated with g a m m a dose in the phantoms.
Further study is being undertaken to fully characterise the response of
these detectors and eliminate spurious results before clinical application
will be considered. These are possibly the most stringent tests of Monte
Carlo modelling to date for epithermal neutrons.

Flux and dose calculations for the head and torso phantoms are
superimposed upon C T scans, illustrating the latest software in three
dimensional medical image visualization. Calculations are also displayed in
a similar manner for the hypothetical 2S2 Cf brachytherapy for cervical cancer
treatment plan. These results indicate that the potential for boron neutron
capture dose enhancement using 252 Cf brachytherapy for cervical cancer is
limited to very bulky tumours.

MCNP was also used with an ellipsoidal head model to examine the effect
on treatment planning figures of merit of, i) boron ratios and concentrations,
and ii) heavy water uptake. For a fixed tumour to blood boron ratio, little
benefit is gained by increasing the blood boron level once the boron dose
component dominates the healthy tissue dose. This limit is dependent upon
the compound in use, or more precisely its pharmacokinetics and
associated "compound factor". The effect of incorporating heavy water in
brain tissues to improve B N C T efficacy is also examined. For bilateral
irradiation with the Petten H F R beam, deuteration below toxicity limits
provides an increase of approximately 2 0 % in the therapeutic ratio
throughout the midbrain region.
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1. INTRODUCTION

The theoretically optimum therapy for cancer is a 100% kill rate of all
cancerous cells with zero d a m a g e to healthy tissue. Such an ideal therapy
is currently, and will probably remain, impossible to achieve. Thus the
clinical oncologist is forced to push healthy tissue tolerances to their
extreme to achieve maximum tumour cell kill. This is essential as, unless
every tumour cell is damaged beyond reproductive ability, the danger exists
that the tumour m a y

re-establish itself. Although today's standard

treatments, like surgery, radiation therapy and chemotherapy have been
successful in curing s o m e types of cancers, this certainly is not all
encompassing. The prognosis of certain cancers has not improved with
advances

in

radiotherapy,

chemotherapy

and

modern

diagnostic

techniques. Early detection and surgical excision offer the best prospects
for cure of m a n y types of cancers - to this end diagnostic advances in
nuclear medicine, Computer Tomography (CT) Magnetic Resonance
Imaging (MRI) have been exceptional, however therapeutic advances have
not kept pace.

There are a number of cancers with particularly poor prognoses such that
life expectancy after diagnosis is often less than 12 months. High grade
brain tumours (astrocytoma grades 3, 4), melanoma metastatic to the brain,
liver cancer (primary or secondary) and pancreatic cancer are ail in this
category with their c o m m o n feature being infiltrating malignant cells
preventing curative surgery. Primary brain, liver and pancreatic cancers
accounted for the deaths of over 2,000 Australians in 1982.1 Conventional
therapy for these patients is palliative only and highlights the need for
advancement in therapeutic techniques.
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For patients with anaplastic astrocytoma and glioblastoma multiforme, the
median survival time following surgery alone is about 17 weeks. 2
Combining radiotherapy with surgery doubles the median survival to about
36 weeks, whilst incorporating chemotherapy has given only marginal
benefit. T h e 5 year survival rate for patients with high grade brain tumours
is extremely low.3-4 In 1982, 663 Australians died from brain tumours1.
Melanoma metastases to the brain account for about 50 - 7 5 % of ail
disseminated melanoma and are responsible for 3 0 % of the mortality rate.
Conventional fractionated radiotherapy can improve survival and quality of
life, however is most useful only as a palliative treatment. The median
survival of patients with brain metastases after the initiation of radiotherapy
in recent studies w a s 8 and 14 weeks, and 36 weeks for patients after
resection of a single brain metastasis.5-6 Chemotherapy w a s associated
with decreased survival in this series. High dose per fraction schedules 6
are under consideration to overcome the enhanced repair which can occur
in melanoma cells.

Most liver cancers are hepatocellular carcinomas, and are linked to
hepatitis B virus infections, alcohol and aflatoxins. The incidence and
mortality rates are similar, reflecting the poor prognosis and 5 year survival
rate of only 5 % .

In 1982, 282 Australians died of liver cancer.1 Most

pancreatic cancers are adenocarcinomas arising in the ductal system or in
the parenchyma in the head of the pancreas. Similar to liver cancer,
pancreatic cancers have comparable

incidence and mortality rates

indicating low 5 year survival rates of 5 % for males and 3 % for females. In
1982, 1168 patients died of pancreatic cancer in Australia.1

These statistics illustrate that, for these cancers, increasing the survival
rate is going to require a dramatic shift in treatment techniques. Improving
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life expectancy will undoubtedly require the exploration of alternative
approaches which, from a fundamental level, need to be more effective at
selectively killing cancer cells. Binary therapies offer this fundamental
advantage. T h e conceptual advantage of binary therapies is that two levels
of selectivity are utilised. Firstly, a non-toxic compound (at prescribed
concentration) is preferentially taken up by cancer cells. T h e second level
of selectivity results from this compound being activated in-situ by an
applied trigger (usually external radiation) focused upon the region of
interest. Photodynamic therapy employs hemato-porphyrin derivatives, and
can be an effective adjunct to surgery.2 However, the penetration of the
activating laser light is only a few millimetres, thus for high grade brain
tumours infiltrating cells distant from the tumour mass are not killed.

Considering the neutron was discovered in 1932,7 and the description of
the 10B(n,a)7Li reaction occurred in 1935, 8 it is quite remarkable that Locher
proposed the basic idea to use neutron capture reactions in cancer
treatment

as

early

as

1936. 9

Boron

Neutron

Capture

Therapy

(BNCT)10'11'12-13'14'15-16 uses non-toxic compounds containing boron atoms,
but is effective at m u c h greater depths in tissue than photodynamic therapy.
Elements of both radiotherapy and chemotherapy are combined in the two
stage approaches of B N C T to the regression of infiltrating tumours. A nontoxic boron compound with demonstrated affinity for specific cancer cells is
selectively taken up by the tumour, and then activated by an incident
neutron beam.

T h e isotope boron-10 has a very high probability of

capturing thermal neutrons and emitting short range, highly ionising
radiation. This radiation comprises alpha particles and lithium-7 ions, both
of which have high linear energy transfer (LET) properties and a short
range of about one cell diameter. W h e n the boron-10 is located in the cell,
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highly specific cell killing can be achieved and individual cancer cells are
selectively killed in the midst of normal cells in the host tissue.

Depending on the boron carrier compound used and the characteristics of
normal and tumour cells, tumour to tissue boron-10 ratios of greater than 5
can be achieved.

However, concomitant non-specific radiation always

accompanies the neutron capture reaction in boron-10, and therapeutic
gains of 2-3, (ratio of tumour dose to m a x i m u m normal tissue dose), m a y be
realised depending on the tumour depth in tissue and type of neutron beam
employed. These therapeutic gains represent a major advance in potential
efficacy in the treatment of localised infiltrating cancer.

In principle, BNCT is a straight forward method of destroying tumour cells however in practice several factors need to be optimised to deliver the
promised selectivity of the method. Firstly, significant
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B must be

concentrated within the tumour to enable cell kill. Secondly, a sufficient
thermal neutron flux must be delivered to the tumour site. And third, in
conjunction with these factors that would enable tumour cell kill, healthy
tissue must be preserved. T o achieve these goals, the requirements are:(i) boron compounds exhibiting strong tumour affinity, and (ii) a pure
epithermal neutron b e a m that enables sufficient delivery of neutrons to the
tumour site whilst minimising healthy tissue dose from fast neutrons
(energy greater than a few tens of keV) and b e a m contaminating g a m m a
rays.

Clinical trials have proceeded in the past with these two factors being, in
hindsight, clearly unsatisfied. Boron compounds with infinite tumour to
blood ratios and high flux purely epithermal neutron b e a m s are probably
unattainable goals, and so too is the possibility of B N C T achieving 1 0 0 %
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tumour cell kill with zero healthy tissue damage. N o conventional therapy is
near this scenario - B N C T promises to go closer to this ideal goal than any
other technique.

The success or otherwise of BNCT must be measured against the current
benchmark of radiotherapy. It is for this reason that the B N C T community
is particularly targeting glioblastoma multiforme. Manifesting itself as a
central tumour m a s s with radiating fingerlets of subclinical metastases,
glioblastoma multiforme exposes the inherent limitation of current
surgery/radiotherapy. Outlying fingerlets of tumour cells escape surgical
removal and almost always lead to the formation of n e w tumours in the
surrounding

normal brain tissue, resulting in the patient's death.

Radiotherapy achieves its current therapeutic ratios by m e a n s of knowing,
prior to exposure, where the tumour is located. Application of b e a m s from
various pre-determined angles achieves elevated dose to tumour tissue via
geometric m e a n s - there is little intrinsic selectivity in the method. Thus
radiotherapy cannot treat the subclinical metastases as:- (i) their location
is unknown, and (ii) any attempt to enlarge the treatment volume results in
excessive d a m a g e to normal tissue.17 It is for these reasons that
glioblastoma

multiforme

has

such

poor

prognoses

with

current

surgery/radiotherapy techniques.

It is here that BNCT promises to come into its own. Selectivity is not
achieved via geometrical overlapping of beams on a pre-determined
volume, but occurs intrinsically. S o even in a situation where radiotherapy
and B N C T offer an identical therapeutic ratio to the main tumour mass,
B N C T offers the greatest potential for removal of subclinical metastases.
Recent studies have shown that disseminated nests consisting of just a few
cancerous cells uptake boron-phenylaJanine (BPA) at over five times the
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level of surrounding healthy tissues.18 T h e ability to target microscopic
cancerous cell nests implicitly gives the B N C T treatment technique a
significant advantage in attempting to control disseminated diseases.

Clearly what is required is the planning and delivery of accurate doses with
optimal tumour to healthy tissue ratios. This is not just for B N C T , but for
any treatment modality. In this project the treatment planning stage for
B N C T is demonstrated using the Monte Carlo code M C N P 1 9 (Monte Carlo
Neutron and Photon Transport) utilising both cylindrical and ellipsoidal
models of the head. The effects of varying boron biodistribution and also
heavy water uptake are examined. For applicability to individual patients,
however, Monte Carlo models generated from C T or MRI Scans are
required.

In conventional radiotherapy, Monte Carlo modelling from CT scans is
being pursued vigorously using the Electron G a m m a Shower (EGS4)
code.20'21 Patient geometry is modelled by rectilinear geometry - or voxels.
Such an approach has been taken in this project to develop a treatment
planning technique suitable for neutron transport using the M C N P code.
With such a general approach, modelling is not limited to the head.
Extension to more complex geometry such as that around the liver/lung,
pelvic region, or even the complex throat area m a y be undertaken. A n
ability to specify "regions of interest" where higher resolution anatomical
structure and dose information m a y

be obtained has also been

incorporated. Three dimensional dose distribution calculations for an
external neutron b e a m applied to cranial and abdominal anatomy are
presented. These dose distributions are displayed superimposed upon C T
scans, illustrating the latest software in three dimensional medical image
visualisation. Dose distribution calculations are also displayed in a similar
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manner for a hypothetical 252 Cf brachytherapy treatment plan for cervical
cancer.

Construction of phantoms was undertaken to facilitate validation of Monte
Carlo dose calculations. For this project, cylindrical, head and torso
phantoms were designed and constructed with neutron tissue equivalent
materials based on the G o o d m a n muscle mix22. For neutron and g a m m a
ray detection, perspex plugs have been incorporated to enable positioning
of gold, manganese and copper activation foils in addition to Metal-Oxide
Semiconductor

Field

Effect Transistors ( M O S F E T )

and

P/N

type

semiconductors (PIN) within the phantoms. Calculated responses of these
detectors are compared to measured values. (The theory and operation of
these detectors will be detailed by Carolan23.)
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2.

PRINCIPLES A N D H I S T O R Y O F N E U T R O N C A P T U R E T H E R A P Y

Neutron Capture Therapy (NCT) was born when Locher 19369 proposed:

"There exists the possibilities of introducing small quantities of strong
neutron absorbers into the regions where it is desired to liberate ionisation
energy (a simple illustration would be the injection of a soluble, non-toxic
compound of boron, lithium, gadolinium, or gold into a superficial cancer)
followed by bombardment with slow neutrons"

2.1. Radiobiological Considerations

A high propensity of absorbing thermal neutrons necessary for use in NCT
is satisfied by a number of nuclides24-25'26 (Table 2.1.1). The probability of a
nucleus capturing a thermal neutron, referred to as the thermal neutron
capture cross section (c^), is measured in barns (1b = 10- 28 m 2 ). Of all the
nuclides listed in Table 2.1.1, the stable isotope 10 B, which occurs as 2 0 %
of naturally occurring boron, is the most attractive for clinical applications.
The two m o d e s of the 10B(n,cc)7Li reaction are shown below:

71 4He + 7Li + 2.79 MeV (6.1 %)
1

°B + 1 n ^ [ 1 1 B * ]
iJ

4

H e + 7Li* + 2.31 M e V

(93.9%)

7

Li + y(0.48MeV)

Not only does 10B possess a high thermal neutron absorption cross section
of 3838 barns, but the products of the 10B(n,a)7Li reaction have high Linear
Energy Transfer (LET) characteristics and thus greater concentration of
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energy deposition. The a particle deposits approximately 150 keV^nr 1 with
the 7Li nucleus approximately 175 keV^im-1. The path lengths of these
reaction products are in the range 10(j.m and 4.5|im, hence the energy
deposition is limited to the diameter of a single cell (Figure 2.1.1). At most,
it takes only a few 1.7 M e V a particles from the 10B(n,a)7Li reaction to
discharge their energy within a malignant cell to achieve cell death.27

Nuclide Reaction Cross-section gth(b)
3

He

(n,p)

5 333

Li

(n,a)

941

(n,a)

3 838

6

1

°B

113

Cd

(n,y)

20 600

135

Xe*

(n,y)

2 720 000

9Sm

(n,y)

40 140

14

151

Eu

(n,y)

9 200

155

Gd

(n,y)

60 900

7Qd

(n,y)

254 000

i74Hf

(n,y)

561

i99Hg

(n,y)

2 150

23sy*

(n,f)

681

174

Pu*

(n,f)

1 380

242

Am*

(Of)

8 000
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Table 2.1.1. Nuclides with high values of thermal neutron capture cross-sections
(* radioactive).24-2526

Thus, on a theoretical basis at least, it is possible to selectively irra
those cells that have taken up a sufficient amount of10 B and simultaneously
spare normal cells. Such a situation is not even theoretically possible with
current radiotherapy.
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Figure 2.1.1. Boron fission upon neutron capture results in two high linear energy transfer
particles with energy deposition occuring approximately within one cell diameter.

M a n y of the other nuclides listed in Table 2.1.1, despite having significantly
large capture cross sections, are not suitable for N C T . Those interacting
via the (n,y) reaction do not restrict energy deposition to the labelled
"target-cells", thereby failing to achieve the selective killing goal. 6Li and
235

U m a y be of interest in N C T , despite having lower thermal neutron

capture cross sections than 10 B. The products of the 6Li(n,a) and
reactions have larger biological effects than
energy and mass. Practical use of 6Li and

10

235

235

U(n,f)

B due to their higher kinetic

U, however, m a y be limited

due to chemical instability and toxicity. T h e use of 2 3 5 U seeds in N C T has
been proposed recently28 to avoid this toxicity. Only a few experiments with
6

Li and

235

U have been performed29'30'31 >32 inspite of a report of a higher

biological efficiency of 6Li compared to 1 0 B in early investigations.33

3 0009 03201173 1

14

Despite the extremely high thermal neutron capture cross section of
254000 barns, 1 5 7 Gd had escaped attention of the N C T community due to
the unfavourable (n,y) reaction. During the last few years, however,
increasing attention has been focussed on

157

Gd.34-35 This has been

prompted by the hypothesis of Martin et al34 to look at another aspect of
this reaction, the production of Auger electrons resulting from internal
conversion and to use them in N C T . The range of the high L E T Auger
electrons is on the molecular level. Thus, to be effective, the gadolinium
must not just be within the tumour cell but localised to the DNA. 3 6

10

B

however, has been viewed as the most likely nuclide to allow the success
of N C T and this is reflected in its dominance in experimentation.

As outlined in the introduction, the 10B(n,a)7Li reaction has the potential for
intrinsic selectivity in treatment of cancer ceils, as opposed to current radiotherapy. The a and 7Li particles have other biological advantages. For
sparsely ionising radiations, such as the electrons produced by x-rays and
g a m m a rays, oxygen is needed to enhance their biological effectiveness. If
oxygen is present, it easily reacts with the free radicals which are produced
by charged particles from the absorption of radiation. These free radicals
are highly reactive molecules because they have an unpaired valence
electron. This reaction results in a change in the chemical composition of
the material that accounts for the final expression of biological damage.
This reaction cannot take place in the absence of oxygen. A rapidly
expanding tumour frequently outgrows its blood supply, so that some
regions receive less oxygen than the normal tissue does. A s a result of the
oxygen depletion, the tumour becomes more resistant to the effects of
traditional radiation therapy by x-rays and g a m m a rays. For densely
ionising radiation, such as a and 7Li particles, there is little or no oxygen
enhancement effect. These particles can attack all parts of a tumour with
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equal vigour. Thus, the tumour sensitivity to these particles is retained
without oxygen in the tumour. Other advantages of the a and 7Li particles
is that they can kill dividing and non-dividing cancer cells alike. Other forms
of radiation therapy and chemotherapy tend to work more effectively on the
dividing cells. In addition, because the a and 7Li are high L E T particles,
they will give a more pronounced treatment effect w h e n the Relative
Biological Effectiveness (RBE) is taken into account. This assumes that the
10

B microscopic biodistribution is not biased away from the cancer cell

nucleus (i.e. the compound factor applicable to cancerous tissues is not
less than unity - see chapter 3).

There has been controversy concerning the relative biological effectiveness
(RBE) value that should be assigned to the a particles produced in the
10

B(n,ct)7Li capture

reaction. These

5 0137,38,39,40,41 depending

on

the

have

ranged

biological

from

system.

1.94

and

Experimental

determination of the R B E depends on a number of factors, the most
important of which is the intracellular boron concentration. Until recently,
this has been impossible to measure. However, the development of new
analytical techniques including inductively coupled,42 and direct current
plasma atomic emission spectroscopy,43 ion microscopy44 and electron
energy loss spectroscopy/election spectroscopic imaging45 are powerful
techniques that should provide data on the intracellular concentrations of a
variety of boron compounds that are currently being investigated as
possible delivery agents. Because B N C T is based on microdosimetry,
specialised methods that have been recently developed should eventually
yield more precise R B E values for the 10B(n,ct)7Li reaction.46'47 T h e precise
intracellular localisation of the

10

B also has a strong influence on

radiobiologic effects. Microdosimetry Monte Carlo calculations show that
the dose delivered by a uniform 10 B distribution in the cell is 10 times that of
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B external to the cell. Cytoplasmic and nuclear localisation would each

deliver a further 2.5 times increase in the dose from a uniform distribution.48

Healthy cells and tissues, that have low levels of 10B, would not be
subjected to the high L E T radiation resulting from the 10B(n,a)7Li capture
reaction to the extent of malignant cells that have accumulated a sufficient
amount of 10 B. Capture reactions also occur with nitrogen 14N(n,p)14C and
hydrogen 1H(n,y)2H. The neutron capture cross sections of those atoms are
so small compared with 10 B (0.332, 1.75 and 3 838 boron respectively) that
the probability of interaction, on an atom for atom basis, is m u c h smaller for
normal tissues. However, because normal tissues have quantities of N and
H ( 3 % and 1 0 % by weight respectively) m u c h greater than that of 10 B,
significant doses due to the
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N(n,p)14C and 1H(n,y)2H reactions are

delivered to these tissues.

The upper limit of the neutron fluence that can be delivered is thus
determined by the tolerance of the surrounding normal tissues to protons
and g a m m a rays produced by these capture reactions. It is for this reason
that, (i) a high effective concentration differential for 10 B must be achieved
between normal and neoplastic cells (after subcellular 1 0 B biodistribution
effects are taken into account), and (ii) the absolute concentration of 10 B
that must be delivered to the tumour is in the range 30-50 |ig/g.49'50>51
Theoretically, it should be possible with B N C T to increase significantly and
selectively the radiation dose delivered to tumours to levels greater than
those achieved with conventional therapy52 while simultaneously restricting
the normal tissue doses to levels less than their tolerance.53-54 This will
depend on the energy of the neutrons,55 dose rate,56 and fractionation.57'58
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2.2.

Boron Chemistry

Prior to the 1960's, clinical trials in BNCT proceeded despite the little
knowledge of the pharmacokinetics of the boron drugs involved. Boron
accumulation in tumour cells w a s based on the optimistic assumption that
the blood and the brain barrier would effectively exclude boron from normal
brain tissue. The first active attempts to develop tumour selective boron
compounds for B N C T

originated with studies carried out at the

Massachusetts General Hospital ( M G H ) by Soloway, Sweet and Browned in
the 1960's.59'60-61 T w o compounds, p-carboxy-benzeneboronic acid and
sodium decahydrodecaborate, amongst the many compounds screened in
animals, had favourable tumour localising properties. These were non-toxic
and gave tumour-to-brain boron concentration ratios of over 5 to 1, which
were maintained for several hours.60

10

B enriched analogues were

subsequently synthesised and evaluated in clinical trials at the M G H and
the Massachusetts Institute of Technology (MIT). Unfortunately, these
boron compounds were not retained in the tumour long enough to allow
blood clearance,62 resulting in significant radiation damage to the vascular
endothelium of normal blood vessels in all patients. Although these trials
failed,62-63 the tumours were destroyed and it w a s clear that boron
compounds were needed that would attain both high tumour-to-normal
tissue and tumour-to-blood ratios.

2.2.1. Sodium Borocaptate (BSH)

A new method of evaluating boron drugs was required and developed using
mice bearing a subcutaneously transplanted ependymoblastoma. 64 After
administration, blood levels were allowed to fall before various tissues were
analysed. T w o

sulfhydryl containing boron anions, B ^ H u S H 2 -

and
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BioCI8(SH)22-

were subsequently identified.65 Promising animal studies

using N32BT2HHSH (sodium borocaptate or B S H ) led to the commencement
in 1968, by Dr. Hiroshi Hatanaka in Japan, to treat patients with brain
tumours with BNCT.66-67'68 His results stimulated renewed worldwide
interest in B N C T with research continuing on the synthesis of n e w boron
compounds that would preferentially localise in neoplastic cells. B S H does
not pass the blood-brain-barrier for normal brain cells, but utilises the
breakdown of the barrier of glioblastoma cells to establish therapeutic
quantities within the tumour. Whether small fingerlets of glioma cells take
up the B S H , and are subsequently killed by N C T is not yet known.

2.2.2. Boronophenylalanine (BPA)

While BSH utilises the breakdown of the blood brain barrier for selective
uptake in glioblastoma, more tumour specific compounds would permit
improved tumour to blood boron ratios. M u c h interest has been shown in
developing agents that could be used to target malignant melanomas.
Because the biosynthetic pathway for melanin required phenylalanine as a
precursor, it w a s reasoned that 10 B containing derivatives of this amino acid
might preferentially be incorporated into melanoma cells.69 Mishima et al
have carried out extensive in-vitro and in-vivo experiments using pboronophenylalanine70-71 and have initiated clinical studies in a group of
patients with cutaneous melanomas. 72 - 73

There is some evidence that BPA is taken up in the synthesis of melanin,
but B P A is also involved in amino acid transport mechanisms as melanotic
tumours also exhibit therapeutic barren concentrations but within faster
uptake and wash out kinetics.7475 While B P A w a s not taken up
preferentially by an adenocarcinoma of the breast carried in Haie-Stoner
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mice,76 therapeutic concentrations have recently been reported in a murine
m a m m a r y tumour (KHJJ) carried subscutaneously in BALB/C mice, the G S 9L rat glioma carried both sub-cutaneously and intracranially in F-344 rats,
and in the h u m a n U-87 M G glioma xenograft carried subcutaneously in
nude mice.77

BPA does pass through the blood brain barrier, and for mice boron
concentrations in brain are comparable to that observed in muscle.75
However, if active incorporation occurs in glioma cells combined with blood
clearance of boron, then improved tumour to blood rates should result.
Further, B P A would be taken up at the cellular level regardless of the state
of the blood brain barrier. Thus the characteristic glioblastoma, consisting
of a main tumour mass with radiating fingerlets, should not pose a problem
for N C T and long term patient cure could be expected.78

2.2.3. Other Boron Compounds Under Development

The use of antibodies as boron delivery agents for selectively targeting
tumours of B N C T w a s first proposed by Bale and Spar.79 Boron containing
compounds were first linked to protein molecules by Sneath et al.80 Shortly
thereafter, the incorporation of a boron-containing diazonium salt into
polyclonal antibodies directed against h u m a n and murine histocompatibility
antigens w a s reported by Hantharne et al.81 Kohler and Milstein discovered
a w a y to produce monoclonal antibodies,82 and interest rapidly developed
in using these to target drugs, radioisotopes and toxins to cancer cells. A
number of groups over the past decade have developed methods by which
boron containing compounds can be linked to antibody molecules.83.84-85-86
Initially a

low

molecular

weight

compound

{N-Succinimidyl-3-(un-

decahydrododeca-boranyldithio) propionate}, (SBDP) containing ten boron
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atoms per molecule, which could be covalently attached to antibody
molecules w a s synthesised.86 Assuming an antigen site density of 10 6 per
tumour cell, this would require approximately 1000 10 B atoms per antibody
molecule to attain approximately 20-50|ig 10 B per gram of tumour.87 With
compounds containing only 10 boron atoms per molecule, 100 separate
reaction sites on the antibody have to be boronated to achieve the objective
of 1000 boron atoms per antibody molecule. This approach so markedly
alters monoclonal antibodies that their immunoreactivity is lost.88 The move
to higher molecular weight attaching compound led to the synthesis of
polylysine (BPL), 89 a boronated polymer having more than 1000 10 B atoms
per polymetric unit. The resulting immunoconjugates contained several
thousand

10

B atoms per antibody molecule and retained their in-vitro

immunoreactivity.

However, w h e n

these

conjugates

were

injected

intravenously or intraperitoneally, they lost their in-vivo tumour localising
properties and accumulated primarily in the liver.90

From the work of

several groups,91-92'93-94 it currently appears unlikely that monoclonal
antibodies alone will be able to deliver the required amount of boron to
sustain a lethal 10B(n,a)7Li reaction and they probably will be used with
other tumor-localising compounds.

Interest in the synthesis of boron-containing precursors of nucleic acids has
been stimulated by the fact that malignant cells undergo an increased rate
of mitosis. A potential advantage of nucleic acid precursors for targeting,
especially of brain tumours, is that the mitotic index of glioma cells is many
times greater than that of surrounding normal glial cells, and m u c h larger
amounts of the compound

might be incorporated into the rapidly

proliferating tumour cell population. These boron containing nucleic acids
incorporated into D N A , would greatly enhance the destructive effects of a
particles and 7Li nuclei.95 Several groups have synthesised boron -
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containing

nucleosides96-97'98 showing

high in-vitro cellular uptake99

especially w h e n compared with B S H . O n e nucleoside, 2'-0(o-carboran-1-ylmethyl) uridine (CBU-2 1 ), which has been studied intensively, also appears
to have a high in vivo uptake w h e n injected intratumorally into brain tumour
bearing rats.100 Uptake has been shown to be independent of nucleoside
transport systems and cell division101 with initial data indicating that CBU-2'
is not incorporated in R N A or D N A . Of great importance will be the
correlation of tumour cell-localising properties with the chemical structure of
these compounds.

Other classes of low molecular weight boron compounds synthesised thus
far include phthalocianines,102 promazines,102-103 and thiouracils.104-105
Several authors have shown that thiouracil is strongly taken up by
melanotic melanoma in murine models, and in-vitro experiments indicate
that both high tyrosinase and melanin levels are required for enhanced
incorporation. Boron containing thiouracils have been synthesised in
Australia104 and Germany, 106 and tested in syngeneic and nude mice
models with murine and

human

melanomas. 107 Therapeutic

boron

concentrations in the tumour and tumour to liver boron ratios of 10 have
been achieved. Liposome carriers of insoluble carboronyl thiouracil
derivatives have been found to be useful for selected cell lines.107

Porphyrin derivatives108-109 are known to have an affinity for tumours but are
not specific for a given type of cancer. Kahl et al. has synthesised a
tetrakis-carborone

carboxylate

ester

of

2,4(a,p-dihydroxyethyl)

deuteroporphyrin IX (BOPP) 1 0 8 which shows high in vitro uptake and
persistence. The boronated porphyrins, however, show significant tumour
and normal tissue uptake110.111 and the latter m a y prove to be a significant
limitation for in-vivo B N C T .
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Low-density lipoproteins (LDL) and liposomes also have the potential to
selectively deliver

10

B to tumour cells. Kahl et al. have synthesised

boronated L D L in which carborane carboxylic acid esters of fatty alcohols
were used to replace the cholesterol ester core.112 C H O and V-79 Chinese
hamster cells exposed to the boronated LDL and irradiated by Brookhaven
National Laboratory (BNL) Medical Research Reactor ( B M R R ) showed
steep reductions in percent survival compared with control subjects. If BLDL show high tumour and low normal tissue uptake levels in-vivo, they
m a y be excellent delivery agents for B N C T . This has recently been
reported by Setiwan et al.113 A related approach is to use boron-containing
liposomes as tumour - targeting agents.114 Although in the early stages of
development, these appear to have some potential for selectively delivering
10

B to tumour cells.

Other boron compounds under development include the bisbenzimidazoles.
These are known to bind to the minor groove of the D N A helix and boron
containing compounds are under investigation at Melbourne University and
the Peter MacCallum Cancer Institute, Australia. Therapeutic quantities of
boron being attached to D N A promise an attractive target for NCT.

2.3. Neutron Sources

The exclusive source of neutrons for BNCT has been that from nuclear
reactors. Neutron beams are broadly divided into the categories of thermal
with energies in the range of 0.025eV,epithermal with energies of 1-10,000
eV, or fast neutron beams with energies greater than 10,000eV. Neutrons
originating in nuclear reactors are produced in the fission-reaction with a
most probable energy of 0.75MeV (average energy, 2MeV). With the use
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of moderators and/or filters that are interfaced with the reactor core,
modification of the b e a m m a y be achieved.

Little or no moderation or

filtration results in fast neutrons. Such neutrons have been tried for fast
neutron therapy115 in which the radiation dose is delivered w h e n energetic
neutrons collide with elements in tissues such as hydrogen and produce
forward recoiling protons, which in turn produce biological d a m a g e through
ionisations. Fast neutron therapy produces no radiation localisation at the
cellular level, as is possible with B N C T , thus there is little advantage for the
use of such beams. Incorporating a moderating material such as heavy or
light water or graphite results in the fast neutrons born in the fission
reaction being sufficiently slowed to thermal energies. Unfortunately, these
neutrons are attenuated rapidly in tissues. It is difficult to obtain sufficient
thermal neutrons at depth within the patient, required for B N C T , without
severely irradiating surface tissues.116 Thermal neutron b e a m s have been
used in Japan for treating superficial melanoma brain tumours66-67-68-72.73.117
with best results for surface lesions.

Using a filter and moderator, fast neutrons can be slowed to produce an
epithermal b e a m (1-10,000eV). Thermal neutrons m a y be filtered out with
absorbers such as B, Li or Cd leaving a relatively pure epithermal beam. 118
Epithermal neutrons are relatively non-destructive in tissue transferring little
energy to H atoms by collisions and seldom being captured by H or N to
produce g a m m a rays and protons. Thus, w h e n used to irradiate tissues, an
epithermal b e a m provides better penetration than thermal neutrons, but still
produces thermal neutrons at depth in tissue because of the moderating
effects of the tissue itself. The epithermal neutrons become thermalized as
they pass through biological tissues. T h e thermal neutron flux from an
epithermal b e a m rises to a m a x i m u m at a few centimetres beneath the
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tissue surface.119 This avoids problems with thermal neutrons b e a m s with
regard to poor penetration.

Current worldwide efforts are directed toward the production of epithermal
neutron b e a m s which will yield neutron fluences with energies in the 110,000 e V range.120 With reactor powers of a few megawatts, suitable
b e a m intensities of greater than 10 9 neutrons/cm2/sec can be produced.
Several reactors with this power output now have epithermal neutron
b e a m s or could be converted to produce them including H F R Petten,
BMRR, 57 . 119 MIT Reactor (MITR), 121 University of Missouri Research
Reactor,122 and Georgia Institute of Technology Research

Reactor

(GTRR). 123 - 124

The dependence of a neutron source upon nuclear reactors, given their
high cost and strong resistance to locating them in major metropolitan
areas, is seen as a limitation of B N C T . A number of alternative means of
generating neutrons have been considered including califomium-252,125-126
spallation sources 127 and low energy accelerators.128-129-130 Tungsten and
uranium amongst other heavy elements, produce neutrons of varying
energies on irradiation with high-energy protons by means of the spallation
reaction. T h e possibility of moderating these neutrons, s o m e with energies
higher than those in the fission spectra, to produce epithermal beams
suitable for B N C T is being investigated. Measurements to date, however,
have not yet demonstrated a satisfactory epithermal beam. 127 L o w energy
proton accelerators can be used as a source of epithermal neutrons for
B N C T by irradiating Li targets.99.100 It is anticipated that proton beam
currents of more than 2 0 m A would be required, and that additional neutron
moderation with materials such as B e O and alumina will be necessary to
obtain suitable numbers of epithermal neutrons.130 The feasibility of such
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high current b e a m s has yet to be demonstrated experimentally, although
milliampere b e a m currents are n o w commercially available.

2.4. Clinical Studies

Essentially all experimental work and clinical approaches in NCT are based
on

10

B. Kruger131 performed the first

10

B - N C T experiments by treating

tumour fragments in-vitro with boric acid and irradiation. These tumours
showed a lower transplantation efficiency in mice compared to control which
have been treated only by boric acid or thermal neutrons. The efficiency of
N C T in-vivo after injection of boric acid or boron in oily suspension in a
m o u s e sarcoma has been the subject of investigation by other authors.132

Soon after the treatment of brain tumours by NCT was proposed32-49
suggesting a selective uptake of boron compounds in the tumour due to
localised blood brain barrier breakdown. Higher boron concentrations in
brain tumours than a normal brain tissue were demonstrated in humans. 1 3 3
Early clinical trials on the use of B N C T were carried out at B N L by Farr et
a|i34,i35 anc|at

M G H / M I T by Sweet et al 136137 during the 1950's and early

1960's. Treatment w a s directed at malignant glioblastomas at both centres
in particular glioblastoma multiforme. This focus of attention stemmed from
the fact that even w h e n the tumour w a s surgically removed as completely
as possible, glioblastomas invariably recurred, with a m e a n life expectancy
of less than 6 months. Neoplastic cells in the healthy brain that escaped
excision served as foci for tumour regrowth and death. It w a s reasoned that
if these residual glioblastoma cells could be destroyed by

BNCT

prolongation of life or even a cure might be possible.137 Based on the
optimistic assumption that the blood brain barrier would effectively exclude
boron from normal brain tissue, a series of patient irradiations were carried
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out at BNL. From February 1951 to January 1953 the first ten patients
suffering from glioblastoma multiforme were treated by N C T at the
Brookhaven Graphite Research Reactor (BGRR). 138 - 139 - 140 . 134 . 14163 Eight of
the patients had previously undergone conventional radiation therapy for
their brain tumours. These advanced malignant cerebral gliomas were
irradiated by thermal neutrons. The
(Na 2 B 4 O 7 .10H 2 O) with 9 6 %

10

B and 4 %

boron containing drug
11

borax

B w a s given intravenously.

Immediately before the irradiation, the patients received 100ml of an
aqueous solution containing approximately 20g borax by i.v. injection. The
borax distributed widely throughout the body following the distribution of
body water. N o serious side-effects were observed, although the large
amount of borax led to s o m e transient but mild and tolerable toxic
effects.137.142-143 Irradiations were performed in one, two, or four fractions
with intervals of five to six weeks. Nine of these ten cases showed short
term improvement, which w a s interpreted as a temporary stop of tumour
growth. All of these patients died, however, as a result of their progressive
disease. Results were comparable to treatment with standard radiotherapy
at the time. The median survival of the patients in this first series w a s 97
days, range 43 to 185 days.

Prior to the start of the second series, the reactor was rebuilt with the aim to
optimise the facility. Nine patients suffering from highly malignant brain
tumours

were

irradiated

after

injection

of

sodium

pentaborane

(Na 2 B 1 0 O 1 6 .10H2O) which is less toxic than borax. The administered

10

B

dose w a s higher than in the first series of patients. Serious side effects
occurred in these patients including intractable radiodermatoses of the
scalp, sometimes with deep ulcerations.54 This w a s the result of high scalp
tissue boron buildup combined with the use of thermal neutrons. The
median survival of these patients w a s 147 days (range 93 to 337 days). 63
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In the third series of patients, sodium pentaborane w a s injected into the
internal carotid artery of the tumour bearing hemisphere immediately before
irradiation. This w a s done to avoid high boron concentrations in the scalp,
and thus the serious side effects associated with high scalp dose. The
survival of the nine patients of this series w a s 96 days (range 29 to 158
days), similar to conventional radiotherapy of the time period.144 A s
expected none of these patients developed severe skin reactions.

From previous patient trials, it was recognised that the time of irradiation
had to be reduced into a period where an optimal boron distribution
between brain and tumour w a s expected. This necessitated a higher
fluence rate and thus a compact high flux reactor, the 5 M W
moderated

Brookhaven

Medical

Research

Reactor

(BMRR),

water
was

constructed. This reactor w a s designed and built specifically for medical
and biological research. In addition to a higher thermal neutron flux than the
B G R R , it w a s hoped that the newly constructed patient treatment port
would facilitate irradiations and enhance clinical efficacy by reducing
background radiations due to improvements in reactor design. Four of the
patients died within two weeks after irradiation with cerebral o e d e m a and
intractable shock. The median survival w a s only three months with a range
of 3 to 170 days. Despite the initial enthusiasm it w a s a great
disappointment that the expected success w a s not achieved in 17 brain
tumours, treated between 1959 and 1961. Temporary skin flaps were
reflected and shielded by sheets of 6Li before irradiation. This precaution
did not prevent radiation dermatitis altogether, although non-healing
ulceration of the skin w a s avoided.
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Throughout the s a m e time period, another 17 patients (16 glioblastoma, 1
medulloblastoma) were irradiated at the reactor of the Massachusetts
Institute of Technology (MIT) by Sweet et al.136.137 S o m e of these patients
were injected with

10

B-enriched 4-carboxyl phenyl boronic acid, whilst

others received di-sodium-decahydrodecarborate (Na 2 B 10 H 1 o) I which is less
toxic and contains much more boron.145 The median survival in the MIT
series w a s found to be 5.7 months 62 - 146 - quite similar to the survival time of
patients with

glioblastomas

treated

by

the

same

physicians at

Massachusetts General Hospital by conventional modalities. Additionally,
severe side-effects such as acute brain oedema, perivascular fibroses and
the appearance of brain necroses w a s observed within a few months.62-147
The disappointing results of the B N L and MIT groups led to the termination
of B N C T patient trials in the U S A where no patients were treated by this
modality between 1961 and 1994.

An explanation for these poor results may be the use of boronated
compounds which were not selectively accumulated in tumour tissue.
Unfortunately, the treatment protocol for terminal brain tumour patients was
based on inadequate data and inferior boron compounds that were not
retained in the tumour for long enough to allow blood clearance.62 Part of
the observations m a y be explained by high boron concentrations in the
blood and in the skin. Recent analysis of these results by Slatkin63
indicated that B N C T had arrested the growth of the metastases in at least
one of these patients with metastatic carcinoma. In all other cases, the lack
of therapeutic efficacy w a s attributed to the poor penetration of thermal
neutrons in tissue and the non-selectivity of the boron compounds, which
resulted in boron concentrations in tumour that were only transiently higher
than those in the healthy brain. Moreover, the significance of fast neutrons,
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protons and photons in the beam as well as the gamma-rays produced in
the irradiated volume were well underestimated.63.148.149

The pioneering work of Hatanaka et al66-67-68 has stimulated a worldwide
revival in interest in using B N C T to treat brain tumours. Hatanaka w a s a
m e m b e r of the team led by Sweet at the M G H , and over several years
developed a strong interest in B N C T . Upon return to Japan, Hatanaka
initiated a clinical trial of B N C T for the treatment of brain tumours.66 From
1968 until June 1994, 149 patients have been treated using a combination
of surgery and BNCT. 1 5 0 Initially, as much of the tumour as possible is
surgically excised (debulking). At varying times after surgery the patients
are given an intra-arterial infusion of N a 2 B 1 2 H n S H (sodium borocaptate or
BSH), which has been shown to have favourable tumour localising
properties.65 Thermal neutrons are then directed to the operative site in the
brain from which the tumour had been resected. Irradiation times of 3.5
hours were required as the Mushashi Institute of Technology reactor, used
for the majority of these patients, has such a low neutron flux (1.5 x 10 9
n/cm2/s). Furthermore, the depth of penetration of neutrons w a s reported to
be no more than 6cm, limiting effective treatment to more superficial
tumours. Fourteen hours after an infusion of approximately 40-60 m g
10

B/kg, 1 0 B concentrations in the tumour ranged from 13-60 u.g/gm (mean,

26.3 ucj/gm), m e a n blood concentration w a s 18.2 jig/mg, and tumour to
blood boron ratios of 48 patients w a s 1.69. Hatanaka reported sensational
results, with five year survival rates being 5 8 % in patients suffering from
grade 3 to 4 gliomas, if the tumour w a s located at less than 6 c m depth.151
The m e a n survival time was 44 months (median, 25.6 months). 68 These
included several long term survivors, including a m a n w h o w a s treated in
1972 and has since shown no evidence of tumour recurrence.152
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Although Hakana's results have been extremely encouraging, a number of
questions have been raised about them. These include the use of varying
treatment combinations before the initiation of B N C T . Varying time intervals
between surgery and irradiation, lack of randomisation of patients, and
most importantly, poor depth of penetration of the neutron beam.
Nevertheless, world wide interest has stimulated several groups to initiate
programs that eventually m a y lead to controlled clinical trials.

An interdisciplinary BNCT research team has been assembled in Europe in
a joint community effort in B N C T . This group includes scientists, nuclear
engineers and clinicians. Pharmacokinetic studies of B S H are currently in
progress. Approximately 55 patients with malignant brain tumours of
various types have been injected intravenously with B S H at doses ranging
from 5-25 mg/kg body weight from 3 to 24 hours before surgical resection of
their tumours.153 Considerable variability has been seen in tumour boron
concentrations, most likely attributed to the administration of steroids given
before surgical resection or biopsy. More accurate uptake date can be
obtained in patients w h o have not received steroids, and future distribution
studies will be carried out in such patients.

The High Flux Reactor (HFR) at the Joint Research centre in Petten, The
Netherlands, will be used for clinical trials by the European Collaboration
on Boron Neutron Capture therapy. This is a 4 5 M W water cooled reactor,
one b e a m port of which has been modified for patient irradiations. This
b e a m has been characterised by Moss et al154 at Petten and is capable of
delivering a fluence of up to 5 x 10 8 n/cm2/s with energies in the range of
e V to keV (i.e. epithermal neutrons). Filters used to produce the b e a m
include liquid argon, sulfur, and aluminium to obtain an optimised b e a m that
has minimum fast neutron and g a m m a photon contamination. S o m e 50
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dogs have been irradiated to determine normal tissue tolerance for neutron
flux and boron concentration.

Second phase clinical trials will define the normal brain tolerance to the
epithermal b e a m in patients w h o have glioblastomas.135 Patients will be
divided into three groups. Group I will consist of those having total
resection of their gliomas. Group II will consist of those with partial
resection or even biopsy, and Group III will consist of those with
unresectable tumour with stereotactic biopsy only. After complete or partial
resection, patients will be given BSH, be reoperated on for biopsy of the
tumour bed and boron determinations will be carried out on the biopsied
tissues. Patients in Group I w h o have had maximal surgery will then receive
B N C T , after which they will be monitored closely by computerised axial
tomography (CT) and magnetic resonance imaging {MRI). If tnere is clinical
or radiologic evidence of recurrence or necrosis, tney will be operated on to
remove recurrent tumour and/or necrotic tissue. Patients in Groups II and 111
w h o have unresectable tumours will be treated in the s a m e way as those in
Group I, except re-operation will be sub-optimal and their life expectancy
shorter. Additional treatment (chemotherapy or photon radiation) for those
patients in Group I w h o have recurrence will be left up to the discretion of
the local neurosurgeons and oncologists managing the cases. Although the
Petten study will be complete with m a n y variables, it represents and
attempt to examine the efficacy of B N C T using B S H as the capture agent in
a rigorous, although not randomised study.

In 1987, Mishima et al started to treat malignant melanomas by BNCT.155
T h e specific metabolic activities of this tumour which produces melanin,
opens possibilities for selective boron uptake into the tumour cell. Duroc
pkjs71 having spontaneously ooourring melanomas were initially used to
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establish therapeutic efficacy. Clinical studies were subsequently initiated
using 10B-boronophenylaline (BPA) as the capture agent.72 A s of October
1992, 12 patients with cutaneous melanoma w h o were not candidates for
surgery were treated by BNCT. 1 3 5 O n e patient, an 80 year old man, had a
melanoma on the sole of his foot. Multiple doses of 1 0 B-BPA fructrose
complex were injected perilesionally around the melanoma. The foot was
irradiated with a collimated beam of thermal neutrons after allowing
sufficient time for the B P A to clear from surrounding normal tissues at the
Kyoto University Research Reactor Institute (KURRI). The melanoma
showed signs of regression within only 2 weeks and by 9 weeks only a
small pigmented spot remained. N o evidence of local recurrence was
observed 2 years later. In these treatments, the thermal neutron beam is
ideally suited for the regression of melanoma, because the maximum dose
is delivered to the skin. Additional patients have been treated, and most
recently

the

10

B-BPA-fructose

complex

has

been

administered

intraveneously.

Coderre et al have performed extensive normal tissue tolerance
studies,156-157 and treated mice bearing a transplantable melanoma by
B N C T using ^B-BPA.76-77'158 W h e n boron concentrations in the tumour had
reached a maximum, the animals were irradiated at the B M R R . At the
lowest radiation dose, there w a s a 2-3 week delay in tumour growth,
whereas in animals treated with the highest dose, the tumours either
stopped growing or regressed. This has also been confirmed in Australia
where long term control w a s demonstrated for 7 of 8 mice159-160 irradiated in
the thermal column of the 1 0 0 k W

reactor Moata. Again in these

experiements the thermal neutron beam is ideal because the maximum
dose is delivered to the skin. To reproduce these results at the centre of the
h u m a n brain is the immediate goal of B N C T groups worldwide.
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3.

REVIEW O F T R E A T M E N T PLANNING

3.1. Introduction

Recent progress in the development and application of analytical methods
of calculating macroscopic and microscopic radiation dose distributions for
Boron Neutron Capture Therapy has advanced at a rate parallel to that of
modern

computer technology. Such calculations are an

essential

component of in-vivo B N C T research and will ultimately also be required for
h u m a n B N C T treatment planning. Because B N C T involves particles, nucleii
and photons, calculations of macroscopic absorbed dose distributions are
more complex than for photon transport. Each dose component has its o w n
characteristic spatial distribution, linear energy transfer, and relative
biological effectiveness (RB€). Three-dimensional (3-D) energy-dependent
radiation transport models with a detailed description of particle scattering
are required. Geometric descriptions for such models are typically
constructed directly from medical image data, and both the Monte Carlo
stochastic simulation method and discrete-ordinates deterministic approach
have been successfully used to perform the necessary radiation transport
calculations. The therapeutic benefit that m a y be attainable in B N C T can
be profoundly influenced by microdosimetric effects. These effects must be
careful taken into account in the interpretation of experimental data,
especially w h e n correlating observed in-vivo radiobiological response with
measured or calculated absorbed radiation dose. The Monte Carlo method
is typically used to calculate microdosimetric parameters for B N C T by
generating single event energy deposition frequency distributions for
critical targets in various cell types of interest. This information is used in
the development of apparent R B E factors, or "compound factors" for
various dose components in B N C T .
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In any radiation therapy, photon therapy and B N C T included, the basic
clinical objective is the same. The clinician seeks to provide the patient with
the highest attainable probability of tumour control whilst simultaneously
minimising normal tissue complications. In conventional radiotherapy,
various combinations of several techniques are used to achieve this
outcome. Such techniques include the use of megavoltage x-ray machines
(for surface tissue sparing), detailed pre-treatment radiation transport
calculations to specify optimal b e a m configurations for each patient,
fractionation of treatment and use of certain radioprotective and/or
radiosensitising drugs. It can be expected that optimisation of B N C T will
follow a similar protocol. Minimal normal tissue d a m a g e will arise from the
use of an epithermal neutron b e a m having a high degree of spectral purity,
detailed treatment planning calculations are required, and one can form a
rough analogy between the use of radiosensitisers in photon therapy and
the use of boronated pharmaceuticals in B N C T .

Unlike photon therapy, there are several different physical radiation dose
components associated with B N C T , each of which has a characteristic
spatial distribution and Relative Biological Effectiveness (RBE). In addition
to this, the components themselves are not independent and this
interaction has to be accurately represented. A s a result, radiation transport
and dose distribution analysis for B N C T is more complex than for photon
therapy. Dose due to photon b e a m s typically is deposited after only a few
scattering interactions, thus m a n y simplifying assumptions work well for
radiation transport calculations associated with photon therapy planning. In
B N C T , this situation is not paralleled as most of these dose components
arise from neutron interactions that occur after the incident neutrons from
the treatment b e a m have undergone m a n y scattering interactions. Explicit

35

3-D calculations with a complete treatment of particle scattering are
required as m a n y of the simplifying assumptions that work well for radiation
transport calculations associated with photon therapy planning are not
appropriate for B N C T .

Essentially all of the absorbed dose in photon therapy is generated by the
relatively low linear energy transfer (LET) secondary electrons. In contrast,
most of the major dose components in B N C T are generated by heavy
charged particles that are characterised by much higher linear energy
transfer (LET). These particles include protons and alpha particles
produced in a variety of neutron interactions with naturally occurring tissue
elements, as well as alpha particles and lithium ions produced via neutron
interactions with the pharmaceutically administered 10 B. The most important
B N C T dose component for tumour control is the therapeutic 10B<n,a)7Li
dose. All the other dose components are non-selective and therefore may
reduce the therapeutic advantage. The most significant of these is the
proton-recoil dose produced by elastic scattering interactions between the
incident neutrons in the treatment b e a m and hydrogen nuclei within the
irradiation volume. This dose component is believed to have a particularly
high R B E for normal tissue d a m a g e in s o m e regions of the incident-neutron
energy range, particularly in the "fast" neutron energy range (above
10keV).161'162.163 The proton recoil dose component in B N C T can be
suppressed by the use of a carefully designed epithermal neutron beam,
but as a practical matter it cannot be totally eliminated. Other unavoidable
background dose components result from the nitrogen (n,p) interaction and
from several other less-probable neutron interactions. There is also a
photon dose component in B N C T that results largely from the radiative
capture of neutrons by hydrogen within the irradiation volume, as well as
from the small -design^xxTtrolJable photon component of the incident
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treatment beam. The neutron capture-induced photon component is
generally the predominant contributor to the background dose to healthy
tissue in B N C T , provided that the proton recoil dose component is
appropriately suppressed. Table 3.1.1. from Nigg164 shows a summary of
the major dose components in B N C T along with some typical R B E factors
that are commonly associated with each. Considerable debate continues
over the R B E values, particularly that of the fast neutron dose component
via the proton-recoil reaction. Recent reports suggest the fast neutron R B E
m a y be in excess of 5.O.165-166

Component Typical RBE/compound factors
Boron neutron capture

0.3-2.3

Proton recoil

2.0-5.0

Nitrogen (n,p)

2.5-4.0

G a m m a {incident + capture)

1.0 (single fraction)
0.5 (four fractions)

Other minor components

1XD

Table 3.1.1. Major radiation dose components in boron neutron capture therapy. The
apparent R B E (or compound factor) for the boron neutron capture component and, to
s o m e extent, for the nitrogen (n,p) interaction, can vary because of microdosimetric
effects. T h e proton-recoil R B E varies with the energy of the incident neutrons.164

3.2. Elements of a Treatment Planning system for BNCT

The essential elements required in calculational systems for BNCT analytic
dosimetry and treatment planning are shown in Figure 3.2.1. The core of
any such system is a module for calculating the solution of the 3-D
Boltzman transport equation for neutral particles, given certain -descriptive
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Figure 3.2.1. Flow Diagram for B N C T neutral particle transport and microdosimetry
analysis.164 In this project, the interface between C T scans and M C N P (labelled a) was
acheived via variable voxels, while the 3 0 patient display interface (labelled b) utilised the
software package "VoxelView." 3 D M C N P output w a s integrated with patient geometry
(labelled c) using variable voxels and the software package VoxelView.

information as input parameters. This descriptive information consists of a
geometric model of the irradiation volume, a mathematical description of
the treatment beam, and a complete set of coupled neutron and photon
interaction cross-section data for all significant elements within the
irradiation volume. Ideally the geometric model of the irradiation volume
would be constructed directly from medical image data, however this has
only been possible in recent years with the development of high speed
computer technology. Three methods for constructing the necessary
geometric model have been successfully demonstrated by various research
groups. These methods will be described in detail in following sections.
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T h e b e a m consists of the neutron and photon spectra, angular distributions,
and spatial intensity distributions in a defined plane of incidence (usually
the exit part of the treatment b e a m collimator). This information is normally
constructed from a combination of calculational and experimental data
pertinent to the b e a m of interest. Appropriate multio/oup or continuous
energy format neutron and photon cross sections are preprocessed
typically from standard data collections such as the Evaluated Nuclear Data
File (ENDF). 1 6 7

The complete space and energy dependent solution of the Boltzmann
equation for the situation of interest involves the calculated neutron and
photon fluxes throughout the entire treatment volume. The corresponding
macroscopic absorbed dose distribution is ordinarily constructed in B N C T
applications by multiplying the calculated energy dependent flux data by
appropriate energy dependent flux to dose conversion factors (which m a y
include R B E multipliers and other adjustments) for each radiation dose
component. Integrating over the neutron or photon energy range as
appropriate, and summing all components, yields a single space dependent
dose function. O n a macroscopic scale, it is thus assumed that the spatial
distribution for each dose component follows the weighted spatial
distribution of the original neutron or photon flux within the irradiation
volume. This approximation is quite appropriate for the most part since the
secondary charged particles that generate ail of the dose components in
B N C T (other than the photon dose) have very short ranges of the order of a
few urn in tissue. The photon dose component is less accurately calculated
than the other dose components by this method, especially near voids and
material interfaces. Standard void and interface correction techniques could
be used for the photon dose component in situations where greater
accuracy is desired, although this is not currently a c o m m o n practice in
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B N C T research. O n e might also perform an explicit coupled photonelectron transport calculation to obtain the photon dose component directly.
This can be accomplished using standard software such as the Monte
Carlo E G S 4 1 6 8 package installed on a modern workstation computer.

To obtain the complete space and energy-dependent solution of the
Boltzmann equation for the situation of interest, two fundamentally different
methods are available. Deterministic methods are based on direct
numerical solution of the Boltzmann transport equation. Although relatively
fast with respect to computational time required, these methods are
somewhat restricted in ability to specify more complex geometries. Monte
Carlo stochastic simulation is the current method of choice, since complex
geometries characteristic of biological systems can be very accurately
represented using this technique. Both methods can provide very detailed
spatial dose distributions and dose-volume histogram information as well as
integral data. T h e significant drawback of the Monte Carlo technique is
caused by the stochastic nature of the calculations. Specifically if detailed
spatial resolution of the computed dose distributions is required, it
frequently is necessary to expend large amounts of computing time to
reduce the statistical uncertainties associated with the space-dependent
flux tallies to acceptable levels. Thus the two different methods compliment
each other and each has its o w n appropriate uses.

3.3. Deterministic Methods for BNCT analytic dosimetry

Because of the significant computational time advantage there has been
interest in application of deterministic methods for B N C T dose distribution
analysis. O n e particular deterministic approach that has been used at
various research institutions for one and two<limensional B N C T related
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studies, and which was recently shown169-170 to be feasible for use in full 3D
B N C T applications, is based on the discrete-ordinates method. The
discrete ordinates method provides a detailed numerical solution of the
transport equation for the direction, space, and energy-dependent particle
intensity at ail points in the calculational geometry. O n c e this function is
calculated, it is integrated over direction space to provide 3-D scale flux
data. T h e basic numerical approach involves partitioning the irradiation
volume into a 3-D finite-difference m e s h and, at each space point,
partitioning the angular phase space into a set of prespecified discrete
angular directions. A solution for the particle intensity is then iteratively
calculated for each of these discrete directions at each space point in the
mesh. 171 T h e incident treatment b e a m is represented by a fixed angular flux
boundary condition.

The "voxel-based" geometric reconstruction method lends itself well to use
with the discrete ordinates method. T h e technique involves the partitioning
of medical image data into squares, each of which is assigned material
properties based on average C T density or s o m e other appropriate
criterion. O n c e all of the images are partitioned, the square regions
generated in each plane are mathematically stacked to construct a large 3D array of parallelepipeds. The parallelepiped arrays generated by a voxel
reconstruction of the irradiation volume of interest can serve directly as an
orthogonal spatial m e s h structure for the transport calculation with no
further manipulation. Material properties can vary from one voxel to the next
and the calculated fluxes automatically correspond spatially to the original
voxel array used for reconstruction.

A voxel-based geometric reconstruction of a Labrador Retriever head169 is
shown in figure 3.3.1. This reconstruction w a s generated from photographs
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of actual canine head sections rather than from medical imagery. Radiation
transport calculations for this model were performed at the INEL using a
local adaptation of the T O R T 1 7 2 3-D discrete ordinates transport code,
originally developed at O a k Ridge National Laboratory. The canine head
w a s assumed to be positioned in the epithermal-neutron beam that is
available at the Brookhaven Medical Research Reactor (BMRR). A square
b e a m delimeter having dimensions of 1 0 0 m m on a side w a s assumed and
the b e a m w a s oriented such that the angle of the incidence w a s
perpendicular to the top of the head.

Calculated thermal neutron flux

contours in the sagittal mid plane are shown in figure 3.3.2.169
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Figure 3.3.1. Voxel reconstruction of a Labrador Retriever head positioned in the B M R R
epithermal neutron beam. The saggital midplane is shown.169
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Figure 3.3.2. Calculated thermal neutron flux contours in the sagittal midplane for the
discrete-ordinates Labrador Retriever head model. The 1 0 0 % contour corresponds to a
flux of 7x10 8 neutrons/cm2/s at a B M R R power 1 M W . 1 6 9

Figure 3.3.3. shows some typical total physical dose contours estimated
using the discrete ordinates method for a human glioblastoma multiforme
patient assumed to be positioned in the B M R R epithermal beam with a
100x100mm

square beam

delimeter aperture.164 The

tumour-boron

concentration is assumed to be 30|ig/g with boron excluded from the
normal brain. The 1 0 0 % dose contour passes along the inner margin of the
tumour region at a depth of about 70mm. The actual tumour is surrounded
by a large region of edema. A significant degree of localisation of the dose
distribution to the tumour region is evident. It may also be noted that any
tumour fingerlets with significant boron uptake will also see enhanced dose
levels not shown in figure 3.3.3.
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Calculated total physical dose contours for a human glioblastoma patient

positioned in the B M R R epithermal neutron beam. The tumour boron content is assumed
to be 30(xg/g. Boron is excluded from the normal brain tissue. The 1 0 0 % dose contour
passes along the inner margin of the tumour at a depth of about 7 0 m m and corresponds to
a dose rate of 14.4cGy/min at a B M R R power of 3 M W . 1 6 4
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3.4.

Stochastic methods for B N C T analytic dosimetry

3.4.1 The Monte Carlo Method

The mathematical implementation of the Monte Carlo stochastic simulation
method for the calculation of radiation transport has been continually
developed by various researchers19-173<174 for over 50 years and reached
high levels of sophistication. A brief discussion of the method is presented
here with particular focus upon the Monte Carlo Neutron Photon code
M C N P 1 9 and its applications utilised in this project with respect to B N C T
treatment planning. Almost infinitely more detailed descriptions can be
found in the previously listed references.

Monte Carlo does not solve an explicit equation as in the case of
deterministic techniques such as the discrete ordinates method. Instead
answers are obtained by simulating individual particles and recording some
aspect (tallies) of their average behaviour. The average behaviour of
particles in the physical system is then inferred (using the central limit
theorem) from the average behaviour of the simulated particles. Not only
are Monte Carlo and deterministic methods very different ways of solving a
problem, even what constitutes a solution is different. Deterministic
methods typically give fairly complete information (for example, flux)
throughout the phase space of the problem. Monte Carlo supplies
information only about specific tallies requested by the user.

When Monte Carlo and discrete ordinates methods are compared, it is
often said that Monte Carlo solves the integral transport equation, whereas
discrete ordinates solves the integro-differential transport equation. T w o
things are misleading about this statement. First, the integral and integro-
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differential transport equations are two different forms of the s a m e
equation; if one is solved, the other is solved. Second, Monte Carlo "solves"
a transport problem by simulating particle histories rather than by solving
an equation. N o transport equation need ever be written to solve a
transport problem by Monte Carlo. Nonetheless, one can derive an
equation that describes the probability density of particles in phase space;
this equation turns out to be the s a m e as the integral transport equation.

Without deriving the integral transport equation, it is instructive to
investigate w h y the discrete ordinates method is associated with the
integro-differential equation and Monte Carlo with the integral equation.
The discrete ordinates method visualises the phase space to be divided
into m a n y small boxes, and the particle m o v e s from one box to another. In
the limit as the boxes get progressively smaller, particles moving from box
to box take a differential amount of time to m o v e a differential distance in
space. In the limit this approaches the integro-differential transport
equation, which has derivatives in space and time. By contrast, Monte
Carlo transports particles between events (for example, collisions) that are
separated in space and time. Neither differential space nor time are
inherent parameters of Monte Carlo transport. The integral equation does
not have time or space derivatives.

Monte Carlo is well suited to solving complicated three-dimensional timedependent problems. Because the Monte Carlo method does not use phase
space boxes, there are no averaging approximations required in space,
energy, and time. This is especially important in allowing detailed
representation of all aspects of physical data. The method can be used to
duplicate theoretically a statistical process (such as the interaction of
nuclear particles with materials) and is particularly useful for complex
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problems that cannot be modeled by computer codes that use deterministic
methods. T h e individual probabilistic events that comprise a process are
simulated sequentially. The probability distributions governing these events
are statistically sampled to describe the total phenomenon. In general, the
simulation is performed on a digital computer because the number of trials
necessary to adequately describe the phenomenon is usually quite large.
The statistical sampling process is based oh the selection of randomnumbers - analogous to throwing dice in a gambling casino - hence the
n a m e "Monte Carlo." In particle transport, the Monte Carlo technique is preeminently realistic (a theoretical experiment). It consists of actually
following each of m a n y particles from a source throughout its life to its
death in s o m e terminal category (absorption, escape, etc.). Probability
distributions are randomly sampled using transport data to determine the
outcome at each step of its life. Whether an individual particle (neutron,
photon, electron

) will interact with a material and what kind of

interaction will occur is determined based upon rules (physics) and
probabilities (transport data). A s more and more such histories are
followed, the neutron and photon distributions become better known. The
quantities of interest (whatever the user requests) are tallied, along with
estimates of the statistical precision (uncertainty of the results).

3.4.2. Nuclear Data and Reactions

MCNP uses continuous-energy nuclear and atomic data libraries. The
primary sources of nuclear data are evaluations from the Evaluated Nuclear
Data File ( E N D F ) 1 6 7 system, the Evaluated Nuclear Data Library (ENDL) 1 7 5
and the Activation Library (ACTL) 1 7 6 compilations from Livermore, and
evaluations from the Applied Nuclear Science Group177-178-179 at Los
Alamos. Evaluated data are processed into a format appropriate for M C N P
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by codes such as NJOY 1 8 0 . T h e processed nuclear data libraries retain as
m u c h detail from the original evaluations as is feasible to faithfully
reproduce the evaluator"s intent. Nuclear data tables exist for neutron
interactions, neutron-induced

photons, photon

interactions, neutron

dosimetry or activation, and thermal particle scattering S(a,P). T h e latter
takes into account molecular binding effects that are extremely important in
B N C T applications where accurate simulation of thermal neutron transport
is required.

3.4.3. Source Specification

MCNP's generalised user-input source capability allows the user to specify
a wide variety of source conditions without having to m a k e a code
modification. Independent probability distributions m a y be specified for the
source variables of energy, time, position and direction, and for other
parameters such as starting cell<s) or surface(s). Information about the
geometrical extent of the source can also be given. In addition, source
variables m a y depend on other source variables (for example, energy as a
function of angle) thus extending the built-in source capabilities of the code.
The user can bias all input distributions.

In addition to input probability distributions for source variables, certain
built-in functions are available. These include various analytic functions for
fission and fusion energy spectra such as Watt, Maxwellian and Gaussian
spectra; Gaussian for time; and isotropic, cosine, and monodirectional for
direction. Biasing m a y also be accomplished by special built-in functions.

A surface source allows particles crossing a surface in one problem to be
used as the source for a subsequent problem. T h e decoupling of a
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calculation into several parts allows detailed design or analysis of certain
geometrical regions without having to rerun the entire problem from the
beginning each time. Sectioning the problem into parts can reduce the
required computing time by orders of magnitude - this technique w a s
applied extensively throughout the project.

3.4.4. Tallies and Output

The user can instruct MCNP to make various tallies related to particle
current, particle flux, and energy deposition. M C N P tallies are normalised
to be per starting particle except for a few cases with criticality sources.
Currents can be tallied as a function of direction across any set of surfaces,
surface segments, or sum of surfaces in the problem. Fluxes across any set
of surfaces, surface segments, s u m of surfaces, and in cells, cell segments,
or s u m of cells are also available. Similarly, the fluxes at designated
detectors (points or rings) are standard tallies. Heating and fission tallies
give the energy deposition in specified cells. A pulse height tally provides
the energy distribution of pulses created in a detector by radiation. In
addition, particles m a y be flagged w h e n they cross specified surfaces or
enter designated cells, and the contributions of these flagged particles to
the tallies are listed separately. Tallies such as the number of fissions, the
number of absorptions, the total helium production, or any product of the
flux times the approximately 100 standard E N D F reactions m a y be
calculated with any of the M C N P tallies. In fact any quantity of the form
Cj<ME) f<E) d E
m a y be tallied, where ${E) is the energy-dependent fluence, and f<E) is any
product or summation of the quantities in the cross-section libraries or a
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response function provided by the user. This feature w a s utilised
extensively to calculate dose and foil activation.

3.4.5. Estimation of Monte Carlo Errors

MCNP tallies are normalised to be per starting particle and are contained in
the output accompanied by a second number R, which is the estimated
relative error defined to be one estimated standard deviation of the m e a n S x
divided by the estimated m e a n x. All errors associated with M C N P
calculations in this thesis are R values. In M C N P , the quantities required for
this error estimate - the tally and its second moment - are computed after
each complete Monte Carlo history, which accounts for the fact that the
various contributions to a tally from the s a m e history are correlated. For a
well behaved tally, R will be proportional to 1/VN where N is the number of
histories. Thus, to halve R, w e must increase the total number of histories
fourfold.

The estimated relative error can be used to form confidence intervals about
the estimated mean, allowing one to m a k e a statement about what the true
result is. T h e Central Limit Theorem states that as N approaches infinity
there is a 6 8 % chance that the true result will be in the range x(1±R) and a
9 5 % chance in the range x(1±2R). It is extremely important to note that
these confidence statements refer only to the precision of the Monte Carlo
calculation itself and not to the accuracy of the result compared to the true
physical value. A statement regarding accuracy requires a detailed analysis
of the uncertainties in the physical data, modeling, sampling techniques
and approximations, etc., used in a calculation.

•/
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Despite one's best effort, an important path m a y not be sampled often
enough, causing confidence interval statements to be incorrect. T o try to
inform the user about this behaviour, M C N P calculates a figure of merit
( F O M ) for one tally bin of each tally as a function of the number of histories
and writes the results in the tally fluctuation charts at the end of the output.
The F O M is defined as
FOM=1/(R 2 T),
where T is the computer time in minutes. The more efficient a Monte Carlo
calculation is, the larger the F O M will be because less computer time is
required to reach a given value of R.

The FOM should be approximately constant as N increases because R2 is
proportional to 1/N and T is proportional to N. Tally fluctuation charts
associated with calculations in this project were always examined to ensure
a well behaved tally, as evidenced by a fairly constant F O M . A sharp
decrease in the F O M indicates that a seldom sampled particle path has
significantly affected the tally result and relative error estimate. In this case,
the confidence intervals m a y not be correct the fraction of the time that
statistical theory would indicate. T o resolve a problem of this nature,
variance reduction techniques would have to be applied to sample the
critical path more frequently.

3.4.6. Variance Reduction

As noted in the previous section, R (the estimated relative error) is
proportional to 1/VN, where N is the number of histories. For a given M C N P
run, the computer time T consumed is proportional to N. Thus R=C/VT,
where C is a positive constant. There are two ways to reduce R : (1)
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increase T and/or (2) decrease C. Computer budgets and practical
considerations of clinical software often limit the utility of the first approach.
For example, if it has taken 2 hours to obtain R = 0.10, then 200 hours will
be required to obtain R=0.01. For this reason M C N P has special variance
reduction techniques for decreasing C. (Variance is the square of the
standard deviation.) The constant C depends on the tally choice and/or the
sampling choices (non-analog Monte Carlo).

1. Tally Choice: As an example of the tally choice, note that the
fluence in a cell can be estimated either by a collision estimate or a track
length estimate. T h e collision estimate is obtained by tallying 1/£t
(Zt=macroscopic total cross section) at each collision in the cell and the
track length estimate is obtained by tallying the distance the particle moves
while inside the cell. Note that as St gets very small, very few particles
collide but give enormous tallies when they do, a high variance situation. In
contrast, the track length estimate gets a tally from every particle that
enters the cell. For this reason M C N P has track length tallies as standard
and are those applied in this project.

2. Nonanalog Monte Carlo: Explaining how sampling affects C
requires understanding of the nonanalog Monte Carlo model. The simplest
Monte Carlo model for particle transport problems is the analog model, as
described in section 3.4.1, which uses the natural probabilities of
occurrence of events (for example, collision, fission, capture, etc.). Particles
are followed from event to event by a computer, and the next event is
always sampled (using the random number generator) from a number of
possible next events according to the natural event probabilities. This is
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called the analog Monte Carlo model because it is directly analogous to the
naturally occurring transport.

The analog Monte Carlo model works well when a significant fraction of the
particles contribute to the tally estimate and can be compared to detecting
a significant fraction of the particles in the physical situation. There are
many cases for which the fraction of particles detected is very small, less
than 10"6. For these problems analog Monte Carlo fails because few, if any,
of the particles tally, and the statistical uncertainty in the answer is
unacceptable.

Although the analog Monte Carlo model is the simplest conceptual
probability model, there are other probability models for particle transport.
They estimate the s a m e average value as the analog Monte Carlo model,
while often making the variance (uncertainty) of the estimate much smaller
than the variance for the analog estimate. Practically this means that
problems that would be impossible to solve in days of computer time can be
solved in minutes.

A nonanalog Monte Carlo model attempts to follow "interesting" particles
more often than "uninteresting" ones. A n "interesting" particle is one that
contributes a large amount to the quantity (or quantities) that needs to be
estimated. There are m a n y nonanalog techniques, and they are all meant
to increase the odds that a particle scores (contributes). T o ensure that the
average score is the s a m e in the nonanalog model as in the analog model,
the score is modified to remove the effect of biasing (changing) the natural
odds. Thus, if a particle is artificially m a d e q times as likely to execute a
given random walk, then the particle's score is weighted by (multiplied by)
1/q. T h e average score is thus preserved because the average score is the
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sum, over all random walks, of the probability of a random walk multiplied
by the score resulting from that random walk.

A nonanalog Monte Carlo technique will have the same expected tallies as
an analog technique if the expected weight executing any given random
walk is preserved. For example, a particle can be split into two identical
pieces and the tallies of each piece are weighted by 1/2 of what the tallies
would have been without the split. Such nonanalog, or variance reduction,
techniques can often decrease the relative error by sampling naturally rare
events with an unnaturally high frequency and weighting the tallies
appropriately.

3. Variance Reduction Tools in MCNP: There are four classes of
variance reduction techniques181 generally applicable to the Monte Carlo
method. Truncation Methods

are the simplest of variance reduction

methods. They speed up calculations by truncating parts of phase space
that do not contribute significantly to the solution. The simplest example is
geometry truncation in which unimportant parts of the geometry are simply
not modeled. Specific truncation methods available in M C N P are energy
cutoff and time cutoff.

Population Control Methods use particle splitting and Russian roulette to
control the number of samples taken in various regions of phase space.
Particle splitting refers to the production of more lower weight particles,
while Russian roulette is the inverse of this. In important regions many
samples of low weight are tracked, while in unimportant regions few
samples of high weight are tracked. A weight adjustment is m a d e to ensure
that the problem solution remains unbiased. Specific population control
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methods available in M C N P are geometry splitting and Russian roulette,
energy splitting/roulette, weight cutoff, and weight windows.

Modified Sampling Methods alter the statistical sampling of a problem to
increase the number of tallies per particle. For any Monte Carlo event it is
possible to sample from any arbitrary distribution rather than the physical
probability as long as the particle weights are then adjusted to compensate.
Thus with modified sampling methods, sampling is done from distributions
that send particles in desired directions or into other desired regions of
phase space such as time or energy, or change the location or type of
collisions. Modified sampling methods in M C N P include the exponential
transform, implicit capture, forced collisions, source biasing, and neutroninduced photon production biasing.

Partially - Deterministic Methods are the most complicated class of variance
reduction methods. They circumvent the normal random walk process by
using deterministic-like techniques, such as next event estimators, or by
controlling the random number sequence. These methods, although
available in M C N P , have not been applied in this project.

Variance reduction techniques, used correctly, can greatly help the user to
produce a more efficient calculation. For m a n y problems, variance
reduction is not just a w a y to speed up the problem but is absolutely
necessary to get any answer at all. The following summarises the main
M C N P variance reduction techniques applied in this project.

a. Energy cutoff: Particles whose energy is out of the range of
interest are terminated so that computation time is not spent following them.
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6. Time cutoff: Like the energy cutoff but based on time.

c. Geometry splitting with Russian roulette: Particles transported
from a region of higher importance to a region of lower importance (where
they will probably contribute little to the desired problem result) undergo
Russian roulette; that is, s o m e of those particles will be killed a certain
fraction of the time, but survivors will be counted more by increasing their
weight the remaining fraction of the time. In this way, unimportant particles
are followed less often, yet the problem solution remains undistorted. O n
the other hand, if a particle is transported to a region of higher importance
(where it will likely contribute to the desired problem result), it m a y be split
into two or more particles (or tracks), each with less weight and therefore
counting less. In this way, important particles are followed more often, yet
the solution is undistorted because on average the total weight is
conserved.

d. Energy splitting/Russian roulette: Particles can be split or rouletted
upon entering various user-supplied energy ranges. Thus important energy
ranges can be sampled more frequently by splitting the weight a m o n g
several particles and less important energy ranges can be sampled less
frequently by rouletting particles.

e. Weight cutoff/Russian roulette: If a particle weight becomes so low
that the particle becomes insignificant, it undergoes Russian roulette. Most
particles are killed, and s o m e particles survive with increased weight. The
solution is unbiased because total weight is conserved, but computer time
is not wasted on insignificant particles.
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f. Implicit capture: W h e n a particle collides, there is a probability that
it is captured by the nucleus. In analog capture, the particle is killed with
that probability. In implicit capture, also known as survival biasing, the
particle is never killed by capture; instead its weight is reduced by the
capture probability at each collision. Important particles are permitted to
survive by not being lost to capture. O n the other hand, if particles are no
longer considered useful after undergoing a few collisions, analog capture
efficiently gets rid of them.

g. Source variable biasing: Source particles with phase space
variables of mora importance are emitted with a higher frequency but with a
compensating lower weight than less important source particles.

3.5. Techniques for geometric modelling of the irradiation volume

3.5.1. Geometric reconstruction based on geometric primitives

To construct the geometric description of the irradiation volume for use in
B N C T dosimetric modelling using the Monte Carlo technique, three basic
methods have been developed. The first method, which is computationally
the simplest and therefore the fastest-running, is to approximate the
irradiation volume using logical combinations of a small number of
geometric primitives (spheres, cubes, cylinders, ellipsoids, etc) described
by simple surface equations. This Method is incorporated into the wellknown general-purpose Monte Carlo code M C N P 1 9 and has been widely
used for BNCT-related purposes in the past.182-183-164 More recently,
however, use of the geometric primitive method in B N C T has generally
been limited to calculations of flux and dose distributions in idealised
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cylindrical, spherical, or ellipsoidal tissue-equivalent phantoms, primarily
connection with neutron beam design and characterisation. For actual invivo applications requiring construction of geometric descriptions directly
from medical image data either by computer tomography (CT) or by
magnetic resonance (MR) imaging, the geometric primitive method has
largely been superseded.

3.5.2. Geometric Reconstruction based on Voxel Combinations

The first of the direct geometric reconstruction methods employs the voxel
reconstruction technique. As discussed in the Deterministic Methods
Section, the voxel reconstruction technique involves the partitioning of
medical image data into squares, each of which is assigned material
properties. O n c e stacked, the resultant 3 D array of parallelepipeds can
then be input to a general purpose Monte Carlo code such as M C N P . The
various tissue compartments (including tumour regions of interest) are
thereby represented as combinations of adjacent parallelepipeds. This
reconstruction technique is employed in the S B N C T - P L A N treatment
planning system,185 developed at the State University of N e w York, Stony
Brook, as well as in the N C T - P L A N System,186 developed at the N e w
England Medical Centre.

The voxel reconstruction method permits reconstructions to be generated
relatively quickly and is very amenable to automation, this is because
digital medical image data essentially is acquired and stored as voxels.
Flux and dose distributions can be readily calculated with a spatial
resolution that corresponds to the dimensions of the voxels used for
geometric reconstructions. O n e disadvantage of the voxel method of
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reconstruction lies in the large computational time required to follow
enough

particle

histories

to

provide

acceptably

small

statistical

uncertainties for the spatially detailed fluxes. In the case of clinical trials
where the number of patients is expected to be small, computational time
per treatment plan is not overly critical. Calculation times of hours are
certainly acceptable under these circumstances. However to extend B N C T
treatment to more routine clinical use will require a significant reduction in
calculation time per treatment plan to the order of minutes or less. If this is
to be achieved, advances in both computer hardware performance and
software efficiency will be required.

This project has aimed at improving software efficiency by introducing a
variable voxelsize187 to model patient geometry. Smaller voxels are used in
regions of interest to enable accurate transport and dose calculations, and
larger voxels where precise geometry is less critical. This effectively
decreases the geometrical complexity of the model while maintaining
resolution in critical areas. Decreasing the geometrical complexity of a
Monte Carlo model strongly decreases the transport computational time per
history. This is because the algorithms associated with geometrical
boundary crossing perform a significant amount of the total logical
operations per history. Thus decreasing the number of geometrical
boundaries in a model (i.e. decreasing geometrical complexity) effectively
reduces the computational time per history and thus per treatment plan.

Another disadvantage of the voxel reconstruction method arises from the
fact that the curved surfaces describing anatomical structures of interest
are approximated by combinations of orthogonal voxel facets. Because of
this, both the enclosed volume and the surface area of the structures being
modeled cannot be simultaneously preserved. The voxel approximation
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should be accurate, however, if the volume enclosed by each surface being
modeled is preserved, and the dimensions of the facets used for the
reconstruction are small relative to the local radius of curvature of the
surface. This is easier to achieve in critical areas with the use of a variable
voxel size.

3.5.3. Geometric Reconstruction based on generalised surface equations

Direct construction of geometry from medical image data may also be
achieved with the use of non-uniform rational B-spline fits to the various
tissue compartment (or sub-compartment) surfaces. A B-spline surface
reconstruction capability has been incorporated into the special purpose
bnct-edit/rtt-MC software system for medical dosimetry188189 developed by
the Idaho National Engineering Laboratory (INEL), with the assistance of
the Computer Science Departments of the University of Utah and Montana
State University. With this method, one first outlines the regions of interest
(e.g., skin, skull, brain, various tumour regions, etc.) on each computer
displayed medical image plane in the region outlines for all image slices
are then mathematically combined to produce detailed equations describing
the 3-D surfaces that enclosed each volume of interest.

Figure 3.5.3.1. shows a cranial reconstruction of a Japanese BNCT patient,
using the B-spline surface reconstruction technique.190 T h e surface
equations generated in the B-spline region reconstructions completely
describe the geometry and can subsequently be used in a Monte Carlo
radiation transport calculation. The complex curved surfaces of the various
anatomical structures of interest in B N C T dosimetry can be faithfully
represented and particle tracking can be accomplished with the minimum
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Figure 3.5.3.1. 3 D reconstruction of a human patient cranial geometry using the B-spline
surface reconstruction technique of the INEL developed bnct-edit/rtt-MC software
system. 188 ' 189 - 190 Brain, bone and tumour compartments have been modelled.
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number of boundary crossings. The primary disadvantage is that, unlike the
situation with the voxel-based reconstructions, spatially detailed flux and
dose distributions are not automatically obtained. The development of the
"sub element Monte Carlo" technique189 in the rtt-MC code has, however,
largely addressed this problem without substantial loss of calculational
efficiency.

3.6.1. The sub element Monte Carlo method

Using the voxel reconstruction technique yields simultaneously the
geometry of the irradiation volume, and a 3 D mesh structure in which dose
calculations m a y be performed. Reconstructing geometry with the B-spline
surface technique gives the former, but not the latter - both of which are
essential for an effective treatment planning system. The subelement
Monte Carlo technique overcomes this problem by superimposing a 3-D
subelement m e s h structure upon a pre-existing surface reconstruction of
the irradiation volume. The subelement mesh is based on three orthogonal
sets of parallel planes. It is outwardly similar to the parallelepiped array that
would be generated for the irradiation volume by the standard voxel
reconstruction method, but the subelement mesh is independent of the
model geometry and does not affect the particle tracking process, other
than to moderately increase the computing time requirements. For typical
subelement structures composed of 1 0 m m cubes, the total computing time
for a given application is increased by about 20%. 1 6 4 During particle
tracking through the original surface reconstruction, each path is examined
to determine the path length to tally for each subelement that is intersected.
An additional feature is that flux contributions to subelements that happen
to be intersected by a reconstructed surface are rigorously treated.
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Figure 3.6.2.1. R B E vascular endothelium tissue iso-dose contours. Calculations were
performed using the subelement Monte Carlo method of the INEL developed bnct-edit/rttM C software system, (courtesy G.Storr, A N S T O )

Figure 3.6.2.2. R B E tumour iso-dose contours. Calculations were performed using the
subelement Monte Carlo method of the INEL developed bnct-edit/rtt-MC software system.
(courtesy G.Storr, A N S T O )
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3.6.2. Calculated flux and dose distributions using the subelement Monte
Carlo method

Dose calculations by G.Storr (ANSTO) for the patient model displayed in
Figure 3.5.3.1. are illustrated in Figures 3.6.2.1 and 3.6.2.2.. R B E vascular
endothelium tissue iso-dose contours and R B E tumour iso-dose contours
are displayed respectively. Contours are superimposed upon the MRI of the
plane of interest of the patient. The input parameters described the very
pure thermal neutron beam of the Kyoto University Research Reactor
(KURR). Calculations were performed using the subelement Monte Carlo
method of the INEL developed bnct-edit/rtt-MC software system.188'189-190
These illustrations show that this system is at the forefront of treatment
planning software.

Simulating the BMRR epithermal-neutron beam prior to reactor core
modifications in September 1992, Figure 3.6.2.3 displays calculated
physical depth dose profiles for a B-spline Labrador Retriever head
model.170 The boron-neutron capture dose component follows the spatial
distribution of the thermal neutron flux and is normalised to a uniform

10

B

concentration of 30 parts-per-million (ppm) by weight in tissue. The total
dose curve includes the boron-neutron capture dose, the proton-recoil (fast
neutron) dose, the photon (gamma) dose, the nitrogen (n,p) dose, and a
few other smaller components. The total non-boron dose curve is simply
the difference between the total dose curve and the boron dose curve. The
non-boron dose curve shows the background dose that would, in the ideal
case, be seen by normal tissues, from which boron would be excluded.
The total dose curve shows the dose that would be seen by tissues
containing boron at the assumed concentration. It can be seen that these
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Figure 3.6.2.3. Dose components in the Labrador Retriever head model for the B M R R
epithermal neutron beam calculated using the sub-element Monte Carlo technique.170
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two curves are separated by a factor of as much as 4, depending on the
spatial location.

All doses displayed in figure 3.6.2.3 are the macroscopic physical absorbed
dose. R B E factors and C o m p o u n d Factor adjustments have not been
included. (Compound

Factor adjustments

attempt to account for

microscopic scale spatial inhomogeneity of the dose components in B N C T ,
particularly the boron-neutron capture component, and to a lesser extent
the nitrogen component) The R B E and microdosimetric adjustment factors
for the various dose components are highly dependent upon the detailed
spectral properties of the treatment beam, the biodistribution characteristics
of the boronated pharmaceutical that is used, the tissue type of interest and
the biological endpoint assumed. The effect of including such factors can
often be to increase the effective total absorbed dose (boron-neutron
capture plus background) in the malignant tissue relative to that in normal
tissue. This desirably increases the effective therapeutic advantage relative
to what would be expected on the basis of the physical absorbed dose
alone. This is provided that trie neutron field in the irradiation volume is not
unduly contaminated with fast neutrons.

There is evidence that the RBE for the proton recoil (fast neutron) dose
component in B N C T m a y be quite high for certain incident neutron energies
above 10keV. 165 If the treatment beam were to be contaminated with fast
neutrons to such a degree that the proton-recoil dose component
dominated the background dose, (with R B E

and micro dosimetric

adjustment factors included) then the calculated effective therapeutic
advantage would be decreased relative to that associated with the
unweighted physical absorbed dose. This is certainly not desired, hence, it
is likely to be important in the future to ensure that any neutron b e a m used
•1
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for BNCT has been designed such that the fraction of incident neutrons
having energies above the desirable epithermal energy range has been
reduced to as low a level as practical to maximise the probability of
treatment success. For example, the advanced low-contaminant epithermal
neutron b e a m that has been proposed for installation at the Georgia
Institute of Technology Research Reactor123 has been designed with the
minimisation of the fast neutron component as a primary objective to offer a
more favourable therapeutic advantage for B N C T of certain deep-seated
tumours than is the case for the B M R R beam.

In practice, the ideal limit of a therapeutic concentration of boron in the
tumour and none in the normal tissue is not fully achieved in the currently
available boronated pharmaceutical's (although s o m e c o m e close). Even if
boron were to be totally excluded from normal brain tissue, one could still
reasonably expect to have at least s o m e boron in the blood. Thus, for brain
tumours, the capillary endothelium m a y be expected to be at risk for normal
tissue complications. O n the positive side, however, it can be shown that
the capillary endothelial cells in the brain may, depending on the specific
boronated pharmaceutical that is used, be protected to a large extent from
the boron interaction products because of microdosimetric considerations.
Thus even with appreciable concentrations of boron in the blood a very
favourable therapeutic advantage can still be realised.
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3.7.

Microdosimetry for B N C T

3.7.1. Background

When attempting to correlate absorbed dose with observed radiobiological
effect, microdosimetric phenomena are essential considerations in B N C T .
This is critical in the case of the boron-neutron capture dose component
and to a lesser extent also important for some of the other components in
BNCT, most notably the nitrogen (n,p) component. As noted earlier, the
paths traversed by the charged particles resulting from boron-neutron
capture are comparable in length to typical cell dimensions. In addition, the
intercellular and intracellular spatial distributions of boron within the
irradiation volume are generally non-uniform and are dependent upon the
characteristics of the specific boronated pharmaceutical that is employed.
These factors combine, at any dose level, to create a {general lack of spatial
equilibrium on a microscopic scale for the secondary charged particles
emitted in the boron-neutron capture interaction. This lack of spatial
equilibrium results in the apparent R 8 E of the boron capture dose
component in both normal and malignant tissue to be highly dependent on
both the localisation properties of the boronated compound, as well as on
the geometry of the specific cell type of interest.

This situation is further complicated by the statistical nature of BNCT a
microscopic level. At therapeutic dose levels there are relatively few boronneutron interactions-per-cell (approximately 20-30 on the average) and
even fewer charged particle tracks through the critical targets in the cell in
BNCT. This is opposed to the relatively large number of photon-electron
interactions and electron tracks per cell in photon therapy. Thus, the
statistical nature of the entire neutron interaction and charged particle
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energy deposition process must also be taken into account. S o m e celts
m a y receive a number of boron-neutron capture interactions which happen
to be far from the average. This m a y translate into radiobiologically
significant deviations from the average absorbed dose.

3.7.2. Microdosimetric analysis methods in BNCT

Charged particle track structure data needed for microdosimetric studies in
B N C T are generally determined using Monte Carlo radiation transport
calculations.191-192-193-194 Nuclear cross sections are typically replaced with
charged particle range-energy relationships, and

nuclear scattering

interactions are ordinarily not explicitly considered. Each particle of interest
deposits energy by electromagnetic interactions as it slows down in
accordance with its specified range energyrelationship.Source particles
are sampled from a measured or assumed spatial distribution. Track
lengths are tallied, and the results are typically output the form of singleevent energy-deposition frequency distributions for various critical target
regions of interest within the cells being modelled. This information can be
used to determine the average absorbed dose rate with each critical target
relative to the dose rate that would exist if charged particle equilibrium
existed on both an intra and an intercellular basis. The microscopic scale
geometric dose distribution factor determined in this manner is essential for
proper interpretation of in-vivo and in-vitro radiobiological response
observations in B N C T . It can be used to reasonably account for the fact
that the observed in-vivo relative biological effect of the boron-neutron
capture dose component can sometimes be substantially smaller than unity,
as discussed in the following sections.
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3.7.3. Macroscopic dosimetry with regard for microdosimetry.

The achievable therapeutic advantage with BNCT can be crucially affected
by microdosimetric phenomena. Probably the most critical case in B N C T is
that of capillary endothelia. If the capillary endothelium is taken as the
dose-limiting normal tissue for B N C T of brain tumours and if the boronated
pharmaceutical does not cross the normal blood-brain barrier, then it can
be shown analytically that the nuclei of the capillary endothelial cells will
experience significant geometric protection from the boron-neutron reaction
products. This occurs because local charged particle equilibrium does not
exist. This is believed to be the case with o n e of the most c o m m o n boron
delivery agents, B S H . To account for this phenomena when estimating
effective absorbed radiation ooses in B N C T , the "compound-factor" (CF)
has been

introduced.195 T h e C F is defined as the applicable

microdosimetric geometric adjustment factor multiplied by the expected
R B E associated with a spatially uniform absorbed dose distribution for a
particular absorbed obse component of interest. Calculations by Wheeler et
a|i94,i96 s n o w tnat tne C F for damage to y ^ nLldej of tne c a p j H a r y
endothelial cells can be significantly less than unity. This hypothesis is
strongly supported by in-vivo experimental data for canines using
BSH. 162 . 19 5.197

To provide any therapeutic advantage via microdosimetric means, it is
essential that the C F be higher in the target (tumour) cells than in healthy
tissue cells. This is the case if the microscopic spatial distribution of boron
in the tumour cells is such that there is a significantly smalter degree of
geometric protection than in the capillary endothelial cells. Such an
advantageous situation is thought to exist with glioblastoma multiforme
using B S H . In this situation, one can obtain a very favourable therapeutic
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advantage even for a tumour blood boron ratio that is not significantly
greater than unity - the C F makes the effective ratio much higher. This is
provided that the absolute boron concentration in the target cells is
sufficient to cause the boron-neutron capture dose to dominate the total
absorbed dose.51

Compound Factors and RBE values are currently the topic of substantial
investigation and revision, with further revision expected in the future.
W h e r e consideration of these factors in this project is not crucial, such as
the demonstration of results from a geometry reconstruction algorithm,
physical doses will typically be presented. In all cases either physical doses
or C F and R B E values used will be stated. Currently "accepted" (although
debated by many) R B E factors are 5.0 for the proton recoil dose 162 , 2.7 for
the nitrogen <n,p) dose,53 2.3 for the equilibrium boron-neutron capture
dose,48 and 1.0 for all other components. Substantial upward revision of the
proton recoil dose in particular has occurred over the past 2 years with
considerable effort continuing in this area. These R B E values are then
modified by appropriate geometric adjustment factors to produce the final
CF. The geometric adjustment factors for the boron-neutron capture dose
rates associated with B S H are thought to be 0.14196 for the capillary
endothelium and 1.0 for tumour cells. This geometric adjustment factor
reflects the ratio of the actual microscopic absorbed dose rate in the
endothelial nucleus relative to the equilibrium dose rate in the blood when
using B S H . The geometric adjustment factors for all other dose components
are assumed to be 1.0 in both tumour and normal tissue. Thus the C F s
used for B S H are assumed to be the s a m e as the R B E values for ail dose
components in all tissue types except for the boron-neutron capture
component in the capillary endothelium, where the C F is taken as
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approximately 0.32 (0.14 x 2.3), which is consistent with experimental
data.195

For p-boronophenylaline (p-BPA), which is of particular interest for BNCT of
malignant melanoma 198199 - 200 and studied for use in other tumours,77-200201
biodistribution is very different to B S H and correspondingly exhibits
different microdosimetric properties. B P A has been shown to attain a more
favourable tumour blood boron ratio than BSH, but on the other hand is
also taken up by normal tissue to s o m e extent. This phenomena must be
taken into account w h e n using this agent.196 A geometric adjustment factor
of 0.85 for capillary endothelium and 1.0 for tumour cells202 appears to be
the current thought an this compound. T h e C F values to b e used for any
given clinical application are highly variable. Different boronated
pharmaceuticals will have different biodistributions and correspondingly
different microdosimetric properties.203 W h e n attempting to understand and
predict radiobiological response in B N C T , it is always necessary to
carefully consider microscopic scale radiation transport and interaction
phenomena.
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4.

T4SSUE EQUIVALENT MATERIALS A N D P H A N T O M S

4.1. Introduction

In radiation dosimetry, the aim is to determine the amount of energy
absorbed in an irradiated biological specimen. In the biological specimen
however, the processes involved in radiation absorption are not accessible
to physical instrumentation. Representative measurements are thus
restricted to non-biological phantoms. To achieve results comparable to
those which would occur in a biological system, phantoms must be
designed with materials having equivalent physical properties to biological
tissues. This requirement of tissue equivalence in the measurement of
absorbed dose m a y lead to two basically different realisations, according to
the dosimetric purposes.

First, for absolute dosimetry, one would like a material in which similar
physical interactions lead to the measured signal as they occur during
absorption in tissue. Although, in principle, corrections for material
differences can be made, this m a y be time consuming and inaccurate.
Second, to determine spatial relative dose distributions in clinical
dosimetry, materials are needed which provide equivalent spatial dose
distributions to tissue within a large irradiation volume. The variety of
purposes of clinical dosimetry makes necessary the use of a number of
different phantoms, which, for practical reasons, must often consist of
different materials. All of these materials must yield relative dose
distributions equivalent to those in biological tissue. For measurements of
basic data such as depth dose distributions, standard isodose curves, etc,
for treatment planning, liquid phantoms are used with Tissue Equivalent
(TE) liquids or water. Phantoms with irregular shapes or rigid calibration
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phantoms, however, are usually easier to construct from solid materials.
For versatile construction, these materials should be inexpensive and
easily molded or machinable.

For the verification of treatment planning, especially for complex irradiation
techniques, solid phantoms are required which are suited for holding
distributions of the integrating detectors measuring the dose distribution.
Depending upon the situation, it m a y be necessary to construct an irregular
phantom containing inhomogeneities. Moldable materials such as waxes,
mixtures of resins, and gels are suitable for this purpose. Thus there are a
variety of requirements and properties which, in general, cannot be
satisfied by a single material.

4.2. History

Since the early 1900's certain liquid and solid phantoms have been used in
experimental radiation physics wherever the radiation effects within and
around irradiated h u m a n tissues are being investigated. In such diverse
situations as the measurement of depth doses or the production of
standards in nuclear medicine, the design of dosimeter components or the
manufacture of realistic test objects for quality assurance testing in
diagnostic radiology, so-called "tissue equivalent materials" are frequently
used. A very large diversity in the formulated materials used is evident in
the literature. For example, with the m a n y w a x based products said to
simulate biological tissue, inert fillers such as calcium carbonate, lithium
carbonate, magnesium oxide, polyethylene, silicon dioxide, and titanium
dioxide have been used with varying degrees of success.
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Unfortunately, this concept is often misused, with m a n y materials being
credited with equivalence over extended energy ranges w h e n in fact dose
simulation might occur over a limited energy interval. In particular for*
photons, materials used

for medium

to high-energy

radiotherapy

applications are often used for experimental studies in low energy
diagnostic radiology with the experimentalist believing, quite erroneously,
that the s a m e "equivalence" exists.204

The development of tissue substitutes falls into two phases, in the first
phase (pre 1940) a general awareness of the problems involved developed
with most experimental studies using water or wax. At the end of this period
a more analytical approach evolved and the concept of adding compounds
to wax in order to improve its x-ray and electron attenuation properties is
developed. During the second phase, which continues to the present day,
many mixtures of solids and liquids are derived as substitutes for biological
tissues and other media. This phase is characterised by the gradual
improvement in the manufactured materials and the appearance of
materials specifically designed for neutron tissue equivalence.

4.2.1. Pre-1940

Tissue simulation started in the early part of this century, when the newly
discovered x-rays were being intensively investigated. In 1906, Kienbock 205
reasoned that "an aluminium foil 1 m m thick is equivalent in absorption
power to a layer of water or muscle, 1cm thick". This marked the beginning
of the study of tissue substitutes. In 1913, Swiss radiologist Christen stated
that x-ray b e a m quality should be specified in terms of water attenuation, as
water gave similar results to soft tissue.206 Similarly in 1*922, Baumeister 207
i
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stated that wax had the same absorption and scattering properties as
tissue.

These comments directed the course of future radiation measurements,
evident from the considerable quantities of data produced using water and
wax. Radium and radon isodose curves in water208-209 and wax210-211
together with x-ray measurements 212 - 213 - 214 are reported in numerous papers
in the journals of that time. It w a s not until much later that it w a s realised
that wax w a s not ideal, especially at low photon energies.215-216

In 1924, Westman217 used a "pelvic phantom" made of wax and bolus
alba218 for gynaecological measurement. This is the first documented
"body-phantom" whereby tissue substitutes are moulded into the shape of a
human body. ARhough a few attempts at morerealisticphantom shapes
were reported during this period,219-220.221 the majority of experiments were
performed with tanks of water or blocks of wax. The use of bolus materials
during radiotherapy treatments, to fill interstices over the patients skin, w a s
reported in 1920 by Jungling.222 Talc w a s one of the first materials to be
employed, but bolus atoa, rice, dough, and water-bags are reported by
many

authors.217,219,223,224

RJOQ

was

ar so

used

by

a

number

of

authors 223225226 and pressed wood, a compressed cellutose material, w a s
introduced in 1937 by Failla227 as a muscle substitute. Other simulations
reported pre-1940 include Trubesteins228 use of glycerol triolet (triolein) as
a fat substitute, ivory as a bone substitute,229 the effects of air cavities in
wax phantoms 2 3 0 and the introduction of Siemens Wax. 231 T h e latter is a
mixture of paraffin wax and magnesium oxide which had
attenuation properties compared to wax alone.

improved
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4.2.2. 1940

-PresentDay

Attention was now being given to tissue substitutes other than muscle, and
tissue equivalence for particulate radiations. In 1944, EcHing217 introduced a
cellular lung substitute called zellstaff, while Plaster of Paris and glass were
used by Spiers232-233 to simulate bone. The way in which the substitutes
were applied to dosimetric problems shifted in emphasis during this period
from the techniques based on solid blocks of material or tanks of liquids, to
those based upon body phantoms.

Significant advancements were made in the comparison of a tissue and its
proposed substitute for x<ays and electron beams. Comparison of mass
attenuation and energy absorption coefficients and electron mass stopping
and angular scattering powers for a representative range of energies,
became essential. This spawned a variety of n e w tissue substitutes, with an
ever increasing complexity of fillers to fulfil the ever more stringent
requirements. In 1-949, Jones and Raine 234 produced a water substitute
called 'Mix O'. This w a s a mixture of paraffin wax, polyethylene, magnesium
oxide, and titanium dioxide that could be cast into sheets or more complex
body sections. A series of electrically conducting plastics simulating
muscle, bone, air and polystyrene were manufactured in 1958 by Shonka et
al.235 The materials were compounded from a number of polymers and inert
fillers (for example polyethylene, nylon, silicon dioxide, calcium fluoride).
Due

to

their

conducting

properties, these

plastics, with

some

modification236-237 have been used extensively in the construction of
ionisation chambers.

In 1961, a material to be known at TEMEX was developed in England by
Stacey et al238 at the Royal Marsden Hospital. This w a s basically a
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depolymerised natural rubber with the addition of carbon and titanium
dioxide.239 A year later, the R A N O O system w a s introduced in the United
States by Alderson et al.240 T h e R A N O O

product used a synthetic

isocyanate rubber with fillers of phenolic microspheres and antimony
trioxide.241 T E M E X and R A N O O are both produced in sheet form and
moulded around h u m a n skeletons as sliced body phantoms.

In 1974, White204 introduced two new formulation procedures and some
improved tissue substitutes including a range of epoxy resin based
materials simulating muscle, lung, bone, skin and average breast tissues.
An extensive review of tissue substitutes and their physical characteristics
with relevance to x-ray and electron properties w a s also published by White
in 1978. 242

4.3. Neutron tissue equivalent materials

With the introduction of exotic fillers to improve the x-ray and electron
properties of tissue substitutes, most materials b e c a m e unsuitable as
neutron tissue equivalent materials. In neutron dosimetry, one would like a
similar secondary particle spectrum, thus leading to the s a m e ionisation as
in the biological system. If this condition is met, then the secondary
particles, whose energy deposition is measured in the phantom, can be
assumed to be the s a m e as those which include biological d a m a g e in the
equivalent tissue. In neutron dosimetry, the prerequisite for a similar
secondary particle spectrum is the similar elemental composition of the
tissue and the tissue equivalent phantom material.243

One branch of tissue equivalent materials - intended primarily for x<ay and
electron equivalence - is not based upon incorporating fillers into waxes or
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resins but instead is based upon an approximate formula for soft tissue:
(CsH4oOi8N)n. White 242 states that this elemental equivalence procedure "is
particularly applicable to neutron studies where interactions are strongly
dependent upon hydrogen and sometimes nitrogen concentrations." In
1956 Rossi and Failla244 introduced s o m e liquid and gel systems based on
this approximate formula for soft tissue. These systems, in particular the
liquid mixture of water, glycerol, urea and sucrose have been used
repeatedly over the years for neutron radiation, both in the original form
and also with small variations in composition.22-245-246-247-248

In formulating a tissue equivalent material, it is the hydrogen and nitrogen
densities that must take first priority. Concentrations of carbon and oxygen
are of seoondary importance due to theirrelativelylow interaction with
neutrons. In addition to these requirements, a tissue equivalent material for
use in phantoms should be moderate in cost, compounded of readily
available substances, neither corrosive, toxic, volatile, nor unpleasant, and
stable to radiation. Also over a period of time it should not be subject to
internal chemical reaction, or to absorption of C O 2 etc. from the air.

Table 4.3.1. shows the elemental composition and densities of a number of
tissue-similar materials with ICRU 46 (1992) standard muscle tissue.249
Hensley et al243 state that 'Tissue equivalent liquids as formulated by
Frigerio250 and G o o d m a n 2 2 are recommended as standard material for the
measurement of neutron isodoses in the USA". The G o o d m a n liquid,
composed of 6 5 . 6 % water, 2 6 . 8 % Glycerol and 7.6% Urea (by weight) has
excellent elemental composition and density correlation with muscle tissue,
particularly for the vital elements hydrogen and nitrogen.
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Elemental Composition (% by weight)
Material

H

C

N

O

Others

Density
<g/cm 3 )

H20

11.19

Goodman

10.20

12.01

10.2

76.80

88.81

1.00

3.54

74.25

1.07

3.60

5.90

T E liquid
A-150

F: 1.70

1.12

Ca:1.80
Alderson Muscle

8.87

66.81

Perspex

8.05

59.98

Polystyrene

7.74

92.26

1.05

Polyethylene

14.37

85.63

0.94

ICRU 46 2 4 5

102

14.3

skeletal

3.10

21.13

Sb:0.08

31.96

3.4

7lTo

muscle

0.99
1.17

NatfTi

To?

P:0.2

tissue (Adult a)

S:0.3
Cl:0.1
K:0.4

ICRU 46 Brain

iOJ

l75

zl

whole (Adult a)

TTl

Na: 0.2

1L04

P: 0.4
S:0.2
CI: 0.3
K: 0.3

Table 4.3.1. Physical and chemical properties of several tissue similar materials. The
elemental compositions and densities of the substitutes are taken from White,242 whilst
those of muscle and brain are taken from ICRU 46. 249

Table 4.3.2. illustrates aspects for the use of phantom materials in neutron
dosimetry. Although the tissue equivalence of the G o o d m a n liquid is
excellent, negative aspects centre around geometrical restrictions of liquid
phantoms. Geometrical requirements for individually shaped phantoms for
patient treatment planning are best satisfied by using waxes for the
phantom material. Their less than ideal tissue equivalence, however,
prompts o n e to look for another solution to the geometric problem.
Frigerio250 first applied the idea of adding agarose powdertosolidify tissue
equivalent liquids enabling 3 D structures to be formed.
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Material

Consistency

Positive Aspects

Negative Aspects

Water

Liquid

Reasonable tissue equiv.

Difficult

to

Standard phantom mat. for

phantoms

with

dosimetry intercomparisons

shapes. Difficult to constuct

distributions.

in Europe. Applicable for

phantoms

Comparisons.

quick

measurements

inhomogeneities.

large

series

of

of

Typical Applications
construct
irregular
containing

can only be used in the

distributions in a standard

upright position. Difficult to

cubic

position

phantom.

Remote

of

standard

dose

Phantom

dose

positioning of detectors in

Measurement

distributions

of

integrating detectors.

phantom possible.
Tissue-

Liquid

G o o d tissue equivalence.

S a m e as water.

Equivalent

Standard phantom material

Liquids

for

dosimetry

inter

comparisons in the U S A .
Else: s a m e as water.
A-150

Solid

Good tissue equivalence for

Expensive.

dose buildup. Standard wall

distributions not equivalent

ionisation chambers.

material

to soft tissue.

Dose

for

ionisation

Spatial

dose

Construction

of

measurements

chambers in Europe and

providing

tissue-

U S A . G o o d applicability for

equivalent secondary

simultaneous irradiation of

particle spectra.

distributions of integrating
detectors.
Aiderson

Solid

material

Verification

of

available containing realistic

Expensive. Not exactly
tissue equivalent. Phantoms

treatment planning for

inhomogeneities. Good app

only available for standard

standard cases.

licability for simultaneous

patient shape.

Anthropomorphic

phantom

irradiation of disributions of
integrating detectors.
| Perspex

Solid

Cheap

Simple

irregular

Poor tissue equivalence.

Rigid phantoms for

Polystyrene

shapes can be formed by

Machining of more complex

reproducible

Polyethylene

machining.Good

shapes

positioning.

applicability

for

simultaneous irradiation of

is very

difficult

without computer controlled
tooling machines.

distributions of integrating
detectors.
Waxes

Moldable

Cheap. Irregular shapes can

Poor tissue equivalence.

Individually

Solid

be formed by moulding.

Restricted mechanical and

phantoms for patient

Good

thermal stability.

treatment planning.

applicability

for

simultaneous irradiation of
distributions of integrating
detectors.

Table 4.3.2. Aspects for the use of phantom materials in neutron dosimetry.

shaped
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The basic unit of agarose is galactose, linked alternately a-1,3-(Dgalaotose) and 3-1, 4-(a-L-galactose). With 7.5% hydrogen, 46.5% carbon
and 4 6 % oxygen (by weight) and no nitrogen, agarose makes an ideal
additive into muscle equivalent liquids. In small proportions (less than 5 % )
the addition of agarose does not significantly alter the sensitive hydrogen
and nitrogen components of the G o o d m a n Liquid.

Constituents (by wt % )

Elemental Composition (wt % )

Density
(a/cm3)

Goodman Uquid: Water(65.6%), Glycerol(26.8%),

H(10.20)

C(12.01)

N(3.54)

0(74.25)

1.07

Goodman Uquid{96%), Agarose{4%)

H(10.O9)

C<13.39)

N(3.40)

0(73.12)

1.09*

Skeletal Muscle (ICRU 46, Adutt a)

H(10.2)

C(14.3)

N(3.4)

O(71.0)

1.05

Urea(7.6%)

'density of solidified mix

Table 4.3.3. Goodman Liquid and Goodman Gel in comparison to human muscle tissue.

The density of the goodman gel is somewhat higher than that of muscle,
however if w e compare the elemental densities of hydrogen and nitrogen
(those factors most strongly affecting neutron transport) for muscle and its
substitute (Table 4.3.4.) w e find very close agreement. The small
differences are within individual patient variations. Thus the G o o d m a n
liquid/agarose gel mix was chosen as the basis neutron tissue equivalent
material. Slight variations in nitrogen level were applied for different organs,
most notably the brain.

Agarose is insoluble in cold water, but swells by absorbing over 20 times its
weight of hot water. Dissolved in boiling water and allowed to cooted, it
sets to a firm gel at concentrations as low as 0.5%. Solidification occurs at
approximately 36°C, however the gel does not remelt until heated to
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approximately 85°C. Testing various samples, a 4% concentration of agar
was found to give a strong, rubber like solid, similar to silicon sealant in
texture suitable for moulding phantoms. Best results were obtained using
microwaves to heat the mixture rather than conventional ovens. White 242
states that tissue equivalent gels constructed in this manner are suitable
not only for neutrons, but also for photons above 0.06 M e V and electrons of
all energies.
Material Elemental Density (g/cm3)
G o o d m a n Gel

H(0.11O)

N(0.037)

Skeletal Muscle {ICRtJ 46, Adult a)

H(0.107)

N{0.036)

Table 4.3.4.

Elemental densities of the standard G o o d m a n liquid with 4 % agarose in

comparison to human skeletal muscle.

4.4. Phantom Construction

4.4.1. Cylinder Phantom

Figure 4.4.1.1. depicts the dimensions of the cylinder phantom - known in
the N C T community

as the "Bremen

Phantom".

Constructed of

polycarbonate (see Appendix 1), this phantom w a s modified by the addition
of four polycarbonate detector tubes parallel to the axis. The cylinder w a s
filled with a tissue equivalent gel based on the G o o d m a n Gel formulae, with
the nitrogen content lowered slightly so that the material simulated brain
tissue as opposed to muscle tissue. Table 4.4.1.1. shows the components
of the brain equivalent material used in the cylinder and a comparison with
average grey and white brain tissue.249 The four detector tubes, each at

Figure 4.4.1.1. Modified cylindrical 'Bremen' phantom constructed from polycarbonate with
brain equivalent inner material.

85
2.5cm from the cylinder axis, enable simultaneous measurement at
geometrically equivalent points within the phantom. W h e n irradiated on the
centre of the front face with a circularly symmetric beam, each detector tube
is effectively indistinguishable. This design was facilitated so that intercalibration between different neutron and g a m m a ray detectors could be
achieved in a single irradiation, thus removing the uncertainty between
irradiations. Depths of 2cm and 7cm as measured from the front face of the
phantom to the centre of each detector were chosen as standard locations
in the detector tubes. These represent the predicted maximum in thermal
neutron flux for an epithermal beam, and the midline of the brain,
respectively.
Material: Elemental Composition (by wt %) Density Hydrogen Nitrogen
(g/cm3)

Constituents (by wt % )
H

C

N

O

10.12

13.18

2.07

74.6

10.7

14.2

2.2

71.2

Density
3

Density

(g/cm )

(g/cm3)

1.09

0.110

0.023

1.04

0.111

0.023

Brain Equivalent:
Water(64.91), Glycerol(25.52),
Urea(4.44),Agar(4.12)
50/50 Grey White brain matter
(ICRU 46, Adult a)

Table 4.4.1.1. Elemental and density comparison between the brain equivalent material
and average grey and white brain material. Neutron transport is strongly dependent upon
hydrogen and nitrogen densities - these are in excellent agreement.

Detectors used include magnesium and tissue equivalent ionisation
chambers, gold, copper, and manganese foils - both bare and cadmium
covered, Positive Intrinsic Negative (PIN) semiconductor diodes and Metal
Oxide Semiconductor Field Effect Transistors ( M O S F E T ) g a m m a detectors.

The ionisation tubes, having an outer diameter of 12mm, fit directly inside
the detector tubes. Clearance w a s approximately 0.4 m m . The centre of the
1
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ionisation chamber is 1 2 m m from the front surface of the instrument,
therefore w h e n inserted into the polycarbonate tube, the centre of the
chamber is at a depth of 2 0 m m as shown in figure 4.4.1.2. T o achieve a
7 c m depth, a 5 c m perspex billet w a s first inserted into the polycarbonate
detector tube. Clearance for the billet w a s essentially zero to minimise
neutron streaming effects.

Figure 4.4.1.2. Ionisation chamber positioning at 20mm depth in the cylinder phantom.
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For the remaining detectors, perspex tubing of outer diameter 12.5mm, and
inner diameter 9.5 m m was first inserted into the phantom tubes. Perspex
billets with minimal clearance were again used to locate the various
detectors. Dismantling was at times difficult due to the small clearance,
however this w a s deemed necessary to prevent neutron streaming. Figure
4.4.1.3. illustrates the positioning of bare foils at the 2 0 m m depth position in
one of the four tubes.

Foil LocciTiori

e
6-

2.0mn

Figure 4.4.1.3. Uncovered foil positioning at 2 0 m m depth in the cylinder phantom.

Cadmium covers were constructed from 0.5mm sheet cadmium. Two
interlocking caps were constructed as shown in figure 4.4.1.4. Clearance
between the two caps was approximately 0.1mm - any less than this would
not enable the caps to be separated once together. W h e n cupped together
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the cadmium cover has a total external thickness of 2 m m . Perspex billets
were again used to fit the foil filled C d covers into position in a similar
manner to that shown in figure 4.4.1.3.

T h e front billet used for the

cadmium covered foils w a s 11 m m to allow for the thickness of the covers
thus placing the foils exactly at 2 0 m m depth. A n extra 5 0 m m billet w a s
inserted to place the C d covered foil at 7 0 m m depth (approximately the
lateral depth to the midline of the brain).

Figure 4.4.1.4. Cadmium covers were constructed from 0.5mm sheet cadmium. Two
interlocking caps were constructed as shown. Clearance between the two caps was
approximately 0.1mm
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Figure 4.4.1.5. A PIN diode fixed in place by perspex holders inside the cylinder detector
tubes.

To house the PIN diodes, perspex "holders" were cut to remove any gaps
within the tube construction and to hold the diodes in place. Figure 4.4.1.5.
depicts a PIN diode in place in the detector tube with the perspex holders..
Perspex billets were again used to position the centre of the PIN at depths
of 2 and 7 cm.
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MOSFET

inm

Figure 4.4.1.6. M O S F E T g a m m a detector fixed in place inside a lithium fluoride epoxy
cover to shield out thermal neutrons 23

The M O S F E T g a m m a detectors must be housed in Lithium-6 Fluoride
epoxy covers to shield the device from thermal neutrons.23 Figure 4.4.1.6.
shows a M O S F E T inside a lithium cover inserted in a detector tube.
Perspex billets were used to position the centre of the M O S F E T at depths
of 2cm and 7cm.
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4.4.2. Head

Phantom

The head phantom must be constructed as realistically as possible, in both
composition and geometry. The simplest method is to base the construction
around an actual human skull. This technique is already used to construct
x-ray equivalent phantoms. A n undamaged human skull w a s donated to the
project by the University of N e w South Wales School of Anatomy. Around
this, soft tissue facial and neck features were moulded with plasticine. This
enabled top and bottom half plaster moulds to be created, which were
subsequently used to create a plaster replica of the skull with facial
features.

Cellulose Acetate was chosen as the material for the other shell or "skin" of
the head phantom. This material is used to create vacuum moulded face
supports for radiotherapy patients, its x-ray properties being similar to skin.
Its hydrogen content of 7.8% was regarded as suitable, considering the
material was only going to be used for the outer 1 m m of the phantom.
Upper and lower sections of the sheet were vacuum moulded at
approximately 120°C over the plaster replica of the skull to form the skin.
5 m m flanges on each section of the cellulose acetate skin were left
attached to facilitate connection between the upper and lower surfaces 2 m m diameter nylon screws were used for this purpose.

Polyurethane was inserted into the nasal area and throat region. Upon
expansion and hardening this material forms, essentially, a void region
suitable for simulating these areas. With the plasticine facial moulding
removed, the cellulose acetate skin was fixed around the skull using nylon
screws. Nylon w a s used as opposed to metal to avoid activation following
neutron exposure and because of its closer similarity to biological tissues.
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A brain equivalent material, identical to that given in table 4.4.1.1, w a s
heated to 100°C then poured into the skin filling the brain cavity and
external face and neck features. Figure 4.4.2.1. shows the completed
phantom with skeletal, brain, facial tissue and cavity simulation. The stand,
also shown in figure 4.4.2.1, w a s constructed from perspex and w a s used in
all irradiations.

Figure 4.4.2.1. Head phantom with actual human skull, brain equivalent soft tissues, and
cellulose acetate vacuum moulded skin.
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Perspex tubing of outer diameter 12.5mm inner diameter 9.5mm w a s
inserted into the simulated brain as shown in Fig. 4.4.2.2. This tubing w a s
inserted orthogonally so as to be coincident with the "patient's" lateral,
anterior-posterior and superior-inferior axes. This tubing is identical to the
inner sheath of perspex used to house the detectors in the Bremen
phantom. A s such, the techniques illustrated for housing and locating the
various detectors in the Bremen phantom are equally applicable in the head
phantom.

Figure 4.4.2.2. The dismantled head phantom showing how detectors can be inserted via
the orthogonal perspex tube system.
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Figure 4.4.2.3. Transverse C T scan of the head phantom showing the lateral (A) and
anterior-posterior (H) detector tubes in position. Detector locations are labelled.
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Figure 4.4.2.3. is a Computerised Tomographic (CT) scan of the transverse
plane of the head phantom containing the two horizontal axis detector
tubes. Each detector site labelled is 2 c m apart with A1-A4 being the lateral
axis (left to right) and H1-H5 being the anterior-posterior axis (front to
back). T h e site of this plane is shown in figure 4.4.2.4. Perpendicular to
this plane is the superior-inferior (top to bottom) axis with detector sites
labelled V1 to V5. T h e detector site V 2 lies in the plane of the two
horizontal axes - this site is the origin of the detector array. Figure 4.4.2.5.
is a saggital reconstruction, using the transverse C T scans, of the vertical
slice containing the anterior-posterior and superior-inferior detector tubes.
Detector sites are 2 c m apart and are labelled H1-H5 for the anteriorposterior axis and V1-V5 for the superior-inferior axis. T h e site of this plane
in the phantom is shown in figure 4.4.2.6.

Figure 4.4.2.4. Bounding planes depict the location of the C T image from the previous
figure.
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Figure 4.4.2.5. Saggital C T scan of the head phantom showing the anterior-posterior (H)
and superior-inferior (V) detector tubes in position. Detector locations are labelled.

Figure 4.4.2.6. Bounding planes depict the location of the C T image from the previous
figure.
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4.4.3. Body Phantom

The geometry of the body phantom was based upon the CT scans of a
female melanoma patient. The 38 scans of the patient were spaced 1 6 m m
apart, with the set extending from the shoulder to the hip. The patient w a s
divided into two major regions for modelling. Firstly, the volume containing
the lungs and internal organs of the abdomen. Second, the volume
surrounding the first region containing skeletal, muscular and adipose
tissue. Rigid wire 2 D outlines of both regions for each C T scan were
constructed. Netting wire w a s then used with the wire outlines to create two
3 0 shapes - one representing the outer surface of the patient, the other
representing the lung/abdominal organ surface of the patient. Plaster of
Paris w a s then used to fill the 3 D wire surfaces to produce solid plaster
casts. Cellulose acetate sheets of 2 m m thickness were then heat/vacuum
moulded over the front and back of each cast. Trimming and joining
resulted in cellulose acetate replicas of the exterior surface and body cavity
surface of the "patient".

Plastic organs from a life size anatomy demonstration model were then
used to create plaster moulds of the heart, liver, pancreas, stomach,
large/small intestine, spleen and

kidneys. G o o d m a n

based tissue

equivalent mixtures, modified to suit the composition of each organ, were
then cast into the moulds. Table 4.4.3.1. shows the percentage of
components used to simulate each organ, and the resulting elemental
composition and density.

Lung tissue was simulated using polyurethane foam, cast into the upper
section of the internal cavity cellulose acetate sheet. In the upper section this sheet follows the surface of the lungs as modelled from the C T scans.
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While the lung tissue w a s being cast, the heart tissue w a s placed into
position allowing the simulated lungs to harden around the gel cast of the
heart. T h e remaining organs were held in position by thin wire holders,
while the surrounding volume inside the internal cellulose acetate sheet
w a s filled with muscle equivalent mixture. This completed the construction
Material:
Constituents (by w t % )

Elemental Composition (by wt % )
C

N

Adipose Equivalent:
Wax(98.5), UreaM .5)
Adipose Tissue:
(ICRU 46, Adult a)
Heart Equivalent:
Water(63.43), Glycerol(25.91),
Urea(6.63), Agar(4.03)
Heart Tissue:
(ICRU 46, Adult a)
Intestine Equivalent:
Water(64.91), Glycerol(26.52),
Urea(4.44). Agar(4.12)
Intestine Tissue:
(ICRU 46, Adult a)
Kidney Equivalent:
Water(63.69), Glycerol(2S.02),
Urea(6.24), Agar(4.0S)
Kidney Tissue:
(ICRU 46, Adult a)
Liver Equivalent:
Water(63.69), GIycerol(26.02),
Urea(6.24), Agar(4.05)
Liver Tissue:
(ICRU 46. Adult a)
Lung Equivalent:
Polyurethane Foam
Lung Tissue:
(ICRU 46, Adult a)
Muscle Equivalent:
Water(63.0), Glycerol(25.7),
Urea(7.3), Agar(4.0)
Muscle (Skeletal):
(ICRU 46, Adult a)
Pancreas Equivalent:
Water(64.91), Glycerol(2652),
Urea/4.44). Agar(4.12)
Pancreas Tissue:
(ICRU 46, Adult a)
Spleen Equivalent:
Water(63.43), GlyceroK25.91),
Urea(6.63). A g a r R 0 3 )
Spleen Tissue:
(ICRU 46. Adult a)
Stomach Equivalent:
Water(64.91), Glycerol(26.52),
Urea/4.44). Agar/412)
Stomach Tissue:
(ICRU 46. Adult a^

14.74

84.16

0.70

O
0.4

0.94

0.139

0.0066

11.4

59.8

0.70

27.8

0.95

0.108

0.0067

10.05

13.34

3.09

73.52

1.09

0.109

0.034

10.3

13.2

3.0

72.4

1.05

0.109

0.034

10.12

13.18

2.07

74.6

1.09

0.110

0,023

10.6

11.5

2.2

75.1

1.03

0.109

0.023

10.06

13.31

2.91

73.72

1.09

0.110

0.032

10.3

13.2

3.0

72.4

1.05

0.108

0.032

10.06

13.31

2.91

73.72

1.09

0.110

0.O32

10.2

13.9

2.9

71.8

1.06

0.108

0.032

7.00

60.00

5.00

28.01

0.25

0.018

0.013

10.3

10.5

3.1

74.9

0.26

0.027

0.008

10.09

13.39

3.4

73.12

1.09

0.110

0.037

10.2

14.3

3.4

71.0

1.05

0.107

0.036

10.12

13.18

2.07

74.6

1.09

0.110

0.023

10.6

16.9

2.2

69.4

1.04

0.110

0.023

10.05

13.34

3.09

73.52

1.09

0.109

0.034

10.3

11.3

3.2

74.1

1.06

0.109

0.034

10.12

13.18

2.07

74.6

1.09

0.110

0.023

10.6

11.5

2.2

1.03

0.109

0.023

H

75.1

Density
(g/cm3)

Hydrogen
Density
(g/cm3)

Nitrogen
Density
(g/cm3)

Table 4.4.3.1 shows the percentage of components used to simulate each organ, and the
resulting elemental composition and density.
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of the internal section of the phantom. The outer surface cellulose acetate
sheet w a s fixed into position around the internal filled sheet in accordance
with the C T scan geometry. The space between the internal and external
sheets w a s filled with adipose tissue equivalent material as given in table
4.4.3.1.

Detector tubes, with similar construction to those used in the head phanto
were placed in two orthogonal axes in the right lung, two orthogonal axes
in the liver, and along the length of the pancreas. Figure 4.4.3.1. depicts a
composite image of several C T scans showing the location of the lung
detector tubes. Sites were labelled LUS1, LUS2, LUS3, LUS4, L U S 5 for the
five sites of the lung side axis at 3cm spacing with LUS1 being at 3cm
depth. Similarly five sites were labelled on the lung front axis at 2 c m

Figure 4.4.3.1. Composite image of several CT scans showing the location the location of
the lung detector tubes.
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intervals with the first being 2cm depth - the sites were labelled LUF1 to
LUF5. Figure 4.4.3.2. shows the location of the previous lung composite
image within the body phantom.

Figure 4.4.3.2. Bounding planes depict the location of the C T images from the previous
figure.

Figure 4.4.3.3. depicts a composite image of several CT scans showing the
location of the 'lis' liver side detector tube. Sites were labelled LIS1, LIS2,
LIS3, LIS4, LIS5 for the five sites of the liver side axis at 3cm spacing with
LIS1 being at 3cm depth. Similarly five sites were labelled on the liver front
axis (figure 4.4.3.4) at 2cm intervals with the first being 2cm depth - the
sites were labelled LIF1 to LIF5. Figure 4.4.3.5. shows the location of the
previous liver images within the body phantom.
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Figure 4.4.3.3. Composite image of several C T scans showing the location of the 'lis' liver
side detector tube.

Figure 4.4.3.4. Composite image of several C T scans showing the location of the 'lif liver
front detector tube.
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Figure 4.4.3.5. Planes depict the location of the C T images from the previous liver
detector tube figures.

A detector tube was also inserted from the left side of the patient along
length of the pancreas. Five sites were established at 2 c m intervals along
the pancreas P1

being the left most site approximately at the

pancreas/spleen attachment with P2, P3, P 4 and P 5 extending at the 2cm
intervals along the length of the pancreas. Figure 4.4.3.6. shows a C T scan
of the pancreas region showing the location of the pancreas detector tube
and sites P1 to P5. Figure 4.4.3.7. depicts the location of these C T scans
within the body phantom.
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Figure 4.4.3.6. C T scan showing the location of the pancreas detector tube. The upper
tube was not utilised in the experiment.

Figure 4.4.3.7. The bounding plane depicts the location, within the body phantom, of the
C T image from the previous figure.
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Figure 4.4.3.8. shows the body phantom in the orientation suitable for frontal irradiation
from the horizontal H F R Petten b e a m port.

Figure 4.4.3.8. shows the body phantom in the orientation suitable for
frontal irradiation from the horizontal Petten beam port. The stand was
constructed from perspex and was designed to produce minimal
interference between the beam and the phantom.
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5.

CYLINDER P H A N T O M B E N C H M A R K I N G

To cross calibrate the responses of the detectors with MCNP
calculations prior to use in the complex head and body phantoms,
measurements and calculations were first peformed using the cylindrical
Bremen phantom described in chapter 4. The phantom was modelled in
M C N P with geometry as shown in figure 5.1. The detector tubes were
not modelled in the M C N P simulation. Instead the M C N P tally volumes
in the cylinder were annular shaped with 5 m m radial width and 5 m m
axial thickness. This design was used to take advantage of the high
degree of symmetry in the source-phantom configuration of the Petten
H F R beam. Although not perfectly circular, the deviation is small as
indicated by symmetrical dose profiles across the beam.251,252 Materials
simulated in the M C N P model were brain equivalent material (Chapter
4.) and

polycarbonate. Low

energy

molecular binding effects,

particularly affecting scattering from hydrogen nucleii, were

Figure 5.1. M C N P model of the cylindrical bremen phantom.
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taken into account by applying the s(ct,P) treatment in M C N P . Molecular
effects were modelled as light water at 298K. Irradiation w a s both
performed and simulated with the Petten H F R epithermal b e a m using a
15cm diameter collimator. The 2 0 c m diameter polybor irradiation port
w a s 2 0 c m from the front face of the phantom. The epithermal neutron
spectrum applied in the M C N P model shown in figure 5.2.251'252-253'254
Collimator geometry applied in the M C N P modelling is shown in figure
5.3.251 T h e M C N P input file for the cylinder model is given in appendix I.
Approximately 9x10 5 source neutrons were simulated in 6 0 minutes C P U
time on a Fujitsu V P 2 2 0 0 supercomputer to give a statistical accuracy of
less than 2 % .
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Figure 5.3. Cutaway view of the 1 5 0 m m diameter collimator geometry used in the M C N P
calculations.
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Calculated neutron fluxes in the energy ranges of thermal <0-0.414eV),
epithermal (0.414-10keV), fast (10keV<) and total neutron fluxes are
shown in figure 5.4 as a function of depth. As expected, the fast neutron
flux shows an exponential reduction with depth, whilst the thermal
neutron flux has a maximum approximately 2-3cm from the front surface
of the phantom. This is typical for an epithermal neutron beam.
Normalisation of 1.9x1011 neutrons per second from the source plane
has been applied (see below).
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neutron fluxes as a function of depth.
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Gold foil activation in neutron captures per atom per second were
calculated using cross section tables of endl-7163, April 1976, for Au197 with M C N P

material identifier 79197.10c. Using

the tally

multiplication feature in M C N P , an integral of the form of°<J>(E)R<e)d£
w a s first calculated, where: -

<|>(E) = neutron fluence per source neutron (neutrons/cm2/ns) as
a function of energy

R(E) = 197Au{n,Y)198Au reaction cross section per atom
(barns/atom) as a function of energy.

Multiplying the integral by 10"24 (cm2/barn) and then by the number of
neutrons per second from the source plane O V s =1.9x1011 - see
Appendix II) converts the integral to 197Au(n,y)198Au captures/atom/sec.
Using M C N P , this value w a s calculated as a function of depth for the
cylinder phantom and is displayed in figure 5.5.

The gold foils were placed at depths of 2, 4, 6, 7, and 8cm in the
cylinder phantom and irradiated with the front face of the phantom 20cm
from the b e a m exit. Gold foil activation w a s then measured using a Nal
photomultiplier detector. These measurements were converted to
saturation values of Becquerels/atom and corrected for resonance self
shielding

(see

Appendix

II). At

saturation,

Bq/atom

equals

captures/atom/sec - thus M C N P calculations and gold foil results can be
directly compared. This comparison is given in figure 5.5. A s can be
seen, the agreement between measurements and calculations is
excellent. Also shown are results of the cadmium covered gold foils.
Cadmium effectively blocks neutrons below 0.414eV, thus the gold
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activation is due predominantly to neutrons corresponding to the
resonance energy of 197 Au of 4.91 eV. This was taken into account in the
M C N P calculations by performing the J<KE)R(€)d£ integral over the
energy range 0.414eV to infinity, instead of O.OeV to infinity. The
agreement for the cadmium covered gold foil measurements and
calculations is also good, but there is a tendency for the calculation to
underestimate the measurement at depth.
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Figure 5.5. Calculated and measured saturation gold activation as a function of depth
in the cylinder. Uncovered and cadmium covered foils are displayed, along with their
difference.

Copper and manganese foils were also used to investigate the higher
energy regions of the spectrum of 580 and 337eV respectively.
Calculations were performed using copper cross sections of EN0F/8-IV
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(Mar 76), with M C N P

identifier 29000.10c, and m a n g a n e s e cross

sections of lll-howerton (May 75), with M C N P identifier 25055.01c.
Preprocessing of the foil data w a s identical to that of the gold foil data
and is detailed in Appendix II. Figure 6.6. illustrates the results for
copper foils. Uncovered foil activation results agree extremely well with
calculated results. C a d m i u m covered copper foil calculations agree
reasonably well with the calculated results, however again the tendency
for the high energy calculation to underestimate the measurement at
depth is observed.
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Figure 5.7 gives the results for the manganese foils. The uncovered foils
show good agreement between measured and calculated results. A
significant discrepancy of over 3 0 % exits, however, between the
cadmium covered manganese foil measurements and calculations.
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Figure 5.7. Calculated and measured saturation manganese activation as a function of
depth in the cylinder. Uncovered and cadmium covered foils are displayed, along with
their difference.

PIN diode dosimeters23-255 (responding dominantly to fast neutrons) were
also used to compare measurements with M C N P calculations. Figure
5.8 shows the PIN diode response in the free beam, and also at 2cm
and 7 c m depths. Calculations using the silicon damage

KERMA

factors256 are also displayed as a function of depth. Results have been
normalised using the free beam measurements and calculations.
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Agreement is reasonable, however the discrepancy increases with
depth. This w a s also observed in the head phantom (Chapter 6) and in
the previously displayed cadmium covered foils. This series of
measurements and calculations show a consistent trend of very precise
agreement between Monte Carlo calculations and measurements in the
low energy regime, however the calculations underestimate the
measurements only at depth when high energies are considered. The
origin of this discrepancy was the subject of intensive investigation into
worst case scenarios of cadmium cap leakage, neutron streaming in the
phantom detector tubes and gel dehydration. N o 'phantom uncertainties'

10

-3
!

;

1

1

1

1

i

1

i

I

-

en 10
a

-4

-

z

E
o

I

Q

c
a
o
00
o
o

10

-5

f o

Free Beam Silicon Damage
(Calculated - cGy/sec)
• Free Beam PIN Voltage
(measured normalised to
calculated-200mV/cGy(Si))
A Cylinder Silicon Damage
(calculated - cGy/sec)
• Cylinder PIN Voltage
(measured normalised to
calculated-200mV/cGy(Si))

_

CD

cn
\
O
o

-6

10

r
;

-7

I

10

0

I

1

,

1

,

1

,

1

,

1

.

1

,

1

a

—

1

7

3

i

I

8

i

.

0

Depth (cm)

Figure 5.8. PIN diode response in the free beam, and also at 2cm and 7cm depths.
Calculations using the silicon damage KERMA factors256 are also displayed as a
function of depth.
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were able to provide a consistent match between measurements and
calculations. M C N P input spectrum variations were also analysed,
however these were also unable to resolve the discrepancy and also
contradicted much work of the Petten group.

One possible (and very likely) explanation lies with the divergence of the
Petten beam. Reports up until 1995251-254 had suggested a beam
divergence of 10°. This was applied in the series of calculations
presented here. The accuracy of this figure is however, rather poor.
Recent results (i.e.- as the final version of this thesis was being
produced) comparing calculations to measurements in phantoms
suggest an even more forward directed beam {about 6°) to give the best
agreement.257 Conceptually this could preferentially increase the high
energy detector response calculations at depth while preserving the low
energy depth response characteristics that show excellent agreement
with measurements. More is said by Cardan 23 - 255 about this series of
measurements with particular reference to PIN diode and M O S F E T
characteristics.

Induced gamma dose as a function of depth calculated using MCNP is
shown in figure 5.9. The second calculated profile is the induced g a m m a
component plus a constant 0.347 cGy/sec (1.25 Gy/hr) consistent with
the beam g a m m a ray component.253-254 It should be noted that this is
only a first order approximation of the beam g a m m a dose component.
Also depicted are the lithium-6-epoxy covered MOSFET 2 3 - 2 5 8 g a m m a
dose measurements at 2cm and 7cm depth. The M O S F E T dose w a s
calibrated to a Mg/Ar ionisation chamber in the bare beam, whilst the
induced g a m m a dose calculations were normalised equivalents to the
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foil calculations, i.e. 1.9xt011 neutrons per second leave the source
plane.
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It can be seen from Figure 5.9 that the M O S F E T is under-responding in
comparison to the calculated total g a m m a dose. Although the beam
divergence problem mentioned above should be taken into account, its
effects on the g a m m a dose at relatively shallow depth should be small in
comparison to that seen on high energy neutrons at depth. After
extensive investigation, the source of the discrepancy has possibly been
revealed by a number of recent experiments at Petten.257 Usually the

1t6

idea is that the Lithium-6 covers provide local shielding of the detectors
from the thermal neutron flux to leave a response from the g a m m a ray
component only. This technique w a s utilised by our group and certainly
practiced by the Petten group during the 1994 experiment when these
measurements were taken.

This technique assumes that either i) the gamma and neutron fields are
independent or ii) the effect of the Lithium-6 covers on the neutron field
is local only. In both cases the g a m m a field is not perturbed - which is
the quantity being measured. The first condition is not satisfied since the
induced g a m m a component is dependent on the neutron field, and a
recent series of experiments at Petten indicate that neither m a y be the
second. These experiments indicated that a Lithium-6 thermal neutron
absorber of volume a few c m 3 can perturb the thermal neutron flux over
a large volume (i.e. a factor of 2 reduction or more within 2cm of the
detectors). Such a suppression will result in a significant reduction in the
induced g a m m a dose component and so the measurements will reflect
the incident g a m m a dose profile rather than the total incident plus
induced profile.

The measurements in Figure 5.9 are certainly suppressed with respect
to the total g a m m a dose, however whether the measurements follow the
trend of the incident dose needs a verification at depth where the
incident component falls off rapidly with thermal neutron flux. O n e would
expect the M O S F E T response to be relatively flat with depth in
comparison to the induced g a m m a dose profile - this is indeed seen in
later measurements with the head and torso phantoms. More will b e said
with regard to the M O S F E T results in series of measurements by
Cardan. ^^
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6.1 VARIABLE VOXEL MODELLING PROGRAM
6.2. Introduction
Routine treatment planning using the Monte Carlo technique is
becoming ever more possible with the development of increasingly
powerful computational hardware. This is applicable not just within the
field of Boron Neutron Capture Therapy, but in radiation therapy in
general. In the clinical situation, treatment plans must take into account,
amongst other factors, the individual patient geometry. This is typically
done by incorporating patient C T or MRI information and using surface
reconstruction techniques or with small rectilinear volume elements
termed "voxels".

The voxel based method typically suffers from being inherently
computationally intensive, however this problem m a y be overcome by
introducing a variable voxel size {see section 3.5.2). Regions of interest
may be specified where higher resolution anatomical structure and dose
catenations are required. Surrounding regions m a y be modelled with
lesser resolution, thereby reducing the overall computational effort
required. Applying the Los Alamos Monte Carlo code M C N P , version 3a,
with the use of supercomputing hardware enables dose calculations to
be performed in under 10hrs to a resolution of a few millimetres and
statistical accuracy of less than 5%. The results presented in this thesis
are for the h u m a n head and body phantoms (construction detailed in
sections 4.4.2. and 4.4.3. with results presented in chapters 7 and 8
respectively) with incident neutron spectrum and collimator geometry of
the J R C / E C N Petten epithermal neutron beam. In addition, treatment
plans are presented for the possible boron enhancement of

252

Cf

brachytherapy for cervical cancer. These calculations represent s o m e of
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the most complex voxel models to date and the first to incorporate a
variable voxel size.

In the past, simple geometrical shapes, such as the cylinder or ellipsoid,
have proved extremely useful models to benchmark b e a m parameters
and also for first order treatment planning. To move to a clinical situation
requires modelling for each individual patient. The Monte Carlo method
has gained favour within the radiotherapy community as the most
reliable technique to calculate dose distributions in complex geometries
and areas where low density material such as nasal cavities, throat
passages and lung tissues are present.20 T w o methods have been
developed to model 3 0 patient geometry from C T or M R I images. The
surface reconstruction method has been applied extensively by Wheeler
and Nigg 189 to B N C T treatment planning, whilst voxel reconstruction has
been applied by groups in conventional radiotherapy20 and BNCT. 185 - 259
Each method has its o w n advantages and disadvantages and these are
discussed extensively by Nigg.164 A comparison of results by both
techniques would undoubtedly help treatment planning in preparation for
clinical trials of Boron Neutron Capture Therapy (BNCT) and beyond.

The major advantage of the voxel reconstruction technique lies in its
generality and simplicity - images used in the reconstruction process are
already rastehsed, and so building the voxel model is computationally
quite simple. This enables reconstruction of complex geometries
including the brain, throat passages, lungs, the cervical region - indeed
any geometry. This is because nothing is assumed about the form of the
geometry to be modelled. The trade off for this generality has, in the
past, been at the expense of computational time. To avoid this trade off
it has to be recognised that within a patient not all areas require
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modelling and dose calculations to fine resolution. Introducing a variable
voxel size can help improve the calculational performance of the
technique, yet not at the cost of excessive computational effort.

6.3. Voxel Modelling Program

The modelling program, in Fortran 77, in Appendix III was written by the
author to take patient C T scans in a byte array format and output a
geometrical representation of the patient using the voxel reconstruction
technique. Currently the format of the output is suited to M C N P input
requirements, however it is envisaged that only minor modifications
would be needed to suit E G S 4 (the electron g a m m a shower Monte Carlo
code) input requirements. The user m a y tailor the input parameters to
suit individual modelling requirements. These include control of the
boundaries of the three "regions" of modelling - the innermost region
(number 3), a middle surrounding region (number 2), and an exterior
region (number 1). Voxel dimensions m a y be chosen independently in
each region allowing fine and coarse modelling volumes to be specified.
The user m a y also set the grayscale limits of the materials to be
modelled. Image files of the model are also output so that the user has a
quality control and m a y visually check that what has been modelled and
what the user thinks has been modelled are the same.

Section 1 of the authors modelling program defines the (many) variables
to be used in the program and the input parameters to be set by the
user. Many of these are not independent, however the programming was
made easier to write and read with the additional redundancy. The input
requirements for this program are that the patient images are in a single
byte per pixel format with binary image dimensions (eg 256*256, or
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512*512, or...). Images should be placed in a directory labelled 'a', with
the lowermost image labelled T , the next '2',

Data is read into a 3 0

array in the s a m e manner as the 3 0 visualisation software package
'Voxel-View'.260 With a right-handed orthogonal co-ordinate system
labelled (x,y,z), the first 256 bytes of slice 1 are placed in positions
(1,1,1), (2,1,1)

(256,1,1) respectively. The next 256 bytes of slice 1

are placed in positions(1,2,1), (2,2,1),

(256,2,1), and so on until the

final 256 bytes of slice 1 are placed in positions (1,256,1), (2,256,1),
(256,256,1) respectively. The first 256 bytes of slice 2 are placed in
positions (1,1,2), (2,1,2),

(256,1,2) respectively, until all slices have

been read into the 3 D array. The parameter 'zmax' equals the number of
slices and should be entered in section 1. The parameters 'xmax' and
'ymax' are the binary image dimensions (in pixels) and should also b e
entered in section 1.

Section 2 is a cumbersome way of simply opening a series of files
labelled 1 to 'zmax' in directory 'a' and reading them into a 3 D array. A
more elegant way would be preferred, however is yet to be found.
Section 3 marks the beginning of the actual voxel modelling process.
This section opens with the use of the 'xindex', 'yimtex'. and 'zindex'
variables. Each volume to be specified as a voxel will have a small 3 D
array of pixels from the original medical images within its bounds. Within
this 3 D array of pixels, the one closest to the origin is chosen as the
'index pixel' - xindex, yindex and zindex are the co-ordinates of this
index pixel. The do loops 9000, 8000 and 7000 cycle the z , y and x
dimensions respectively proceeding from index pixel to index pixel of
major groupings of pixels within the 3 D array. This is illustrated for a 2 0
example in figure 6.3.1. Within the outermost volume (region 1), these
major groupings of pixels become the voxels of the 3 0 model. Within the
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inner volumes (regions 2 and 3), these major groupings of pixels are
further subdivided to construct smaller voxels.
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Figure 6.3.1 T w o dimensional example showing how an array of pixels is divided into
major groupings of pixels and regions.

Section 3 of the program principally decides whether the index pixel of
the major grouping of pixels (and hence the grouping of pixels itself) is
in the fine modelling region( number 3), intermediate modelling region
(number 2) or the coarse modelling region (number 1).

The dimensions of voxels in each region, in terms of pixels in the
original images, must be specified in section 1. The parameter 'nopsvlx'
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represents the number of pixels per voxel in the x dimension in regionl.
With three regions and three dimensions there are nine parameters of
this type, each has to be specified. Additionally, parameters of the type
'subv2x' represent the number of voxels in region 2 in the x dimension
that m a k e up a major grouping of pixels. Divisions between the fine,
intermediate and coarse modelling regions are set by specifying values
to the parameters of the type xmin3 and xmax3. Any pixel between the
six limits (also considering the y and z dimensions) lies in region 3. Any
pixel inside the region 2 limits, but outside the region 1 limits, lies in
region 2. Pixels outside region 2 are in regionl.

Figure 6.3.2. illustrates, using a simple example, how these parameters
relate to each other and the voxel building process. The index pixel
starts at coordinate (1,1,1). This is found to be in region 1, so the 8x8
pixels in the voxel labelled '1' in figure 6.3.2 are all processed together
via the 1000, 2000 and 3000 do loops in section 4 of the program. They
are processed together because the variables 'xsfep', 'ncpsvx', and their
y and z counterparts are set accordingly in section 3. These variables
are used to instruct the 1000, 2000, 3000 series do loops to cycle
through all the pixels in the 8x8 major group.

This process is repeated for voxels labelled 2,3,4 and 5 in figure 6.3.2.
Following the processing of pixels in voxel 5, the n e w index pixel has
coordinates (9,9,1). This is found to be in region 2, so the xstep and
nopsvx variables (and their y and z counterparts) are set accordingly.
The only pixels to be processed into a single voxel (with the use of the
1000, 2000, and 3000 do loops) are those labelled voxel 6 in figure
6.3.2. Upon completion of creation of voxel 6, the index pixel cycles to
voxel 7, 8 and 9 (via the use of the 4000, 5000, 6000 do loop series)
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with each group being processed independently. T h e process is
repeated for the next major grouping of pixels that is subdivided into
voxels labelled 10,11,12 and 13. Voxels 14 and 15 are then processed
as region 1 voxels. T h e next index pixel becomes (9,17,1). This is found
to be in region 3, so the xstep and nopsvx type variables are set such
that the 4000, 5000, 6000 do loop series divides the major group of
pixels into 4x4 voxels. T h e pixels in each voxel are processed with the
1000, 2000, 3000 series do loops. T h e process continues with the
ordering of voxel construction indicated by the numbering in figure 6.3.
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The heart of the processing of each group of pixels to give a single
voxel is within the 1000, 2000, 3000 do loops. The pixels within the
voxel group are divided into grayscale 'bins' with upper limits set by the
parameters

'voidlim', 'lunglim', 'fatlim', 'muslim' and

'bonelim*.

Immediately following the 1000, 2000, 3000 do loops, the grey scale
range that possesses the most pixels in the voxel is determined. This
enables a material and density to be assigned to the voxel dependent
upon the most c o m m o n grayscale.

Section 5 establishes if tallies are required in a given slice. If a tally
required in a given voxel, that voxel number is written to a 1D array. All
voxels within that array have the s a m e material type - this effectively has
divided the voxels requiring tallies into material groups enabling the
application of K E R M A factors dependent upon material type. For
example the 1 0 array for bone voxels requiring tallies is labelled
'bonce!()'.

Section 6 of the program defines the geometry of the voxels in MCNP
input format. To define a rectangular volume with boolean operators six
planes are required. Planes perpendicular to the x axis are labelled
according to x pixel number with 1000 added, similarly y planes have
2000 added and z planes have 3000 added. Thus the specification of
voxel number 1 in figure 6.3.2. is written as:
1 'matno''density'1000 -1008 2000 -2008 3000 -3001.

The specification of voxel 29 in figure 6.3.2. is written as:
29'matno''density'1010 -1012 2022 -2024 3000 -3001.

•t
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Section 7 writes a uniform value, dependent upon material, to pixels in a
second 3 0 array at the identical location to the pixels currently being
analysed in the original medical images. This array is essentially the
voxel representation of the medical images. Viewing this array with
appropriate software (such as Voxel-View1260) enables the voxel model
to be observed - an important quality control. Section 8 completes the
4000, 5000, ... 9000 do loops with appropriate initialisation to enable
correct cycling between pixels, voxels, and major groups of pixels.

To complete the program, section 9 contains the calibration to enable
the M C N P planes to be defined in real space. Section 10 writes out the
telly voxels defined in section 5, and section 11 writes the images of the
voxel model to a directory labelled 'b' with file numbering and structure
equivalent to the requirements for the input medical image files. In
summary, the 7000, 8000 and-9000 d o loops cycle through major groups
of pixels, (8x8x1 in the simple illustration), the 4000, 5000 and 6000 do
loops cycle through voxels within each major group of pixels, and the
1000, 2000, and 3000 d o loops cycle through pixels from the original
medical images contained in each voxel. Considerable scope exists for
the user not only to vary parameters for individual models, but to insert
processing models tailored to the requirements of the images. For
example, the processing heart (section 4) would have to be adapted to
suit MRI images because of the different response to various tissues.

Upon running the MCNP calculation, the output consists of a data file
containing voxel numbers and tallies. To place these tallies in image
files in their correct spatial location, program

'drecon.f (dose

reconstruction) is used (see Appendix IV). This is a modification of the
model construction program. The most significant changes are in
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sections 6 and 7 - instead of writing an M C N P description of the current
voxel to file, the program finds the voxel number in the M C N P output file
and assigns the corresponding tally to ail pixel locations contained in the
current voxel. This effectively gives a 3 D array of M C N P tallies that
corresponds spatially to the original patient medical images. These two
data sets m a y be superimposed using a visualisation package such as
'Voxel-View*. The user has control over a wide range of visualisation
parameters including colour/grayscale spectrum, opacity, brightness,
contrast, lighting, view orientation, slice removal to n a m e a few.

Two dimensional treatment planning systems are able to use contour
lines to display dose information. This is not possible when displaying
3 0 dose calculations <as contour lines of course then b e c o m e surfaces).
The current clinical practice for 3 0 treatment planning software261 is to
display anatomical information in grayscale and dose/flux in colour providing an image that gives distinct visual discrimination between the
two data sets. Throughout this thesis (in correspondence with current
clinical practice) red corresponds to maximum dose/flux through the
visual spectrum to violet corresponding to minimum dose/flux on a linear
scale. Voxel-View gives the user complete control over choice of colour
code used. For example discrete colours m a y be used to define 3 0
isodose surfaces.
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7. WOLLONGONG HEAD PHANTOM

CT scans were taken at 5mm intervals along the inferior -superior

(bottom to top) axis of the prototype 'patient'. This patient consi

human skull with simulated tissue as described in chapter 5. The 42

images were modelled with parameters given in table 7.1. Effectivel
only two regions were applied - region 1 consisted of large voxels

outside the head, and region 2 consisted of smaller voxels consisti

4x4x1 pixels (5mm x 5mm x 5mm) making up the head itself. As can be

seen from the parameters, region 3 is a point and so has not been u

in this model. Figure 7.1. shows an x-y plane of the modelling proc
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Figure 7.1. X-Y plane illustrating the modelling parameters of the head phantom.
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Each voxel contains 16 pixels which were analysed to find the most
c o m m o n material type - either bone, brain, or cavity dependent upon
predetermined grayscale limits. Elemental composition and density were
taken from ICRU 46.249 To take into account molecular binding effects,
hydrogen was bonded as light water at 298K using the s(a,£) treatment

Parameter

Value

Parameter

Valu

xmax

256
256

yindex

1
1

voxno

subvlx

42
1

xmin3

0
65

subvly

1

xmax3

65

subvlz

ymin3

225

ymax3

225
1
1
66

subv3y

1
8
8
1
16
16

subv3z

1

ymin2

192
65

nopsvlx

ymax2

224

zmin2

1

nopsvlz

32
32
1

zmax2

nopsvZx

4

tlystel

42
31

nopsv2y

4

tlyslc2

0

nopsv2z

1

tlystc3

nopsv3x

2

tlyslc4

0
0

nopsv3y

2

tlyslcS

0

nopsv3z

1

tlyslc6

0

voidlim

20

tlyslc7

0

lunglim

20

lungceli

0

fatlim

20

fatceli

0

muslim*

180

musceli

0

bonelim

2S6

bonceli

0

xindex

1

ymax
zmax

subv2x
subv2y
subv2z
subv3x

nopsvly

zindex

zfflin3
zmax3
xmin2
xmax2

Table 7.1 Parameters used in section 1 of the modelling program for the head
phantom. <* Brain tissue)
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in M C N P . A saggital view of a 3 D reconstruction of the voxel model of
the head is shown in figure 7.2 - only bone tissue is displayed for clarity.
Figure 7.3 shows bone and soft tissues. These figures show that the
geometry has been modelled extremely well. Over 50 000 uniform size
voxels were used to model the 42 C T scans. Six compartmentalised
transverse planes are shown in figure 7.4 where bone, brain, muscle
and throat cavity voxels can be seen. Figure 7.5 shows six
compartmentalised saggital planes of the M C N P head model. Tally
voxels were designated as those in the z = 31 transverse C T scan
(figure 7.4b) and the x = 128 saggital plane (figure 7.5d). These
correspond with the detector tube array within the head phantom.

Figure 7.2. Saggital view of a 3D reconstruction of the voxel model of the head, only
bone tissue is displayed for clarity.

1

Figure 7.3. Saggital view of a 3 D reconstruction of the voxel model of the head
showing bone and soft tissues.

Figure 7.4 Six compartmentalised transverse planes of the M C N P model of the head
phantom. Bone, brain, muscle and throat cavity voxels can be seen.

131

Figure 7.5 Six compartmentalised saggital planes of the M C N P head model. Materials
are the s a m e as those in figure 7.4.

The epithermal neutron beam spectrum and collimator geometry used in
the Monte Carlo simulation were of the JRC/ECN Petten H F R facility in
the Netherlands. These were described in chapter 5. The head model
was irradiated from the left with the beam axis in the z = 31 slice of the
model (figure 7.6), 72.5mm from the back of the skull (figure 7.7). The
distance from the polybor beam exit to the surface of the skull was
19.5cm. T w o million source neutrons were simulated to reach a
statistical accuracy of 5 % for the dose in each voxel using 19hours C P U
time on a Fujitsu VP2200 supercomputer.
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Figure 7.6 The head model was irradiated from the left with the b e a m axis in the z = 31
slice of the model, 72.5mm from the back of the skull, at the site indicated.

Figure 7.7 The distance from the polybor beam exit to the surface of the skull was
19.5cm.
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Figure 7.8 depicts the thermal neutron flux distribution throughout the
head. The maximum is 6.8x108 neutrons/cm2/sec with normalisation of
1.9x1011 neutrons/sec from the source plane - as explained in chapter 4.
The spectrum is a linear scale with red corresponding to the maximum
flux. The epithermal neutron beam produces a maximum thermal
neutron flux several centimetres inside the head surface.

Figure 7.8. depicts the thermal neutron flux distribution throughout the head phantom.
The m a x i m u m is 6.8x10 8 neutrons/cm2/sec corresponding to red. The linear colour bar
chart shown is used in all similar figures (with specified maxima) throughout the thesis
and will not always be explicitly shown.
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Figure 7.9 and 7.10 show the epithermal and fast neutron flux
respectively. A s expected these show a m a x i m u m at the surface of the
model and a rapid reduction with depth. The m a x i m u m epithermal flux is
5.3x108 n/cm2/sec, whilst the maximum fast neutron flux is 4.5x107
n/cm2/sec. Adding all flux components gives the total neutron flux
distribution shown in figure 7.11, with a m a x i m u m of 1.0x109 n/cm2/sec.

Using KERMA factors for average brain tissue from ICRU 46, calculated
thermal, epithermal, and fast neutron dose rates (in Gy/hr) are given in
figures 7.12, 7.13, and 7.14 respectively. Total physical neutron
absorbed dose is given in figure 7.15. N o R B E has been applied in this

Figure 7.9 depicts the epithermal neutron flux distribution throughout the head
phantom. The maximum is 5.3x108 neutrons/cm^/sec.
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figure, although it would be a relatively simple task to incorporate RBE
as a function of energy. A high R B E of approximately 5 for fast neutrons
would significantly alter the R B E neutron dose distribution compared to
the physical dose distribution. As R B E factors are currently under
intense scrutiny (see Chapter 3), only physical doses are presented
here as the goal of this chapter is to demonstrate the viability of using
the Monte Carlo technique to perform 3 D dose calculations with models
based on patient scans. Even physical dose measurement is the subject
of continual review in conventional radiotherapy, let alone neutron
therapy. Without even considering R B E , this is often the source of
discrepancy between calculations and measurements.

Figure 7.10 depicts the fast neutron flux distribution throughout the head phantom. The
m a x i m u m is 4.5x10 7 neutrons/cm2/sec.
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Figure 7.11 depicts the total neutron flux distribution throughout the head phantom.
The m a x i m u m is 1.0x109 neutrons/cm2/sec.

Figure 7.12 shows dose due to thermal neutrons only. The m a x i m u m is 0.27 Gy/hr.
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Figure 7.13 shows dose due to epithermal neutrons only. The maximum is 0.14 Gy/hr.

Figure 7.14 shows dose due to fast neutrons only. The maximum is 0.72 Gy/hr.
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Figure 7.15 shows total neutron dose. The maximum is 0.92 Gy/hr.
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Figure 7.16 Induced g a m m a dose distribution throughout the head phantom. Maximum
= 1.9 Gy/hr.
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Figure 7.17 Dose distribution due to a uniform level of 30^g/g 10 B. Maximum = 5.2
Gy/hr.

1-41
Using J ^ R M A factors from Zamenhof et al,182 dose distributions for
induced g a m m a s and uniform 30u.g/g 1 0 8 are given in figures 7.16 and
7.17 respectively. Again the s a m e colour scale has been applied with
red corresponding to the maximum dose. The induced g a m m a dose is
widespread with a broad maximum of 1.9Gy/hr, slightly deeper than the
thermal neutron flux maximum. Assuming a uniform
30ng/g, the maximum

10

10

B distribution of

B physical dose is 5.2Gy/hr with spatial

distribution closely following the thermal neutron flux distribution. This
final dose component is delivered only to the site of accumulated

10

8-

this is the basis of B N C T selectivity. Recent advancements in boron MRI
and

PET

{Positron

Emission

Tomography) 16

offer

significant

improvements in determining the spatial distribution of this dose
component. This, however, is well beyond the scope of this project.

Phantom measurements to validate these calculations used gold foils,
PIN dosimeters and M O S F E T S (see chapter 5 and Carolan232S5). These
measurements and their equivalent calculations are shown in figures
7.18 to 7.26. Figure 7.18 shows saturation foil activity {see Chapter 5)
both measured and calculated for the transverse (beam) axis of the
head. Figures 7.19 and 7.20 display gold foil results for the anteriorposterior and superior-inferior axes respectively. These results show
excellent agreement between calculated and measured responses for
the uncovered gold foils indicating good thermal neutron modelling. For
the cadmium covered foils (responding only to energies above
0.414eV),

the

calculations

consistently

underestimate

the

measurements only at depth. This is also observed in the PIN dtode
measurements {responding dominantly to fast neutrons) and is
consistent with measurements in the cylinder phantom. As discussed in
Chapter 5, b e a m divergence is thought to b e the origin of this difference.
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Figure 7.18 Calculated and measured saturation gold activation along the transverse
(left to right) axis of the skull phantom. Uncovered and cadmium covered foils are
displayed, along with their difference. Solid lines are best fits to data.
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Figure 7.19 Calculated and measured saturation gold activation along the anteriorposterior (front to back) axis of the skull phantom. Uncovered and cadmium covered
foils are displayed, along with their difference.
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Figure 7.20 Calculated and measured saturation gold activation along the superiorinferior (top to bottom) axis of the skull phantom. Uncovered and cadmium covered
foils are displayed, along with their difference.

The results for the PIN diode ^responding dominantly to fast neutrons)
along the transverse axis, given in figure 7.21, are in reasonable
agreement. Discrepancies appear to be systematically increasing with
depth. This was also observed for the cylinder phantom and was
discussed in terms of beam divergence uncertainty. The behaviour of
PIN diodes is examined in detail by Cardan.23-255 Results for the
anterior-posterior and superior-inferior axes are given in figures 7.22
and 7.23 respectively. Calculated and measured results show good
correlation, however the discrepancy with depth is evident (these a^s
are orthogonal to the beam direction). Calculations used the silicon
damage K E R M A factors of the 1993 A S T M standards.256
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Figure 7.21 PIN diode response along the transverse <teft to right) axis of the skull
phantom. Calculations of silicon damage are also displayed as a function of depth.
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Figure 7.22 PIN diode response along the anterior-posterior (front to back) axis of the
skull phantomXSalculations of silicon damage are also displayed as a function of-depth.
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Figure 7.24- Induced gamma dose along the transverse (left-right) axis of the skull

phantom calculated using MCNP. Also depicted are the lithium covered MOSFET23-25
gamma dose measurements.
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Induced g a m m a dose calculations and measurements by the M O S F E T
devices are given for the three axes in figures 7.24., 7.25, and 7.26. As
discussd in chapter 5, the effect of the lithium-6 caps m a y reduce the
sensitivity to the induced g a m m a component, thereby rendering a flatter
measured dose profile reflecting the b e a m g a m m a component. This may
be the cause of the relatively flat profiles measured in these three
figures. Additional measurements along each axis for both the PIN and
M O S F E T detectors are required, but this was not possible with the
limited time with the Petten beam. Work with these detectors is
continuing with the Ph.D. project of Carolan.255-258
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Figure 7.25 Induced g a m m a dose along the anterior-posterior (front to back) axis of the
skull phantom calculated using M C N P . Also depicted are the lithium covered
MOSFET 2 3 - 2 5 8 g a m m a dose measurements.
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Figure 7.26 Induced gamma dose along the superior-inferior (top to bottom) axis of the
skull phantom calculated using MCNP. Also depicted are the lithium covered
MOSFET 23 - 258 g a m m a dose measurements.

7.2 Conclusion

Monte Carlo treatment planning for the cranial region, with modelling
from C T scans using the voxel technique, has been effectively
demonstrated. Agreement between calculations and measurements for
the Petten H F R beam using bare and cadmium covered gold foils is
generally within 5 to 10%, although beam divergence may explain why
measurements of cadmium covered gold foils at depth exceeded
calculations. Calculations also performed by the author relate to
experimental PIN diode and M O S F E T dosimeters. Characterisation of
these detectors is ongoing by Carolan.23-255'258
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8.

W O L L O N G O N G TORSO PHANTOM

Forty-Five CT scans along the bottom to top axis of a torso phantom
were acquired at 10mm intervals. The "region of interest" was specified
as the liver (the target organ) in addition to the front and right external
surface of the phantom in the region of the liver. Voxel modelling was
undertaken with modelling parameters given in table 8.1. Figure 8.1
shows a view of several C T scans of the liver region, whilst figure 8.2
shows the Monte Carlo model of this region. Tissues modelled included
adipose, liver and lung tissues with elemental composition according to
ICRU 46. Exterior and lung regions were grayscale indistinguishable in
the original images, so a program caHed 'seed' was written by the author
to distinguish between geometrically separate, but grayscale identical
regions. This program is detailed in Appendix V, 'Image Processing'.
The external regions were given the value T, whilst lung regions were
given the value '0', on a scale of 0-255, in the processed medical
images. This effectively mathematically distinguishes the two materials.

Voxels in the detailed region (figure 8.2) were modelled using just fou
pixels (2X2X1) from the original image, giving voxel dimensions of
3.86mm x 3.86mm x 10mm. Voxels in the surrounding region 2 were
modelled using 64 pixels (8x8x1) giving voxel dimensions of 15.44mm x
15.44mm x 10mm. As can be seen in figure 8.2, the liver and external
body contours have been modelled extremely well, this is essential if a
correct dose distribution is to be calculated. The body tissues and
surfaces away from the beam entry position have been modelled with
less resolution reflecting their secondary importance with dose
distribution within the liver. Slices greater than 100mm from the liver
were modelled with extremely large voxels incorporating 1024 pixels
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(32x32x1) with dimensions of 61.76mm x 61.76mm x 10mm. These
regions were deemed to have only a minor effect on the dose
distribution throughout the liver via backscattering. Although higher
resolution w a s achieved in the liver region in comparison to the head
model, only half thetotalnumber of voxels were used.

Parameter Value Parameter Value
xmax
ymax
zmax
subvlx
subvly
subvlz
subv2x
subv2y
subv2z
subv3x
subv3y
subv3z
nopsvlx
nopsvly
nopsvlz
nopsv2x
nopsv2y
nopsv2z
nopsv3x
nopsv3y
nopsv3z

256
256
46
1
1
1
4
4
1
16
16
1
32
32
1
8
8
1
2
2
1

yindex

1

zindex

1

voxno

0

xmin3

97

xmax3

224

ymin3

129

ymax3

192

zmin3

15

zmax3

24

xmin2

33

xmax2

224

ymin2

65

ymax2

192

zmin2

11

zmax2

32

tlysld

17

tlyslc2

18

tlyslcS

19

tlyslc4

20

tlyslc5

27

tlyslc6

28

voidlim

-

tlyslc7

29

lunglim

-

lungoeli

0

fatlim

120
2S0
256
1

fatceli

0

musceli

0

bonceli

0

musllm*
bonelim
xindex

Table 8.1 Parameters used in section 1 of the modelling program for trie whole body
phantom. {* Liver tissue)
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Figure 8.1 shows a view of several C T scans of the liver region of the whole body
phantom.

Figure 8.2 shows the Monte Carlo model of the liver region. The liver and surrounding
surface tissues are modelled extremely accurately. Coarse modelling has been applied
to regions of lesser importance.
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The epithermal neutron beam of the Petten HFR, as described in
Chapter 5, w a s used to irradiate the front surface of the phantom, in the
region of the liver, as shown in figure 8.3. This geometry was modelled
in M C N P using beam spectrum and collimator geometry as descibed in
Chapter 5. Tallies were performed in C T slices 17,18,19, and 20
covering the pancreas and liver regions where detector tubes have been
inserted. Tallies were also performed in C T slices 27,28 and 29 in the
lung and heart regions where detector tubes have been placed.

Figure 8.3 The epithermal neutron beam of the Petten HFR, w a s used to irradiate the
front surface of the phantom in the region of the liver.
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One million source neutrons were simulated, using 9hrs CPU time on a
Fujitsu V P 2 2 O 0 supercomputer, to give a statistical accuracy of dose
calculation in voxels in the region of the liver of less than 5 % . The dose
distribution throughout the liver due to a uniform distribution of 30jjg/g
10

B is shown in figure 8.4. The maximum physical (i.e. no R 6 € ) dose

rate is 6.7 Gy/hr. This distribution indicates that using multifield
irradiation m a y give adequate coverage over the entire liver. This dose
component is delivered only to the site of accumulated 10 B.

Neutron dose distribution to healthy tissue is given in figure 8.5. The
maximum physical dose rate is 1.2 Gy/hr at the surface of the phantom.
The neutron dose is dominated by the fast neutron component. Neutron
dose actually increases as the adipose/liver tissue boundary is crossed,
because the liver has significantly more nitrogen than adipose tissue.
Individual K E R M A factors have been used for the different tissue types
incorporated within the phantom. The liver neutron K E R M A is higher
than that of adipose tissue at the low energy end as a result of the
greater nitrogen content in the liver. This results in the increase in dose
as neutrons pass the low nitrogen / high nitrogen interface. The induced
g a m m a dose rate is, as expected, more widespread with a broad
maximumof 2.5Gy/hr (figure 8.6).

Gold foil measurements were taken along the 5 axes of the whole body
phantom. T w o orthogonal axes are in the lungs, two orthogonal axes are
in the liver and one in the pancreas. These are labelled:luf-

lung front

lis-

liver side

lus-

lung side

p-

pancreas

lif-

liver front
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Figure 8.4 Dose distribution throughout the liver due to a uniform distribution of 30>g/g
10

B. The m a x i m u m physical (no R B E ) dose is 6.7 Gy/hr corresponding to the red area

in the diagram. The linear colour/dose scale applied for the head phantom is also
applied for the torso phantom.
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M

kLA
i

Figure 8.5 Neutron dose distribution to healthy tissue. The m a x i m u m physical dose is
1.2 Gy/hr at the surface of the phantom.

Figure 8.6 The induced g a m m a dose is, as expected, more widespread with a broad
maximum of 2.5Gy/hr.
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The position and construction of these detector sites is detailed in
Chapter 4 - Phantom Construction. Considering the beam was being
applied along the liver front (lif) axis, most effort was aimed at
measurements along the lif and lis axes. Measurements along the other
axes (luf, lus, p) were of lower frequency as these were monitoring
"surrounding organ" doses only - outside of the target organ (the liver).
Ideally measurements at all sites with all detectors would have been
made, however this would have required beam time far in excess of
financial/time constraints of the Petten visit.

Figures 8.7 to 8.11 depict gold activation for the neutron spectrum below
than the cadmium cutoff energy (0.414eV), above the cadmium cutoff,
and total, for the five whole body phantom axes. Calculated results and
measured results for the Petten HFR

b e a m were processed as

described in chapter 4. Normalisation is also identical to chapter 4. The
lif axis coincides with the beam axis. As can be seen in these figures,
the g o W activation in the thermal range shows excellent agreement
between calculations and measurements. Results are also generally
good for the energy range greater than 0.414eV. As can be seen in
figures 8.9 and 8.10 of the lif <beam axis) and lis axes, the cadmium
covered gold foil measurements are greater than the calculations only at
depth. This is consistent with the discussion in previous chapters
regarding beam divergence uncertainty. In figures 8.7 and 8.8 (luf and
lus axes), these measurements were taken in the lung region, over
10cm outside the primary neutron beam targeting the liver. Radiation
intensity is thus much lower in the lung region resulting in higher error
measurements and calculations. This is not inconsistent with the clinical
aims of 5-10% accuracy which is applicable to the target volume only.
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Figure 8.7 Calculated and measured saturation gold activation along the 'luf axis of
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with their difference.
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whole body phantom. Uncovered and cadmium covered foils are displayed, along with
their difference.
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Figure 6.10 Calculated and measured saturation gold activation along the lis' axis of
the whole body phantom. Uncovered and cadmium covered foils are displayed, along
with their difference.

159

-14

£
o

i

CT
CQ
C

o
>
o
<
c
o
o
rs
o
m

-15

10

a Au (bare) MCNP
• Au (bare) measured

1 n-16
0

1

2

3

4

5

6

7

8

Depth ( c m ) rel.to p5, p axis

Figure 8.11 Calculated and measured saturation gold activation along the 'p' axis
the whole body phantom. Uncovered and cadmium covered foils are displayed, along
with their difference.

Figures 8.12 to 8.16 depict silicon damage rates (PIN response), both
calculated and measured, for the five whole body phantom axes. Results
are generally in excellent agreement on the liver axes (close to the
beam entrance). M C N P statistical errors and measurement errors are
high in the other axes away from the beam - this results because the
PIN diodes are dominantly responding to fast neutrons which are heavily
attenuated in regions far from the beam.

Figures 8.17 to 8.21 depict calculated induced gamma dose rates along
the five whole body phantom axes. Also shown are calibrated M O S F E T
responses to total (induced and beam) g a m m a dose. The response of
these devices is still being examined by Cardan.23-258
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Figure 8.12 PIN diode response along the 'luf axis of the whole body.phantom.
Calculations using the silicon damage KERMA factors256 are also displayed as a
function of depth relative to the phantom surface.
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Figure 8.13 PIN diode response along the 'lus' axis of the whole body phantom.
Calculations using the silicon damage KERMA factors256 are also displayed as a
function of depth relative to the phantom surface.
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Figure 8.14 PIN diode response along the 'lif (beam) axis of the whole body phantom.
Calculations using the silicon damage KERMA factors256 are also displayed as a
function of depth relative to the phantom surface.
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dose measurements.
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Figure 8.21 Induced gamma dose along the 'p' axis of the whole body phantom

calculated using MCNP. Also depicted are the lithium covered MOSFET23-2
dose measurements.
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8.2.

Conclusion

Monte Carlo treatment planning with modelling from C T scans using the
variable voxel technique has been effectively demonstrated. Agreement
between calculations and measurements using gold foils for the Petten
H F R beam is generally within 1 0 % within the target volume of the liver.
Experimental PIN diode and M O S F E T responses are also compared to
equivalent M C N P calculations by the author. These dosimeters are
analysed in detail by Carolan.23-255-258

•/

166
9.

M O N T E CARLO T R E A T M E N T PLANNING F O R B O R O N
NEUTRON

CAPTURE D O S E E N H A N C E M E N T OF *2Cf

BRACHYTHERAPY F O R CERVICAL CANCER.

Boron neutron capture has been proposed as a dose enhancement
mechanism for fast neutron therapy.262-263 Brachytherapy of cervical
cancer using 252Cf has been a major focus of interest.264 The Monte
Carlo technique can play a vital role in determining dose distributions in
cancerous and healthy tissues. In addition, the potential for dose
enhancement by incorporating 10B can also be evaluated.

The cervical region of a 'patient' was modelled using 20 256x268 CT
slices at 1<3mm intervals. The C T scans were acquired using a Varian
treatment simulator in CT mode. Using the voxel modelling technique as
described in previous chapters, the region of interest was chosen as a
singte horizontal C T slice containing a simulated implanted 252Cf source.
Materials modelled included bone .(whole femur, adult 30yrs249), skeletal
muscle {adult #a249) adipose tissues (adult #a249) and cavities. Figure
9.1 shows C T slice number 5 {fifth from the base of a stack of 20 scans)
which contains the 252Cf source. Figure 9.2 shows the M C N P model of
slice 5. This slice is the 'region of interest' with voxels being modeled
using just four pixels (2x2x1) from the original image. Voxels in this
region are of dimensions 3.86mm x 3.86mm x 10mm. By comparing
figures 9.1 and 9.2, it can be seen that the geometry of the cervical
region has been modelled extremely well.

Outside the region of interest, voxels of dimensions 7.72mm x 7.72m
10mm incorporated 16 pixels {4x4x1). CTscan number 10 is shown in -
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Figure 9.1 C T slice number 5 which contains the 252 Cf source.

mm

tsmisMam

Figure 9.2 The M C N P model of slice 5.
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Figure 9.3 C T slice number 10.

F
•
•i

Figure 9.4 The M C N P model of slice 10.

*
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Figure 9.5 C T slice number 15.

Figure 9.6 The M C N P model of slice 15.
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figure 9.3, with its M C N P model equivalent shown in figure 9.4. Even
with the larger voxels, the geometrical representation of the patient is
good. Similarly, C T scan number 15 is shown in figure 9.5, with its
M C N P model counterpart in figure 9.6.

A total of 28052 voxels were used to construct the entire model, with
tallies taken in 5857 voxels corresponding to the three planes just
depicted. O n e million source neutrons were simulated from a point
isotropic source, located in plane 5, with a Watt spontaneous fission
spectrum of the form p(E) = Cexp(-E/a)sinh(bE)1/2 (a=1.025 M e V ,
b=2.926 MeV- 1 ) corresponding to the

252

Cf emission spectrum. Total

running time on a Fujitsu V P 2 2 0 0 supercomputer was 9 hours with a
statistical error of less than 5 % for voxel flux and dose calculations
within a 1 0 0 m m radius of the source.

Figure 9.7 Thermal neutron flux distribution throughout the cervical region of slice 5.
Maximum = 1.05x10'2 neutrons/cm2/source neutron.
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Figure 9.8 Epithermal neutron flux distribution throughout the cervical region.
M a x i m u m = 7.7x10-3 neutrons/cm2/source neutron.

Figure 9.9 Fast neutron flux distribution throughout the cervical region. M a x i m u m =
4.4x10"1 neutrons/cm2/source neutron.
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Figures 9.7, 9.6, and 9.9 display the ther-mal, epithermal, and fast
neutron flux distributions respectively. For display purposes, each has
been normalised independently. T o compare magnitudes, figure 9.10
shows a cross section through A-B (see fig. 9.1) of the flux distribution.
Close to the ^ C f source, the fast neutron flux dominates, however
beyond approximately 4cm radius from the source, the thermal neutron
flux is the most significant component.

CM

10
Fast
Epithermal
Thermal

*

E
o

10° \-

10

-1

QJ

O

c

10

CD

10

-2
-3

C

o
-

-4

10

CD

10

-5

>

2

10

-6

15

-10

-5

0

5

10

15

Depth (cm) Relative to 252Cf Source

Figure 9.10 Neutron flux distribution cross section through A-B enables comparison of
magnitudes between the thermal, epithermal and fast energy groups.

Using K E R M A factors for bone, adult skeletal muscle, and adipose
tissue from ICRU 46249, the neutron dose profile through A-B is shown in
figure 9.11. W h e n shown on a linear scale overlaid on the C T scan, the
highly localised nature of the neutron dose can b e seen (figure 9.12).
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Figure 9.11 also displays the 30jig/g 10B and induced gamma dose
profiles calculated using the K E R M A factors of Zamenhof et al.182 A s
with previous chapters, 10 B is not explicitly included in the M C N P model
- the dose in any given voxel is obtained by convolving the calculated
neutron spectrum with the 10 B K E R M A factors.182 The 10 B and induced
g a m m a ray dose components are less localised than the neutron dose.
This is also shown in the 2 D distribution of the 10 B dose (figure 9.13)
and the induced g a m m a dose (figure 9.14).

Although the thermal

neutron flux exceeds the fast neutron flux beyond 4 0 m m from the
source, the 10 B dose does not exceed the neutron dose (figure 9.11) as
a result of the high fast neutron K E R M A . Local variations in the neutron
dose, particularly around -15cm to -10cm are due to differing K E R M A
factors being appliedtobone voxels in this region.
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Figure 9.11 Neutron dose, 30u.g/g

10

B dose, and induced gamma dose profiles throu

A-B. The latter two are much less localised than the neutron dose.
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Figure 9.12 Neutron dose distribution throughout slice 5. The
plane. M a x i m u m = 9.3x10

-12

252

Cf source is in this

Gy/source neutron.

Figure 9.13 Dose throughout slice 5 due to a uniform distribution of 30u.g/g
M a x i m u m = 2.62x10" 14 Gy/source neutron.

10

B.
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Figure 9.14 Induced g a m m a dose distribution throughout slice 5.Maximum =1.31x10- 14
Gy/source neutron.

Figure 9.15 Dose throughout slice 10 due to a uniform distribution of 30u,g/g 1 0 B. Scale
as for 1 0 B dose in slice 5.
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Figure 9.16 Induced g a m m a dose distribution throughout slice 10. Scale as for g a m m a
dose in slice 5.

Figure 9.17 Dose throughout slice 15 due to a uniform distribution of 30u.g/g 1 0 B. Scale
as for 1 0 B dose in slice 5.
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Figure 9.18 Induced g a m m a dose distribution throughout slice 15. Scale as for g a m m a
dose in slice 5.

Boron-10 and induced g a m m a dose distributions in C T slice 10 (50mm
above the source plane) are shown in figures 9.15 and

9.16

respectively. Results are normalised with the corresponding doses in C T
slice 5. Doses to surrounding healthy organs can be evaluated.
Superimposed colour on any given organ is simply matched to the
colour bar chart then scaled for red corresponding to the given
maximum. (The dose/flux colour display scheme in this chapter is
identical to that given in previous chapters) Similarly for C T slice 15,
which is 1 0 0 m m above the source plane, 30|ig/g

10

B and induced

g a m m a dose distributions are shown in figures 9.17 and

9.18

respectively.

Taking the ratio of dose including 10B to dose excluding 10B as a function
of position along the profile A-B gives the results shown in figure 9.19.
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This shows that by incorporating 30ng/g i°B, dose may be enhanced by
up to 3 0 % at approximately 100mm from the source (assuming O^g/g 10 B
in the healthy tissue).
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Figure 9.19 Ratio of dose incl. 1 0 8 to dose excluding 1 0 B along the profile A-B. 30(ig/g
10

B m a y enhance dose by up to 3 0 % at approximately 1 0 0 m m from the source.

Considering a tumour of radius 2 5 m m with the2S2 Cf source at the centre,
the maximum dose to healthy tissue will occur just beyond the periphery
of the tumour (because this is where the healthy tissue is closest to the
source). Thus the maximum

dose to healthy tissue will be given by the

total non-10B dose at a radius of 25mm

from the source. Thus taking

total dose (including 10 B) divided by the healthy tissue dose at 2 5 m m
gives the therapeutic ratio as a function of radius. This is shown in figure
9.20. This figure shows that disseminated

10

8 loaded cancer cells
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beyond the 2 5 m m radius tumour margin will receive a dose greater than
the maximum dose to healthy tissue if they are within 1-2mm of the
tumour surface, ie. where the therapeutic ratio is greater than unity.
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Figure 9.20 Total dose (including 10 B) divided by tine healthy tissue dose at 2 5 m m
gives the therapeutic ratio as a function of radius. This figure shows that disseminated
10

B loaded cancer cells beyond the 2 5 m m radius tumour margin will receive a dose

greater than the maximum dose to healthy tissue if they are within 1-2mm of the
tumour surface, ie. where the therapeutic ratio is greater than 1.

For a 5 0 m m radius tumour, the therapeutic ratio as a function of depth
(with maximum healthy tissue dose occurring at 5 0 m m ) is shown in
figure 9.21. It can be seen for this larger tumour size, disseminated

10

B

loaded cancer cells within 5 m m of the tumour surface will receive a dose
greater than the maximum to healthy tissue. Similarly in figure 9.22, for a
100mm

radius tumour, the therapeutic ratio exceeds

approximately 7 m m beyond the tumour surface.
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Figure 9.21 For a 50mm radius tumour, the therapeutic ratio as a function of radius is
shown. For this larger tumour size, disseminated 10B loaded cancer cells within 5mm of
the tumour surface will receive a dose greater than the maximum to healthy tissue.
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Figure 9.22 The therapeutic ratio for a 1 0 0 m m radius tumour exceeds 1 for the
greatest distance beyond the tumour margin (7mm) where the 10B dose is at its largest
proportion of the total dose. This occurs at approximately 100mm radius.
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This expansion represents a 2 0 % increase in treatment volume beyond
the tumour periphery. The therapeutic ratio exceeds 1 for the greatest
distance beyond the tumour margin where the 10 B dose is at its largest
proportion of the total dose. This occurs at approximately 1 0 0 m m radius.
These results are summarised in figure 9.23 which shows treatment
margin and average therapeutic ratio in the treatment mar-gin as a
function of tumour radius.
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Figure 9.23 Treatment margin and average therapeutic ratio in the treatment margin as
a function of tumour radius.

9.2.

Conclusion

Although 30ng/g 10 B m a y enhance the tumour dose by up to 3 0 % , a
positive therapeutic ratio cannot be maintained for large distances
beyond the surface of the tumour because of the rapid reduction in dose
with distance from the neutron source. Although a simplified

10

8

biodistribution of 30ng/g in tumour cells and 0\tg/g in healthy cells has
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been assumed, the magnitude of these results would not be altered by
taking more realistic biodistribution data. This leads to the conclusion
that

10

B can only have a

dose enhancement effect for very large

tumours w h e n used in conjuction with 252 Cf fast neutron brachytherapy.
Although this dose enhancement effect is small in linear terms, the
improvement

in effective treatment volume can approach 3 0 % .

Peritumour recurrence m a y
enhancement for large tumours.

•/

be significantly reduced with boron
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10.

T R E A T M E N T P L A N N I N G F I G U R E S O F M E R I T IN T H E R M A L

A N D EPITHERMAL B O R O N

NEUTRON CAPTURE THERAPY

OF

BRAIN T U M O U R S

10.1 Introduction

Glioblastoma multiforme (high grade astrocytoma) is characterised by a
main tumour mass with accompanying fingerlets which infiltrate
surrounding healthy tissue. These rapidly growing fingerlets render the
theoretical"cell specifity of B N C T an attractive possible treatment
modality for this form of brain cancer. Hatanaka et ai67-255 have
conducted clinical studies in Japan which suggest that B N C T with
thermal neutrons may offer greatly improved prognoses for patients
suffering from glioblastoma multiforme. Patients participating in the
Japanese B N C T study are treated intraoperatively in an attempt to offset
to some extent the poor penetrability of thermal neutrons, but those
patients in w h o m the deepest tumour margins exceed 6 c m in depth from
the cortical surface are classed as "unfavourable cases". The boron
requirements necessary for the control of these deep seated tumours in
thermal and epithermal B N C T is the subject of this chapter.

Many dose distribution studies have focussed upon the effects of beam
characteristics, particularly energy and diameter, including McGregor
and Allen,163 and Yanch et al.184 Zamenhof et al266 analysed beam
performance figures of merit as a function of boron tumour to blood ratio
and boron concentration. This detailed boron analysis used a one
dimensional, discrete ordinates transport code called

ANISN 2 6 7

incorporating a homogeneous rectangular slab model of the human
head. Later studies by Zamenhof et al182 resulted in the treatment
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planning system N C T P L A N based upon an ellipsoidal "skull/brain"
model of the h u m a n head using the 3 D Monte Carlo Neutron Photon
transport code M C N P . Although b e a m performance figures of merit were
analysed for several 10 B tumour to blood ratios and concentrations in
Zamenhof et al182, a more detailed examination of the effect of varying
these parameters is presented here. The same transport code ( M C N P )
and skull/brain model are employed. In addition, particular attention is
paid to published boron uptake data202 in tumour and blood for D,L,-pboronophenylalanine (BPA) and boron sulfhydryl (BSH) in humans.
Boron requirements necessary to treat the mid-line of the brain are
evaluated and the concepts of Modified Advantage Depth and Maximum
Therapeutic Depth, associated with the reduced capillary dose of
BSH 268 - 203 are also applied.

10.2 Method

10.2.1. Model for Monte Carlo Based Dose Computations

Using the MCNP (Monte Carlo Neutron Photon) transport code, the
human brain and its surrounding structures were modelled using the
geometry originally described by Snyder.269 The Neutron Photon Brain
Equivalent (NPBE) Monte Carlo model consists of two non-concentric
three dimensional ellipsoids. Using a cartesian coordinate system, the
Z-axis is defined as the patient's superior-inferior axis, the X-axis is the
lateral axis, and the Y-axis the anterior-posterior axis. Defining the
volume of the brain, the inner ellipsoid is represented by the equation:<X/6)2 + (Y/9)2 + (Z/6.5)2 - 1 = 0
An outer ellipsoid, represented by:<X/6.8)2 + <Y/9.€)2 + <{Z+13/8.3)2 - 1 = 0
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forms the exterior surface of the skull which surrounds the brain. X,Y
and Z are in cm.

Numerous measurements using X-ray computed tomography scans of
patients heads have indicated that the N P B E model is indeed closely
representative in dimensions to the average human adult brain and
skull.182

Figure 10.1 The central sagittal plane of the head model superimposed on a human
skull cross section. This figure shows how the head model simulates a human head.

This close representation can be graphically seen in figure 10.1,
courtesy Liu.270 The brain volume enclosed by the inner ellipse is
1470cm3, whilst the total bone volume is 847cm3. These volumes are
typical of the average human brain and skull. The elemental composition
and densities were that of average brain and skull as used by Zamenhof
et.al.182 Cells of 0.125cm3 were constructed along the axes of the model.
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These were used as elementary volumes by the Monte Carlo simulation
to record neutron and photon fluxes resulting from incident neutrons.
Approximately 100,000 neutrons were run in each simulation, using
30min C P U time on a Fujitsu VP2200 supercomputer.

An 18.4cm diameter neutron beam was applied from a lateral aspect
onto the N P B E model. This "idealised" beam consists of a current of
monoenengetic neutrons. T w o cases were run, a 0.025eV thermal beam,
and a 35eV epithermal beam. 35eV corresponds to the minimum point
on the brain tissue neutron kerma curve. Undesirable contaminating
radiation such as fast neutrons, reactor core gammas, and induced
gammas

from structural materials were not included

in these

calculations. The cose components from these ideal b e a m s include:

1. epithermal neutron dose, principally resulting from 1H<n,n')1H
epithermal neutron scattering reactions,
2. thermal neutron dose, resulting from

14

N<n,p)14C thermal

neutron capture reactions,
3. tissue induced g a m m a

dose, principally resulting from

^(n.y^H thermal neutron capture reactions, and
4. Boron-10 dose, resulting from

10

B<n,a)7Li thermal neutron

capture reactions.

10.2.2. Fluence to Dose Conversion and Choice of RBE Factors

Photon and neutron fluences computed for each tally are normalised per
source neutron. These fluences were converted to dose (Gy) per source
neutron using K E R M A factors of Zamenhof et al.182

1<

B doses were

computed implicitly, ie 1 0 8 was not actually included as part of the brain
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material composition. These doses were calculated by spectrally
integrating neutron fluence convolved with the

10

B K E R M A factors.

Zamenhof et al182 have shown that excluding 1 0 8 in such a manner only
introduces errors "similar to, or less than, the statistical errors of the
Monte Carlo calculations themselves".

All doses used in this chapter are the product of absorbed dose and
assumed R B E values. R B E factors were taken from Zamenhof et al182
and are as follows:

Radiation Tvoe

Recommended R 8 €

Epithermal Neutrons

1.6

Thermal Neutrons

1.6

G a m m a Rays, single Dose

1.0

10

2.3

8 Reaction

it is acknowledged that the neutron RBE of 1.6 is lower than that quoted
and applied elsewhere in this thesis. These calculations were performed
and submitted for publication51 in 1992. Since this time the subject of
R B E in B N C T has undergone much investigation, discussion and
revision. This is expected to continue for the foreseeable future.

10.2.3. Definiton of NCT Dosimetric Terminology

Dosimetric criteria and figures of merit have been developed for neutron
beam quality and treatment planning in B N C T . These include:
1 ."Advantage Depth"(AO) - depth at which dose to tumour equals
maximum dose to healthy tissue.
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2."Therapeutic Depth"(TD) - depth at which dose to tumour
equals twice the maximum dose to healthy tissue.202
3. "Modified Advantage Depth" (MAD) - in the case of BSH, the
Capillary Dose

Reduction

Factor (CDF) of 0.3, derived

from

microdosimetry calculations, must be incorporated.202-203-268 The M A D is
the depth at which the dose to tumour equals maximum dose to healthy
tissue with C D F = 0.3 included.
4. "Maximum Therapeutic Depth" (MTD) - depth at which the dose
to tumour equals twice the C D F modified maximum dose to healthy
tissue.202-68
5. "Therapeutic Ratio" (TR) - ratio of tumour dose to maximum
healthy tissue dose.

Maximum healthy tissue dose is considered in the brain volume only, not
the skull, as brain capillary endothelia are considered to be the dose
limiting tissue. In thermal B N C T , the scalp is the dose limiting tissue.
However, this is spared by reflection and withdrawal of scalp tissue from
the beam.67-265 Thus the depths used in this chapter are relative to the
brain surface. Advantage Depth is equivalent to the Maximum Usable
Depth with a Therapeutic Ratio of 1.0 applied by Zamenhof et al.266
These authors also examine the effect of relaxing the therapeutic ratio to
0.5. In effect, this becomes the depth at which dose to tumour equals
half the maximum dose to healthy tissue which is opposed to clinical
requirements. This chapter examines the effect of a Therapeutic Ratio of
2.0. Such a restriction results in dose to tumour equal to twice the
maximum dose to healthy tissue and is more in line with clinical
requirements. A s such this Figure of Merit is termed the "Therapeutic
Depth".
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10.3. Results and Discussion

10.3.1. Thermal Beam

Figures of merit for the thermal beam have been calculated along the
lateral (beam) axis of the N P B E model. Figure 10.2 displays the AD, TD,
M A D and M T D figures of merit as a function of blood 10 B concentration.
The A D and T D are evaluated for a Tumour to Blood 10 B ratio (T/B) =
4.3, characteristic of BPA.202 As can be seen, the A D and T D increase
3.5
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Blood Boron Concentration micro g / g

Figure 10.2 Figures of merit for the 0.025eV thermal neutron beam as a function of
blood 1 0 B concentration. For the Advantage Depth and Therapeutic Depth, the tumour
to blood 1 °B ratio is held constant at 4.3 typical of 8PA. For the M a x i m u m Advantage
Depth and Modified Therapeutic Depth, a 0.3 Capillary Dose Reduction Factor has
been incorporated with the tumour to blood 1 °B ratio held constant at 1.4, typical of
BSH.
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strongly with 10B concentration in blood independent of the tumour to
blood

10

B ratio. To deliver the s a m e tar-get dose to the tumour for a

higher boron concentration, a shorter irradiation time is required. This
results in a lower dose to healthy tissues due to reduced non-boron
dose components which increases the A D and TO. Regarding this,
Coderre et al158 state "These are very important aspects of B N C T
radiobiology, essential for planning patient trials, that are commonly
misunderstood".

Beyond 10(ig/g (parts per million by mass) boron in the blood, both
tumour and healthy tissue doses are dominated by the boron dose
component. Increasing 1 0 8 concentration without altering the tumour to
blood ratio can thus only increase the tumour and healthy tissue doses
at proportionately the s a m e rate. This results in asymptotic A D and T D
values of 3.2cm and 1.4cm respectively beyond lOyo/g blood 10 B.
Although not modelled here, one would expect a reduction in the figures
of merit associated with boron levels extending beyond 1O0ng/g in the
tumour due to neutron flux perturbation.182 Thus whilst it is necessary to
increase the B P A level to 10|ag/g 10 B in the blood to achieve maximum
figures of merit, increasing the 1 0 8 level further produces insignificant
benefit, or m a y even decrease the effectiveness of the treatment at
much higher concentrations.

The MAD and MTO also shown in Figure 10.2 are evaluated for a
tumour to blood 10 B ratio of 1.4 and a C D F of 0.3 characteristic of B S H
in normal brain.202 D u e to the C D F , the effective 10 B blood concentration
is 0.3 times the actual level in the blood. Thus, the figures of merit do
not reach a maximum until approximately the 30ng/g blood 10 B level, as
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opposed to 10n>g/g for BPA. At the 30p£/g blood level, the M A D is
3.25cm, whilst the M T D is 1.35cm - approximately equivalent to the
limiting A D and T D values of BPA. The equivalence of figures of merit
between B S H and B P A is in agreement with calculations by Gavin et
al271 and Allen.202 Beyond SO^g/g, the healthy tissue capillary dose is
dominated by the 10 B dose component, resulting in constant M A D and
M T D values. A 30|ig/g blood 10 B level throughout the entire brain m a y
incur a significant flux perturbation, however B S H does not pass the
blood brain barrier, so a much lower healthy tissue boron level occurs
with negligible flux perturbation.

10.3.2. Epithermal Beam

Figure K).3 shows AD and TD for T/B=4.3 as for BPA202 as a function of
blood

10

B concentration for the epithermal beam. As for the thermal

case, an initial rise is followed by a levelling in the figures of merit at
approximately K3|j.g/g. At this point, the epithermal Advantage Depth has
a value of 7.3cm, whilst the Therapeutic Depth extends to 5.2cm. The
Modified Advantage Depth and Maximum Therapeutic Depth for T/B =
1.4 as for BSH, 2 0 2 also illustrated in figure 10.3, follow a similar pattern.
Little benefit is exhibited beyond 30jj<g/g blood 10B at which point the
M A D is 7.5cm and the M T D is 5.4cm - close to the epithermal A D and
T D values of BPA. This equivalence in epithermal figures of merit
between B S H and B P A is in agreement with calculations by Gavin et
al.271

Table 10.1 gives a comparative summary of the major results of this
study. A s expected, the figures of merit are far superior for the
epithermal beam. Ateocatoulated are the tumourtoblood boron ratios of
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Figure t0.3 Figures of merit for the 3SeV epithermal neutron beam as a function of
blood 1 0 B concentration. For the Advantage Depth and Therapeutic Depth, the tumour
to blood 1 °B ratio is held constant at 4.3 typical of BPA. For the Maximum Advantage
Depth and Modified Therapeutic Depth, a 0.3 Capillary Dose Reduction Factor has
been incorporated with the tumour to blood t^B ratio held constant at 1.4 typical of
BSH.

BPA required for the TD to reach the midline of the brain. Note that for
the thermal beam, a required ratio of 25 is far in excess of the currently
achievable 4.3 in humans. T h e epithermal requirement of 5.7 however,
is only marginally above this level. Similarly, the tumour to blood boron
requirement for the M T D of B S H to reach the brain midline is 8.5 for the
thermal b e a m and 1.9 for the epithermal beam. The latter value is again
only marginally above currency achievable levels.
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BSH*

jn/fg|=1.4

fB130n9/g

BPA

m/fBl=4.3

[BUOug/g

MAO(cm^

MTP(cm)

Reg. T/B

AD(.cm)

TD/cm
is±

Reg. T/B

Thermal
(0.O25eV)

3.3

1.5

8.5

3.2

1.4

25

7.5

5.4

1.9

7.3

5.2

5.7

Epithermal
(3SeV)

* 0.3 capillary dose reduction factor Incorporated

Table 10.1 Figures of merit for B S H (tumour to blood
of 30ng/g) and B P A {tumour to blood

10

10

B ratio is 1.4 with a blood level

B ratio is 4.3 with a blood level of 10fig/g)

whilst using monoenergetic thermal (0.02SeV) and epithermal (3SeV) neutron b e a m s .
T u m o u r to blood ratios required to extend therapeutic depths to the midline of the brain
are also s h o w n , with 30|xg/g blood
Tumour

10

10

B for B S H and 1^g/g blood

B concentration (ng/g), IB] = Blood

10

10

B for B P A . fT] =

B concentration (yg/g).

Assuming a worst case scenario of a tumour situated near the midline of
the brain, Figure 10.4 (thermal) illustrates the depth dose profile for the
0.025eV beam using the currently achievable T/B of 4.3 for B P A with
lOpg/g in the blood. As can be seen in the local region of the tumour
(5.25-6.25cm), the dose selectivity is high, however the large dose near
the beam side surface of the brain negates any beneficial tumour dose.
At this deep level, a tumour to blood boron ratio of 25:1 is required (with
10ng/g i°B in the blood) to give a Therapeutic Ratio (TR) of 2. Such a
situation is unlikely with current boron compounds in clinical use. The
depth dose profile for B S H with a tumour to blood

10

B ratio of 1.4,

30ng/g blood IOB and 0.3 C D F is almost identical and is not displayed.

Repeating the above case but with the 35eV epithermal beam gives a
depth dose profile shown in figure 4 (epithermal). Again the dose to the
tumour is highly localised, but the surface dose sparing characteristic of
the epithermal beam has resulted in a much more favourable overall
dose distribution. Whereas the T R is mar-ginally less than 2 at mid-brain,
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a T R of more than 3 for tumours at approximately 3cm depth m a y be
possible with current boron drugs. These therapeutic ratios will increase
markedly with improvements in boron selectivity.
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Figure 10.4 Dose rate (RBE Gy/neutron) along beam axis vs. depth for 10ng/g blood
IOB and 43*ig/g tumour 108 (T/B = 4.3 for BPA) - tumour site 5.2S to 6.2Scm from orain
surface. Oose profiles for the thermal and epithermal beam are shown. This study has
only 0.5cm resolution. The transition from tumour to healthy tissue dose is expected to
be much sharper. B S H dose profiles for 42^ig/g tumour and 30M.g/g blood (T/B = 1.4)
with a 0.3 Capillary Dose Factor are very similar and thus not shown.

10.4. Conclusion

An 18.4cm diameter idealized neutron beam incident upon an ellipsoidal
neutron photon brain equivalent model w a s simulated using the Monte
Carlo Neutron Photon transport code. Monoeneroetic beams of 0.025eV
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(thermal) and 35eV (epithermal) were studied. The BNCT figures of
merit of Advantage Depth, Therapeutic Depth, Modified Advantage
Depth, and Maximum Therapeutic Depth were investigated as functions
of tumour to blood 10 B ratio and absolute levels of 10 B.

All figures of merit improved with an increasing tumour to blood 10B ratio.
10

B concentration at lower levels was shown to have a strong influence

on the figures of merit. This is due to the presence of the non-boron
dependent background dose components. These trends were also
observed by Zamenhof et al.266 For a tumour to blood

10

B ratio of 1.4

with a 0.3 C D F , characteristic of BSH, little advantage is gained beyond
a blood

10

B level of 30^g/g. In this case MAD=3.25cm, whilst

MTO=1.35cm for the thermal beam. Similar values for the A D and T O
are found with the thermal beam for B P A with a 4.3 tumour to blood 10 B
ratio and limiting 10^g/g blood level. These results are consistent with
those of Allen.203 This equivalence between the B S H and B P A figures of
merit w a s also observed for the epithermal beam. In this case however,
increased values of MAD=7.5cm and MTD=5.4om were found. For the
10

B ratios used by Zamenhof et al182, agreement was within 5%, the

statistical error of these calculations.

To achieve a therapeutic depth of 6cm, (brain midline) a tumour to blood
10

B ratio of 25 with 10ng/g 10 B in the blood is required for B P A using the

thermal beam. This ratio is five times current average results in humans.
Similarly, a ratio of 8.5 with 30ng/g blood 10 B is required for the M T D of
B S H to reach the brain midline. H u m a n data are again well below this
value. The epithermal b e a m with BPA, however, requires of a tumour to
blood

10

B ratio of 5.7 with blood level of 10fig/g for the Therapeutic

Depth to reach the brain midline. The comparable requirement for B S H
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is a tumour to blood ratio of 1.9 with 30|ig/g Wood

10

B. Average human

tumour to blood ratios of 4.3 for B P A and 1.4 for B S H are only
marginally below these requirements. These 10 B requirements are lower
limits as beam g a m m a and fast neutron components are not included in
this study. Results, however, would be improved by bilateral irradiation
and intake of heavy water. The effect of these factors is examined in
Chapter 11.
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11.

T H E BENEFITS O F H E A V Y W A T E R F O R
BORON NEUTRON CAPTURE THERAPY

11.1. Introduction

The neutron scattering and absorption properties of deuterium are quite
different to that of hydrogen. The absorption macroscopic cross section
for heavy water is 757 times smaller than that of water, whilst the
diffusion length is 62.5 times greater for heavy water. The impact of
deuterium replacement of hydrogen on neutron transport has been
studied by Levine et al,274 Slatkin et al,276 and Kiszenick et al.276 In
biological applications, deuterium is best used as heavy water.
Deuteration in m a m m a l s has been extensively studied277'278'279'280-281 with
conclusions that transient partial deuteration of body water is slightly to
severely toxic to mice at the 20-50% level, whilst long term deuteration
is toxic at the 3 0 % level. Blagojevic et al282 report heavy water
concentrations in humans of up to 2 3 % with no observed toxicity.
Moderate deuteration (20%) of body water provides partial protection
against whole body low L E T radiation from hydrogen capture278-281'283'284
but not high L E T radiation from the 10 B capture reaction.284

The BNCT mechanism requires two vital occurrences for success, i)
selective boron accumulation within the cancerous tissues, and ii)
adequate thermalised neutron flux penetration. W h e n limitations in the
efficacy of B N C T with thermal neutrons became apparent in the clinical
studies of Hatanaka,68 heavy water replacement of light water w a s
practiced in an endeavour to enhance the maximum therapeutic depth
for thermal B N C T . Inclusion of heavy water in tissues significantly
increases thermal neutron transmission with reduced capture g a m m a
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ray absorbed dose rates,285 thus significantly improving the likelihood of
therapeutic treatment and impacting on 10 B requirements.

This chapter evaluates treatment planning figures or merit as a function
of heavy water replacement and tumour to blood boron ratios. Using
M C N P , Monte Carlo calculations were performed using an ellipsoidal
heterogeneous skull/brain equivalent model as described in chapter 9.
Advantage Depth and Therapeutic Depth parameters are studied as a
function of D 2 0 replacement ranging from 0 to 2 0 % (molar). Ideal
thermal (0.025eV) and epithermal (2-7keV) beams are examined with
10

B tumour to blood ratios ranging from 1 to 10. Particular attention is

paid

to effective

10

8

uptake

ratios in humans 2 0 2

of D,L,-p-

boronophenylalanine (BPA) and Boron Sulfhydryl {BSH), and their
requirements for therapeutic treatment of the midline of the brain.

For a practical reactor based epithermal neutron beam, thermal neutron
flux and induced g a m m a depth dose distributions calculated for
standard brain and skull materials and 2 0 % D 2 0 replaced materials.
Results are presented for both unilateral and bilateral irradiation with
spectrum and collimator geometry of the Petten H F R epithermal neutron
beam.2S3-2S4(see chapter 4) The therapeutic ratio as a function of depth
is also examined and compared for 0 % and 2 0 % D 2 0 .

11.2. Method

11.2.1. Model for Monte Carlo Based Dose Computations

Using the MCNP transport code, the human brain and its surrounding
structures were modelled using the geometry described in chapter 9.
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The elemental composition and densities of the 0 % D 2 0 model were that
of average brain and skull as published in ICRU Report 46.249 To
include molecular effects upon thermal neutron scattering, the 1 H within
the skull and brain materials was modelled as light water using the
thermal neutron S(a,b) tables within M C N P .

Tally volumes of 0.125cm3 (0.5cm cubes) were constructed along the
axes of the model. These were used as elementary volumes by the
Monte Carlo simulation to record neutron and photon fluences resulting
from incident neutrons. Measurement volumes were chosen on the basis
of the results of Storr,286 showing that using too large a tally volume
(>1cm 3 ) results in erroneous Advantage Depth calculations.

11.2.2. Heavy Water Replacement

Deuterium was introduced via replacement of hydrogen in the elemental
composition of the constituent materially) of the models. 2 0 % heavy
water corresponds to 2 0 % molar replacement of the entire hydrogen
content of the material with deuterium. Equilibration of heavy water in
areas of the body with differing permeability, as assumed with the
elliptical model, takes place within 2 to 3 hours with a half-life in the
body of about 9 days.282 Thus deuterium replacement in the brain and
skull of the elliptical model are in equal proportion.

712.3. Simulated Beams

Two "ideal" 15cm diameter neutron beams were applied from a lateral
aspect onto the skull/brain model. These idealised beams consisted of a
current of monceneroetic 0.025eV neutrons for the thermal beam, and a
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uniform 2-7keV spectrum representing the epithermal beam. Yanch et
a|i83,i84

j-, ave reported that a few keV is the most likely optimum neutron

beam energy for use in B N C T . Ten cases were run, five each for both
the thermal and epithermal beams, for molar heavy water replacements
of 0, 5, 10, 15, and 2 0 % . Each simulation involved approximately
1.0X106 source neutrons, using 60 minutes C P U time on the A N S A M S
Fujitsu V P 2 2 0 0

supercomputer with a final statistical error of

approximately 5%.

In addition to the ideal beams, a 15cm diameter epithermal neutron
b e a m with spectrum and collimator geometry simulating the Petten H F R
facility253'254 was applied both unilaterally and bilaterally onto the
ellipsoidal model. The phantom was positioned with its X (lateral) axis
coincident with the beam axis with a distance of 20cm between the
polybor exit port of the beam and the phantom. Simulations for 0 % and
2 0 % D 2 0 replacement each involved approximately 2.0x106 source
neutrons, using 2hrs C P U time on a Fujitsu VP2200 supercomputer with
a final statistical error in flux and dose calculations of approximately 5%.

11.2.4. Dose Calculation

(i) Ideal Beams

Doses were calculated in the same manner as described in chapter 9.
The blood boron level (B) chosen for these calculations is 10^ig/g. This
is not too excessive to induce significant 10 8 dose depression, yet high
enough to obtain maximum dose contrast between tumour and healthy
tissue.51 Tumour

10

B levels (T) were taken to vary from 10^g/g to

1O0uo/g to provide a broad coverage over the possible tumour to blood
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boron range. M C N P calculations by the author have shown that the
inclusion of

10

B at concentrations as high as 1O0ng/g, in localised

volumes of approximately 1cm 3 introduce a 10 B dose depression of less
than 3 % within the localised site. This is opposed to the 10 B level in the
entire brain volume which causes significant thermal neutron flux
perturbation at levels much lower than tOO^g/g. As such the author
chose to vary the tumour

10

B concentration, yet hold the blood boron

level constant. Thus the tumour to healthy tissue dose ratio is
maximised via boron levels high enough to produce maximum dose
contrast,51 yet low enough to prevent significant thermal neutron flux
perturbation and

10

B dose depression. Tumour to blood boron ratios

(T/B) of 1,2,3,4,5 and 10 are studied with all having a 10^ig/g

10

B

concentration in the blood.

Doses used in the ideal beam analysis are the product of absorbed dose
and assumed R 8 £ values. R B E factors, were taken from Nigg 164 and are
as follows:

Radiation Type

Reccrnmended. R g £

G a m m a Rays (single Dose)

1.0

Thermal Neutrons

2.5

Epithermal Neutrons

2.5

Fast Neutrons

5.0

10

2.3

B Reaction

(ii) Petten HFR Reactor Beam

Neutron and photon fluences were computed for each tally volume using
a track length estimate technique incorporated into M C N P . The thermal
neutron fluence is expressed per source neutron whilst the photon
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fluence was converted to dose (Gy) per source neutron using K E R M A
conversion factors.182 Reactor core g a m m a s were not included in this
calculation. Photons included in this calculation were those induced by
incident neutrons within the collimator geometry or the phantom itself, ie
the 1H(n,y)2H thermal neutron capture reaction. The blood 10 B level was
taken as 10ug/g with a tumour 10 B level of 43ng/g. This is consistent
with the average B P A tumour to blood 10 B ratio documented in humans
by Mallesch et al200 R B E values used are the same as those for the
ideal beams.

11.3. Results and Discussion

11.3.1. Thermal Beam (0.025eV)

Figure 11.1 displays the Advantage Depth as measured from the brain
surface as a function of D 2 0 replacement for the 0.025eV thermal
neutron beam. Improvement can be seen as the heavy water
concentration rises, however the extent of the increase is dependent
upon the tumour to blood boron ratio (T/B). For a T/B ratio in the range
of 4 to 5, a clinically feasible 2 0 % heavy water replacement increases
the advantage depth by approximately 0.7cm. Figure 11.2 shows the
Therapeutic Depth for the thermal beam. T/B ratios below 3 gave a T R
of less than 2 and thus cannot have a Therapeutic Depth. For a T/B in
the range of 4 to 5, 2 0 % heavy water replacement increases the T D by
approximately 0.4cm. Thus for shallow tumours, significant gains with
thermal neutrons can be m a d e by the relatively simple process of heavy
water replacement. Even with 2 0 % heavy water replacement, however,
the effective T/B required for the therapeutic depth to reach the midline
of the brain {6cm from the brain surface) is of the order of 20. This is far
in excess of ratios exhibited by current boron compounds.
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Figure 11.1. Advantage Depth as a function of D z O replacement in the elliptical
skull/brain model for the 0.025eV thermal neutron beam. Curves depicting tumour to
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10

B ratios of 1,2,3,4,5, and 10 are shown, all for TOfig/g blood

10

B concentrati

10

Tumour/Blood

B Ratio

10

E
u
a
Q

o
D
01

a
o
sz

0
0

10

15

20

Deuterium (atom%)

Figure 11.2 Therapeutic Deptti as a function of O 2 O replacement in the elliptical
skull/brain model for the 0.025eV thermal neutron beam. Curves depicting tumour to
Wood
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11.3.2. Ideal Epithermal Beam (2-7keV)

Figure 11.3 displays the Advantage Depth as measured from the brain
surface as a function of D 2 0 replacement for the 2-7keV epithermal
neutron beam. A s for the thermal beam, improvement can be seen as
the heavy water concentration rises, however the extent of the increase
is dependent upon the T/B ratio. For a T/B in the range of 4 to 5, 2 0 %
heavy water replacement increases the advantage depth by over Tern.
Figure 11.4 shows the Therapeutic Depth for the epithermal beam. A s
for the thermal case, T/B ratios below 3 gave a T R of less than 2 and
thus cannot have a Therapeutic Depth. For a T/B in the range of 4 to 5,
2 0 % heavy water replacement increases the Therapeutic Depth by over
1cm to well beyond the midline of the brain.
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Figure 11.3 Advantage Depth as a function of D 2 0 replacement in the elliptical
skull/brain model for the 2-7keV epithermal neutron beam. Curves depicting tumour to
blood 10 B ratios of 1,2,3,4,5, and 10 are shown, all for 10|*g/g blood 10 8 concentration.
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Figure 11.4 Therapeutic Depth as a function of 0 2 O replacement in the elliptical
skull/brain model for the 2-7keV epithermal neutron beam. Curves depicting
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reach the brain midline <6cm from brain surface) using 2-7keV epithermal ne
a function of heavy water replacement.
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T h e effective T/B required for the therapeutic depth to reach the midline
of the brain is s h o w n in figure 11.5 as a function of heavy water
replacement. For 2 0 % replacement, the reduction in the effective T/B
requirement is from 5.0 to 3.6. Considering the effective

10

B T/B

measured in h u m a n s is of the order of 4 to 5 for both B P A and B S H
(taking into account the Capillary D o s e Factor), it can b e seen that
heavy

water

replacement

offers significant improvement

for the

therapeutic treatment of deep-seated tumours with epithermal neutrons
and current generation

10

B drugs.
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Figure 11.6 Dose (RB£ Gy/source neutron) along beam axis vs. depth for 10ng/g
blood 10 B and 43(xg/g tumour 10 B (T/B = 4.3) - tumour site 5.25 to 6.25cm from brain
surface. Dose profiles for the 2-7keV epithermal beam are shown for 0 % and 2 0 %
heavy wafer replacement. The boron dose component to the tumour is increased with
heavy water present due to improved neutron flux penetration. Healthy tissue dose is
also reduced as a result of less induced gammas. This study has only O.Scm
resolution. A sharper transition from tumour to healthy tissue dose is expected.
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Assuming a worst case scenario of a tumour situated near the midline of
the brain, Figure 11.6 illustrates depth dose profiles for 0 % and 2 0 %
D 2 0 for the 2-7keV b e a m using the average value T/B of 4.3.202 With
the 2 0 % heavy water replacement, the

10

B dose component to the

tumour has increased due to improved thermal neutron flux penetration.
Additionally, the heavy water has the effect of reducing the healthy
tissue dose via less induced g a m m a s . This has a twofold effect in
improving the Therapeutic Ratio.

11.3.3. Petten HFR epithermal beam

Figure 11.7 displays thermal neutron fluence distribution as a function of
depth relative to the brain surface for 0 % and 2 0 % D 2 0 replacement.
Thermalisation is reduced in the first few centimetres with heavy water
replacement, enabling deeper penetration and thus increased thermal
neutron flux at depth. The thermal flux peak shifts from 2.0cm to 2.2cm.
More important is the 1 5 % reduction in peak flux which has a significant
impact w h e n bilateral irradiation is considered (Figure 11.8). The effect
of reducing the thermal flux in the first few centimetres gives an
extremely uniform flux throughout the brain w h e n bilateral irradiation is
used. The peak to valley ratio reduces from 2.6 to 1.05 with the
incorporation of 2 0 % D 2 0 .

This uniform thermal neutron flux distribution has a much greater
potential to destroy isolated tumour cell nests loaded with

10

B in the

midbrain area whilst avoiding thermal peak "hot spots" at 2-3cm. The
rationale for heavy water replacement lies in the increased neutron
penetration through tissue. A s can be seen in figures 11.7 and 11.8, this
rationale is certainly justified.
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Figure 11.7 Calculated thermal neutron fluence as a function of depth for the Petten
HFR epithermal neutron beam. Heavy water replacement improves neutron
penetration.
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Figure 11.8 For bilateral irradiation, the improved neutron penetration as a result of
heavy water replacement promotes a homogeneous thermal neutron flux distribution.
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D 2 0 however has a two fold benefit extending beyond increasing
neutron penetration. Not only is the thermal neutron flux distribution
improved, but the induced g a m m a dose is significantly reduced,
predominantly due to reduced hydrogen capture reactions. Figure 11.9
illustrates the effect with unilateral irradiation with the Petten beam. The
peak dose d u e to induced g a m m a s is reduced by over 3 0 % . With
bilateral irradiation, substantial reduction in induced g a m m a dose is
similarly observed as in Figure 11.10. Such a decrease can potentially
have a major effect on the efficacy of therapy by increasing the
differential between the tumour dose and healthy tissue dose.
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Figure 11.9 Heavy water replacement significantly lowers induced g a m m a dose to
healthy tissue. For unilateral irradiation, the reduction in peak dose is over 3 0 % .

Figure 11.11 depicts the dose profile using unilateral irradiation for a
tumour of approximately 1cm diameter situated near the midline of the
brain. A n increase in the tumour dose with a decrease in the healthy
tissue dose is observed w h e n heavy water is introduced at a level of -
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Figure 11.10 Induced gamma dose distribution for bilateral irradiation using the Petten
HFR epithermal neutron beam. Heavy water replacement not only allows a
homogeneous thermal neutron flux throughout the brain for widespread cancer cell kill,
but also substantially reduces healthy tissue induced gamma dose.
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Figure 11.11 Dose profiles using unilateral irradiation with the Petten H F R b e a m for a
tumour of approximately 1cm diameter situated near the midline of the brain. 0% and
20% heavy water profiles are shown.
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2 0 % . This improvement is even more significant for bilateral irradiation
(figure 11.12). To quantify these benefits, figure 11.13 illustrates the
unilateral therapeutic ratio as a function of depth for 0% and 20% heavy
water replacement. The therapeutic ratio at depth d cm, TR<d), is
defined as:-

TR(d) = (Dn(d)+Dr(d)+43ug/g10B dose(d)) / (On+Oy+10^g/g10B dose)

max

It can b e seen in figure 11.13 that beyond a few centimetres depth the
TR is improved significantly. Figure 11.14 shows the increase in TR with
the incorporation of 20% D20 is up to approximately 40%. This
improvement, however is only on the far side of the brain where the TR
remains below unity.
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Figure 11.12 Dose profiles using bilateral irradiation with the Petten HFR beam for a
tumour of approximately 1cm diameter situated near the midline of the brain. 0%
20% heavy water profiles are shown.
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Figure 11.13 Unilateral therapeutic ratio as a function of depth for0% and 2 0 % heavy
water replacement.
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Figure 11.14 Unilateral 2 0 % heavy water therapeutic ratio divided by 0 % heavy water
therapeutic ratio. Up to 40% enhancement from a low base is observed.
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Of more clinical relevance are the results for bilateral irradiation. Figure
11.15 compares the T R for 0 % and 2 0 % heavy water. The incorporation
of heavy water increases the T R from approximately 2.25 to 2.75 for a
large volume of the midbrain. This represents a 2 0 % increase, whilst
also dramatically improving T R homogeneity. This uniform T R has a
much greater potential to destroy isolated tumour cell nests loaded with
10

B in the midbrain region whilst avoiding healthy tissue "hot spots" at 2-

3cm depth in comparison to the T R for 0 % D 2 0 . Figure 12.16 shows that
the 2 0 % improvement in T R with heavy water covers approximately 5cm
throughout the midbrain region.
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Figure 11.15 Bilateral therapeutic ratio as a function of depth for 0 % and 2 0 % heavy
water replacement. The T R throughout the midbrain is significantly improved with 2 0 %
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Figure 11.16 Bilateral 2 0 % heavy water therapeutic ratio divided by 0 % heavy water
therapeutic ratio. 2 0 % enhancement for 4 c m throughout the mid brain region can be
seen.

11.3. Conclusion

Heavy water replacement prior to B N C T has the effect of increasing
thermal neutron flux penetration and thus dose to tumour cells whilst
lowering the healthy tissue dose via reduced induced gammas. Using
the M C N P transport code with an elliptical skull / brain model, the
parameters of advantage depth and therapeutic depth were studied as a
function of D 2 0 replacement. Analysis w a s performed for tumour to
blood

10

B ratios in the range 1 to 10 with 10ng/g in the blood. For

thermal neutrons, 2 0 % heavy water replacement extended the
advantage depth by approximately 0.7cm and the therapeutic depth by
approximately 0.4cm for an effective tumour to blood

10

B ratio in the

range of 4 to 5 {average range of B S H and BPA). The T/B required for
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the therapeutic depth to reach the midline of the brain is of the order of
20 even with 2 0 % heavy water replacement. Thus for shallow tumours,
significant gains with thermal neutrons can be m a d e by the relatively
simple process of heavy water replacement. It must be stated, however
that the financial cost of such quantities of heavy water is not
insignificant.

Improvement in treatment planning figures of merit for the ideal 2-7keV
neutron b e a m can be seen as the heavy water concentration rises, with
the extent of the increase dependent upon the T/B ratio. For a T/B in the
range of 4 to 5, 2 0 % heavy water replacement increases the advantage
depth and the therapeutic depth by over 1cm to well beyond the midline
of the brain. The effective T/B required for the epithermal therapeutic
depth to reach the midline of the brain reduces from 5.0 to 3.6 with 2 0 %
heavy water replacement. Considering that the effective

10

B T/8

measured in humans is of the order of 4 to 5 for both B P A and B S H , it
can be seen that heavy water replacement offers significant benefit for
the therapeutic treatment of deep-seated tumours with epithermal
neutrons and current generation 10 B drugs.

For the Petten HFR epithermal neutron beam, the incorporation of heavy
water should promote a more uniform thermal neutron flux distribution
throughout the brain. This is particularly so when bilateral irradiation is
used. Equally significant is the reduction in induced g a m m a dose to
healthy tissue. This arises through a reduction in the 1H(n,y)2H thermal
neutron capture reaction. For bilateral irradiation, the incorporation of
2 0 % heavy water promotes a uniform T R throughout the brain with an
increase from 2.25 to 2.75 throughout the midbrain volume. Such a
therapeutic ratio distribution would

enable

widespread

kill of
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disseminated cancer cells loaded with

10

B whilst minimising any local

extremes in healthy tissue dose. Considering the significant benefits of
heavy water replacement in epithermal B N C T , its inclusion in treatment
protocol can only serve to improve the statistical outcome of impending
clinical trials.
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12.

CONCLUSION

Recent results show that localised nests of as few as three cancer cells
have preferential uptake of B P A by as much as five times that in
surrounding tissue. This adds significant support to the proposed
cellular selectivity of the B N C T treatment modality. B N C T has intrinsic
selectivity and does not rely on extrinsic techniques to boost the
therapeutic ratio to cancerous cells. This implies therapeutic treatment
of subclinical metastases throughout the diseased organ m a y be
possible with B N C T . This is simply impossible with current radiotherapy
/ surgical techniques. W h e n consideration is given that the profile of a
number of cancers throughout the western world has been static (or
rising) for almost fifty years despite massive funding, it is dear that
fundamental changes in mainstream research are required.

This project first details the construction of anthropomorphic head and
torso phantoms suitable for use with neutron radiation. Tissues
simulated include brain, liver, muscle, heart, lungs, stomach, intestines,
pancreas, spleen, kidney and adipose. These phantoms were used to
validate M C N P treatment planning calculations targeting the brain and
liver using a variable voxel geometric reconstruction directly from
"patient" C T scans. The user m a y specify "regions of interest" where
small voxels m a y be applied giving detailed geometrical modelling and
dose planning. Larger voxels m a y be applied to surrounding regions
where detailed modelling is not required. Body tissues are discriminated
on the C T scan on the basis of greyscale number. Programs are
presented to enable the discrimination of spatially isolated tissues with
c o m m o n g/eyscale numbers.
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M C N P calculations were initially benchmarked against the Petten H F R
epithermal neutron beam using the geometrically simple cylindrical
phantom. Epithermal neutron beam facilities are not available in
Australia and the Petten facility is unique to Europe and one of the few
in the world. Gold and copper foil activation measurements generally
show agreement to within 1 0 % of the calculations. Larger discrepancies
with the cadmium covered manganese foils are possibly the result of a
number of causes. The results of the experimental PIN detector
(responding dominantly to fast neutrons) showed good agreement with
the calculated response. Similarly M O S F E T g a m m a detectors showed
excellent correlation with the induced g a m m a dose. (The authors role in
the PIN and M O S F E T detectors is limited to calculations of predicted
response)

The prototype "patients" modelled from CT scans using the variable
voxel technique include: i) the head phantom, ii) the torso phantom, and
iii) the cervical region using C T scans of a cervical cancer patient. For
the head and torso phantoms, M C N P calculations show agreement
generally to within 1 0 % of bare and cadmium covered gold foil
measurements in the brain, liver, lungs and pancreas irradiated in the
Petten H F R epithermal neutron beam. PIN diode measurements are
also well correlated to M C N P predicted results, however there is
evidence of increasing discrepancy with depth from the beam entrance
surface of the phantoms. M O S F E T response also appears to be well
correlated with g a m m a dose in the phantoms. Further study is being
undertaken to fully characterise the response of these detectors and
eliminate spurious results before clinical application will be considered.
These are possibly the most stringent tests of Monte Carlo modelling to
date for epithermal neutrons.
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Calculations for the head and torso phantoms are superimposed upon
C T scans, illustrating the latest software in three dimensional medical
image visualization. Calculations are also displayed in a similar manner
for the hypothetical z^Cf brachytherapy for cervical cancer treatment
plan. These results indicate that the potential for boron neutron capture
dose enhancement using ^ C f brachytherapy for cervical cancer is
limited to very bulky tumours.

MCNP was also used with an ellipsoidal head model to examine the
effect on treatment planning figures of merit of, i) boron ratios and
concentrations, and ii) heavy water uptake. For a fixed tumour to blood
boron ratio, little benefit is gained by increasing the blood boron level
once the boron dose component dominates the healthy tissue dose.
This limit is dependent upon the compound in use, or more precisely its
pharmacokinetics and associated "compound factor". The effect of
incorporating heavy water in brain tissues to improve B N C T efficacy is
also examined. For bilateral irradiation with the Petten H F R beam,
deuteration below toxicity limits provides an increase of approximately
2 0 % in the therapeutic ratio throughout the midbrain region. Such a
therapeutic

ratio distribution would

disseminated cancer cells loaded with

enable
10

widespread

kill of

B whilst minimising any local

extremes in healthy tissue dose. Considering the significant benefits of
heavy water replacement in epithermal B N C T , its inclusion in treatment
protocol can only serve to improve the outcome of clinical trials.
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APPENDIX I. M C N P INPUT FOR THE CYLINDER M O D E L WITH THE PETTEN HFR
EPITHERMAL NEUTRON B E A M SPECTRUM A N D 15CM DIAMETER COLLIMATOR
/home/saw/bin/mcnpsaw cylpet2 cylpet2.runtpe «'eof
c Cylinder, HFR petten source
c
0-31 central core tally cells
c
101-131 annuius tally cells
c
200- other cylinder cells
500- source/collimator structure
c
1 1-1.2-150 101-102
2 1 -1.2 -150 102 -103
3 2 -1.04 -150 103 -104
4 2 -1.04 -150 104 -105
5 2 -1.04 -150 105 -106
6 2 -1.04 -150 106 -107
7 2 -1.04 -150 107 -108
8 2 -1.04 -150 108 -109
9 2-1.04-150 109-110
10 2-1.04-150 110-111
11 2-1.04-150 111-112
12 2-1.04-150 112-113
13 2-1.04-150 113-114
14 2-1.04-150 114-115
15 2-1.04-150 115-116
16 2-1.04-150 116-117
17 2-1.04-150 117-118
18 2-1.04-150 118-119
19 2-1.04-150 119-120
20 2-1.04-150 120-121
21 2-1.04-150 121-122
22 2 -1.04 -150 122 -123
23 2 -1.04 -150 123 -124
24 2 -1.04 -150 124 -125
25 2 -1.04 -150 125 -126
26 2 -1.04 -150 126 -127
27 2 -1.04 -150 127 -128
28 2 -1.04 -150 128 -129
29 2-1.04-150I29-13O
30 2-1.04-150 130-131
31 2-1.04-150 131-132
101 1-1.2-152 151101-102
102 1-1.2-152 151102-103
103 2-1.04-152 151103-104
104 2-1.04-152 151104-105
105 2-1.04-152 151105-106
106 2-1.04-152 151106-107
107 2-1.04-152 151107-108
108 2-1.04-152 151108-109
109 2-1.04-152 151109-110
110 2-1.04-152 151 110-111
111 2-1.04-152 151 111-112
112 2-1.04-152 151 112-113
113 2-1.04-152 151113-114
114 2-1.04-152 151114-115
115 2-1.04-152 151115-116
116 2-1.04-152 151116-117
117 2-1.04-152 151 117-118
118 2-1.04-152 151118-119
119 2-1.04-152 151 119-120

120 2-1.04-152 151120-121
121 2-1.04-152 151 121-122
122 2-1.04-152 151 122-123
123 2-1.04-152 151123-124
124 2-1.04-152 151124-125
125 2-1.04-152 151125-126
126 2-1.04-152 151126-127
127 2-1.04-152 151127-128
128 2-1.04-152 151128-129
129 2-1.04-152 151129-130
130 2-1.04-152 151130-131
131 2-1.04-152 151131-132
201 1-1.2 150-151101-103
202 2-1.04 150-151103-132
203 1 -1.2 152 -153 101 -103
204 2 -1.04 152 -153 103 -132
205 2 -1.04 132 -140 -153
c Remaining volume.
501
0
(-540: 539: -513 : 537 : -545:546)
c
c Treatment-room
506
6 5.33684e-05 540-539 532-537 545-546
(-101:140:153) $ phantom bounds
507 6 5.33684e-05 570 -532 -533 $ beam port in polybor
508 6 5.33684e-05 540-539 530-570 545-546
c
$ air gap behind polybor door
509 0
513-511540-539 545-546
SSourcecell
c Poly-boron lining of therapy room
518 38 1.33039e-01 540 -539 570 -532 533 545 -546
c
c Collimation blocks behind beam-shutter
519 25 8.84597e-02 511 -534 540 -539 545 -546 510
520 25 8.84597e-02 534 -530 540 -539 545 -546
(-554 : 555 : -550 : 560) 552 553
521 38 1.33039e-01 534 -556 515
(( 554 -555 550 -560 ): -552 : -553 )
522 5 3.30e-02 556-557 515
(( 554 -555 550 -560 ): -552 : -553 )
523 38 1.33039e-01 557 -558 515
(( 554 -555 550 -560 ): -552 : -553 )
524 5 3.30e-02 558-559 515
(( 554 -555 550 -560 ): -552 : -553 )
525 6 5.33684e-05 559 -530 (( 554 -555 550 -560 ): -552 : -553 )
526 26-3.79
511 -534-510 515
528 6 5.33684e-05 511 -559 -515
c Surface Cards.
c

c
c
c
c
101
102
103
104
105
106
107

•••

These are grouped as follows;
501 -> 599 Configuration planes
1 -> 100 Patient phantom planes.
2py0.0
2py0.25
2py0.75
2 py 1.25
2pyl.75
2py2.25
2py2.75

108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
140
150
151
152

2 py 3.25
2 py 3.75
2 py 4.25
2 py 4.75
2 py 5.25
2 py 5.75
2 py 6.25
2 py 6.75
2 py 7.25
2 py 7.75
2 py 8.25
2 py 8.75
2 py 9.25
2 py 9.75
2 py 10.25
2 py 10.75
2 py 11.25
2 py 11.75
2 py 12.25
2 py 12.75
2 py 13.25
2 py 13.75
2 py 14.25
2 py 14.75
2 py 15.25
2 py 23.0
2 cy 0.25
2 cy 2.25
2 cy 2.75
153 2cy8.0
c
c
c Extra surfaces for the pseudo-collimator in the shutter
5K1 1 cy 15.0 $ 30 c m diameter beam shutter.
51J py
0.0
512i py -10.0
c
21.75 to 15 c m diameter cone hole in concrete
5 Ifi 1 ky 126.68167 0.0073694
c
c
c
c
53C• py 40.575
570 1 py 45.1
$ polybor plate at 5 deg
532 1 py 50.1 $ polybor plate at 5 deg
533 1 cy 10.0 $ port in polybor
534 py 20.285
537 lpy 100.1
539 1 px
25.0
540 1 px -25.0
545 pz -25.0
546 pz 40.0
c
c
c Extra concrete shielding with sliding B.S. and collimator

550
552
553
554

pz -0.5
c/y-2.812-5.0 16.9
c/y -2.812 20.0 16.9
px -19.712
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555
556
557
558
559
560

px 14.088
py 25.315
py 30.315
py 34.315
py 39.315
pz 20.0

c data cards
mode n p
m l 1001 -5.55 6012 -75.58 8016 -18.88
$ polycarbonate
m 2 1001 -10.7 6012 -14.5 7014 -2.2 8016 -71.2
11023 -0.2 15031 -0.4 16032 -0.2 17000 -0.3 19000 -0.3
SBrain I C R U 92
mt2 lwtr.Olt
mtl poly.Olt
m S 82000 -1.0
$ lead
m 6 7014.04c -76.7 8016 -23.3 18000-1.4 $ air
c materials for hematite concrete
m25 26000 -52.50 20000 -8.24 14000 -2.17
8016 -35.61 6012 -0.82 1001 -0.66
m 2 6 10010.21 6012 0.07 5010 0.005
$ Lead/wax
50110.07 82000 0.63
c
m 3 8 5010 -1.0 5011-4.0 1001 -13.62 6012-81.38 $ Poly-boron
m51 79197 1 $gold
m 5 2 29000 1 $ copper
m53 25055 1 SManganese
c m 5 4 49115 1 $ indium
c no indium xsections present
imp:n 1 66r 0 1 13r
imp:p5 66r0 1 13r
pwt -0.1 81r
*trl 0.0 0.0 -5.0 5.0 85.0 90.0 95.0 5.0 90.0 90.0 90.0 0.0
c in accordance with petten irradiation of cyl
*tr2 -6.169.8 -5.0 5.0 85.0 90.0 95.0 5.0 90.0 90.0 90.0 0.0
c
c Source definition.
c Uniform over 10 degree cone, uniform over 6.0 c m radius circle
c with correct spectrum.
sdef sur=511 pos=0.0 0.0 -5.0 dir=d4 erg=d2 rad=d3 vec=-0.0872 0.9962 0
si2 h 1.0000e-09 1.0000e-07 1.0000e-06 2.4400e-06 4.8800e-06
9.7700e-06 1.9500e-05 3.9100e-05 7.8100e-05 1.5600e-04
3.1300e-04 6.2500e-04 1.2500e-03 1.7700e-03 2.5000e-03
3.5400e-03 5.0000e-03 7.0700e-03 1.0000e-02 1.1900e-02
1.4100e-02 1.6800e-02 2.0000e-02 2.3800e-02 2.8300e-02
3.3600e-02 4.0000e-02 5.6600e-02 8.0000e-02 1.1300e-0I
1.6000e-01 2.2600e-01 3.2000e-01 4.5300e-01 6.4000e-01
9.0500e-01 1.8100e+00 3.6200e+O0 7.2400e+00 1.4500e+01
sp2 dO.O
7.47176e+05 1.62553e+07 2.95510e+07 4.89181e+07
7.10666e+07 7.29720e+07 7.83839e+07 7.54184e+07 7.96694e+07
8.45759e+07 8.81150e+07 8.69080e+07 4.57182e+07 4.53842e+07
3.29368e+07 3.48218e+07 3.53290e+07 2.74408e+07 7.39184e+06
3.69138e+06 1.11962e+06 6.34946e+05 1.06478e+07 2.47447e-K)7
1.56035e+07 5.64153e+04 2.36364e+07 2.39106e+07 3.38056e+O4
1.57833e+06 7.99557e+05 6.88162e+06 4.94684e+06 2.82759e+06
1.53347e+05 1.05296e+O5 4.85148e+03 1.15202e+04 1.09130e+04
si3 0.0 12.5

sp3 -21 1.0
si4 0.98481 1.0
sp4 0.0 1.0
c
c G E N E R A L program data
c

' ' • • - •

i

•• ..-•t

•-

fqO ft S vertical listing of cell scores in each tally
c tally cards
f4:n 1 29i 31 101 29i 131
fc4 neutron flux
e4 0.414e-6 1.0e-2 14.5
fq4 fe
fl4:n 1 29i 31 101 29i 131
fcl4 neutron dose
el4 35e-6 10e-3 14.5
fql4 fe
f24:n 1 29i 31 101 29i 131
fc24 30ppm 10B dose
f34:p 129J31 101 29i 131
fc34 photon dose
f44:n 1 29i 31 101 29i 131
fc44 silicon damage cGy
c neutron tissue dose conversion
del4 2.5e-8 2e-6 2e-5 2e-4 2e-3 2e-2 1.05e-l 1.05e+00
1.05e+l 1.55e+l S M e V
dfl4 1.5e-ll 1.73e-12 7.51e-13 2.29e-12 2.10e-ll 1.89e-10
6.95e-10 2.56e-9 5.98e-9 7.03e-9 SKerma cGy*cm**2
c 30ppm BIO dose conversion
de24 le-8 2.5e-8 3.6e-8 2.51e-76.84e-7 1.86e-6 5e-6
1.37e-5 3.73e-5 1.01e-4 2.75e-4 7.49e-4 2.03e-3 S M e V
df24 4.14e-10 2.62e-10 2.19e-10 8.76e-ll 5.43e-ll 3.27e-ll
1.91e-ll 1.2e-ll 7e-12 4.4ie-12 2.7e-12 1.64e-12
9.8e-13 SKerma cGy*cm**2 30ppmB10 dose only
c photon tissue dose conversion
de34 le-3 2e-3 5e-3 le-2 2e-2 5e-2 le-1 2e-l 5e-l le+0
2e+0 5e+0 le+1 2e+l $ M e v
df34 5.99e-08 1.8e-8 3.24e-9 7.75e-10 1.75e-10 3.24e-ll
4.04e-ll 9.46e-ll 2.63e-10 4.94e-10 8.29e-10
1.52e-9 2.48e-9 4.38e-9 SKerma cGy*cm**2
de44 2.24068e-09 $Si damage kerma ( M e V energy)
3.69425e-09 $oGy*cm**2*sec
6.09079e-09
1.0042e-08
l.31589e-08
1.45429e-08
1.60723e-08
1.77626e-08
1.96307e-08
2.16954e-08
2.39771e-08
2.64988e-08
2.92856e-08
3.23656e-08
3.57697e-08
3.95316e-08
4.36892e-08
4.82839e-08
5.33619e-08
5.89743e-08

6.51765e-08
7.203 llle-08
7.96066e-08
8.79788e-08
9.72321e-08
1.07458e-07
1.18759e-07
1.31249e-07
1.45053e-O7
1.60309e-07
1.77168e-07
1.95801e-07
2.16393e-07
2.39151e-07
2.64305e-07
2.92101e-07
3.22821e-07
3.56772e-07
3.94294e-07
4.35765e-07
4.81594e-07
5.32243e-07
5.88218e-07
6.5008e-07
7.18454e-07
7.94014e4)7
8.7752e-07
9.69806e-07
l.O718e-06
1.18453e-06
1.3091 le-06
1.44679e-06
1.59895e-06
1.7671 Ie-06
1.95295e-06
2.15835e-06
2.38535e-06
2.63622e-06
2.91347e-06
3.49344e-06
4.48567e-06
5.7597le-06
7.39562e-06
9.496I4e-06
1.21933e-05
1.56565e-05
2.01034e-05
2.58132e-05
3.31448e-05
4.25588e-05
5.46466e-05
7.01676e-05
9.0097 le-05
l.l5687e-04
1.48545e-04
1.90735e-04
2.44909e-04
3.14469e-04
4.03787e-04

5.18473e-04
6.65732e-04
8.54816e-04
1.09761e-03
1.31626e-03
1.4915 le-03
.0016901
1.91514e-03
2.17014e-03
2.45909e-03
2.78652e-03
3.15754e-03
3.57796e-03
4.05435e-03
4.59418e-03
5.20589e-03
5.89905e-O3
.0066845
7.57453e-03
8.58307 le-03
.0097259
.0110209
.0124883
.0141511
.0160353
.0181703
.0205897
.0233312
.0264377
.0299578
.0339467
.0384666
.0435884
.0493922
.0559687
.0634207
.0718651
.0814339
.0922766
.104563
.118486
.134262
.147242
.156739
.166847
.177608
.189063
.201256
.214236
.228053
.242761
.258418
.275085
.292826
.311712
.331816
.353216
.375996
.400246

.426059
.453538
.482789
.513926
.547071
.582355
.619913
.659894
.702454
.747758
.795984
.84732
.901968
.96014
1.02206
1.08798
1.15815
1.23285
1.31236
1.397
1.4871
1.58301
1.6851
1.79378
1.90947
2.03262
2.16371
2.30326
2.45181
2.60993
2.77826
2.95744
3.14818
3.35122
3.56735
3.79743
4.04234
4.30305
4.58057
4.876
5.19047
5.52522
5.88157
6.2609
6.66469
7.09453
7.55209
8.03915
8.55762
9.10954
9.69706
10.3224
10.9882
11.6969
12.4513
13.044
13.4581
13.8853
14.3261

14.7808
df44 1.139608e-13 $Si damage kerma (kerma)
8.872022e-14 ScGy*cm**2*sec
6.911985e-14
5.382809e-14
4.698947e-14
4.467793e-14
4.249707e-14
4.042712e-14
3.845414e-14
3.658561e-14
3.479285e-14
3.307903e-14
3.146068e-14
2.991504e-14
2.84542le-14
2.705426e-14
2.572107e-14
2.44644e-14
2.32737e-14
2.214843e-14
2.108652e-14
2.00926ie-14
1.913243e-14
1.820844e-14
1.73249e-14
1.649836e-14
1.570998e-14
1.496096e-14
1.423965e-14
1.354101e-14
1.285803e-14
l.221635e-14
1.163057e-14
1.10634e-I4
1.05213e-14
1.00054e-14
9.516939e-15
9.023816e-15
8.575672e-15
8.172521e-15
7.780097e-15
7.406513e-l5
7.048285e-15
6.712682e-15
6.374564e-15
6.064049e-15
5.7865le-15
5.494637e-15
5.231793e-15
4.968984e-15
4.714971e-15
4.477693e-15
4.260399e-15
4.053349e-15
3.86217le-15
3:687897e-15
3.507276e-15
3.334228e-15

3.170209e-15
2.878356e-15
2.541229e-15
2.240582e-15
1.98293 le-15
1.75226e-15
1.549848e-15
1.371894e-15
1.20275e-15
1.063582e-15
9.378355e-16
8.263944e-16
7.314748e-16
6.441276e-16
5.681734e-16
5.024657e-16
4.410407e-16
1.01183e-15
4.943858e-15
8.634314e-15
1.310663e-14
1.935209e-14
2.556637e-I4
3.365582e-14
4.320152e-14
5.229323e-14
5.955156e-14
6.725444e-14
7.583%2e-14
8.567795e-14
9.688433e-14
1.092836e-13
1.230059e-13
1.383673e-13
1.55641 le-13
1.778341e-13
2.030548e-13
2.268539e-13
2.540585e-13
2.842102e-13
3.170536e-13
3.540249e-13
3.939739e-13
4.406613e-13
4.95467e-13
5.550313e-13
6.170442e-13
6.830327e-13
7.464381e-13
8.175346e-13
9.01417e-13
9.916632e-13
1.207613e-12
1.045831e-12
7.946789e-13
1.46968 le-11
2.524801e-12
2.318469e-12
2.133843e-12

1.964938e-12
1.742369e-12
1.335893e-I2
7.838897e-13
5.806286e-13
2.368042e-12
9.439942e-12
2.663609e-ll
3.885624e-ll
3.409585e-ll
2.740755e-ll
2.339778e-ll
2.084227e-ll
1.923364e-ll
1.807755e-ll
1.760321e-ll
1.725335e-ll
1.697778e-ll
1.721205c-11
1.735033e-U
1.789191e-ll
1.79938e-ll
1.830144e-ll
1.893635e-ll
2.015418e-ll
3.295358e-11
2.475467e-ll
1.825112e-ll
1.92720 le-11
2.032588e-ll
2.377295e-ll
3.696862e-ll
3.332297e-ll
3.059793e-ll
3.840454e-il
3.099449e-ll
2.4337le-11
2.229745e-ll
2.9061 le-11
3.056374e-ll
3.218565e-ll
3.494228e-ll
4.293426e-ll
4.58545 le-11
3.461053e-ll
4.44871le-11
3.479863e-ll
3.671302e-ll
3.579939e-ll
4.098488e-ll
4.192978e-ll
3.951167e-ll
3.454923e-ll
4.516524e-ll
3.919306e-ll
3.578532e-ll
3.857847e-ll
4.53553e-ll
5.11644e-ll

4.973329e-ll
5.391368e-ll
5.51605e-ll
4.520707e-ll
5.365942e-ll
5.938245e-ll
5.248903e-ll
5.205755e-ll
5.609426e-ll
5.755874e-ll
5.6993 89e-11
5.581579e-ll
5.464705e-ll
5.652209e-ll
5.488637e-ll
5.700434e-ll
5.752392e-ll
5.801822e-ll
5.762e-ll
5.699998e-ll
5.770559e-ll
5.83297le-11
f54:nl29i31 101 29i 131
fc54 Gold Activation
e54 0.414e-60.5e-6 14.5
fm54 1 51 102
fq54 fe
f64:nl29i31 101 29i 131
fc64 Copper Activation
e64 0.414e-6 0.5e-6 14.5
fm64 1 52 102
fq64 fe
f74:nl29i31 101 29i 131
fc74 Manganese Activation
e74 0.414e-6 0.5e-6 14.5
fm74 1 53 102
fq74 fe
c £84:n 1 29i 31 101 29i 131
c fc84 Indium Activation
c e84 0.414e-6 0.5e-6 14.5
c fm84 1 54 102
c fq84 fe
c no indium xs present in tables
ctme 59
nps 2000000
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APPENDDCII

P R O C E S S I N G O F FOIL A C T I V A T I O N D A T A

Calculation of Saturation Activation from Measured Activation
Foils from the cylinder and head phantoms were counted on calibrated HPGe counting chains,
whilst foils from the whole body phantom were counted using a low background Nal counting
chain. Calibration of the low background counting chain took place by counting five foils of
different sizes at both counting chains. The standard deviation in the conversion factor was
1.34%. Three foils were counted twice as a check on accuracy, with no significant
discrepancies being found. All foil activities werefirstcorrected to R(0,te) values,287 ie. the
activity present immediately after irradiation of exposure time te. This value is then converted
to a saturation activation
Ro = RCO.toyO-e**) where X = ln2/ti/2
and ti/2 = half life of decay reaction being
measured

Saturation foil activity is the activity the foil would have if it were irradiated for an infinite
long te. Ro has the units of disintegrations per second or Becquerels (Bq). Dividing by the
number of atoms in the sample (mass(kg) * 6.022e26/(Atomic Wt.)) leaves the saturation foil
activation R * 0 in Bq/atom.
It is the saturation activation that may be compared to the MCNP calculations. The foil
activation measurements enable the calculation of the rate of the reaction 1 9 8 Au*->- 1 9 8 Au + y at
saturation. The integral Cj(KE)R(E)d£, calculated using M C N P , gives the rate of the reaction
197
Au(n,y) 198 Au*. These two values m a y be directly compared because at saturation the
number of captures equals the number of decays.
Resonance Self Shielding Corrections
Corrections must also be made for the finite thickness of the foil used in the measurements.
Near surface nucleii actually shield underlying nuclei, most dominantly at the resonance energy
of the nuclide being used. This means that the activation per nucleus will be less for a finite
thickness foil than compared to an infinitely dilute foil. Defining f as the resonance self
shielding factor for a thickness, t, of a given nuclei, w e have:
f = (Resonance Integral for thickness t)/(Resonance Integral for infinitely dilute foil)
For the foils used in this experiment, we have288:
f(197Au, 25um) = 0.473
f( 5 5 Mn, 1 2 7 ^ ) = 0.818
f( 63 Cu, 45u.m) =0.909
At each phantom site bare and cadmium covered foil activations were measured. Corrections
were applied in the following manner: Ath = Ab - ACd
Ares
Atot

=
=

(1/f) * A C d
Au, + A r e s

-

measured activation of bare foil
measured activation of cadmium covered foil
activation due to thermal neutrons
resonance activation (corrected for self shielding)
total activation (corrected for resonance self shielding)

where,
Ab
Aca
Ath
Ares
Atot

=

=
=
=
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T h e ^elf shielding correction has been applied only to the resonance activation, not the thermal
activation. Ath is compared to the M C N P calculated activation below 0.414eV, A r e s is
compared to the M C N P calculated activation above 0.414eV, whilst A tot is compared to the
total M C N P calculated activation.
Normalisation factor between measured and calculated results.
As discussed in chapter 6, integrals of the form j<KE)R(E)dE may be performed using the fm
M C N P card to calculate reaction rates.
<|>(E)
=
neutron fluence per source neutron (neutrons/cm2/ns)
as a function of energy
n
X(n,y) n+1 X* reaction cross section (barns/atom)
R(E)
=
as a function of energy
Multiplying the integral by IO"24 (cm2/barn) and then by the number of source neutrons per
second (ng) yields the number of captures per atom per second for the reaction nX(n,y)n"t"^X*,
which is equal to the saturation activation of the decay reaction n + 1 X * - » n + 1 X + y. The rate of
this reaction m a y be established using the activation measurements. Thus w e have:
Saturation Activation (Bq)/atom

=

n^s* 10-240|°°4)(E)R(E)dE

Three bare gold foils and three cadmium covered gold foils were placed in the 15cm diameter
collimated H F R Petten beam 2 0 c m from the polybor exit face, 2.5cm radius from the beam
axis. Saturation activations per atom with self shielding corrections were applied as described
earlier. This gives the L H S of the above equation. The integrals 04|4eVfCO<t>(E)R(E)dE and J00*)*
(E)R(E)dE were calculated at the corresponding site as the foils using M C N P . Equating to the
C d covered and bare A u measured activation respectively, the value of number of source
neutrons per second (ns/sec) was calculated as 1.9xlO u +/- 3 % . This effectively is the
normalisation between M C N P calculations and 15cm diameter beam measurements.

A P P E N D I X III V O X E L M O D E L L I N G P R O G R A M
program automat4
converts binary C T scans to M C N P models
logical* 1 voxel_byte(4), voxel_pixel(300,300,200),
$mcnp_byte(4),
$voxel_pix(65536),mcnp_pix(65536)
integer*4 voxel(300,300,200), mcnp(300,300,200),
$mcnp_word,
$voxel_word, xmax, ymax, zmax, subvlx,
Ssubvly, subvlz, subv2x, subv2y, subv2z, subv3x, subv3y,
$subv3z, nopsv3x, nopsv3y, nopsv3z, nopsv2x, nopsv2y,
Snopsv2z, nopsvlx, nopsvly, nopsvlz,
Sfatlim, muslim, bonelim, xindex, yindex, zindex, voxno,
Sxmin3, xmax3, ymin3, ymax3, zmin3, zmax3, xmin2, xmax2,
Symin2, ymax2, zmin2, zmax2, xstep, ystep, zstep, nopsvx,
Snopsvy, nopsvz, xvoxmin, xvoxmax, yvoxmin,
Syvoxmax, zvoxmin, zvoxmax, void, lung, fat, muscle,
Sbone, mode, matno, xplmin, xplmax, yplmin, yplmax,
Szplmin, zplmax, xmajmin, ymajmin, zmajmin,
Stlyslcl,tlyslc2,tlyslc3,tlyslc4,lungceli,fatceli,
Stlyslc5, tlyslc6, tlyslc7,
$musceli,bonceli,lungcel( 100000), muscel(100000),taltot,
$fatael(100000),boncel( 100000), xpl,xpla, xmin2p, xmin3p,
Sypl, ypla, ymin2p, ymin3p, zpl, zpla, zmin2p, zmin3p
Svoidlim, lunglim,
real*8 density, xplane, yplane, zplane
character*5 flnmhd
dataflnmhd/'a/V
character*4 flnmtn
data flnmtn/'a/ 7
character*3 flnmun
dataflnmun/'a/7
character* 5 mcnphd
data mcnphd/'b/ 7
character*4 mcnptn
data mcnptn/'b/ '/
character*3 mcnpun
data mcnpun/'b/ 7
equivalence(voxel_word,voxel_byte)
equivalence(mcnp_word,mcnp_byte)
!no. pixels in x
xmax = 256
ymax = 256
zmax = 46
subvlx = 1
! no div per major voxel in x in reg 1
subvly = 1
subvlz = 1
subv2x = 4
! no divisions per major voxel in x in reg 2
subv2y = 4
! no divisions per major voxel in y in reg 2
subv2z =1
! no divisions per major voxel in z in reg 2
subv3x = 1 6 ! no divisions per major voxel in x in reg 3
subv3y = 16 ! no divisions per major voxel in y in reg 3
! no divisions per major voxel in z in reg 3
subv3z = 1
nopsv3x= 2 ! no pixels per sub voxel in x in reg 3
nopsv3y= 2 ! no pixels per sub voxel in y in reg 3
nopsv3z= 1 ! no pixels per sub voxel in z in reg 3
nopsv2x= 8 ! no pixels per sub voxel in x in reg 2
nopsv2y= 8 ! no pixels per sub voxel in y in reg 2
nopsv2z= 1 ! no pixels per sub voxel in z in reg 2

nopsvlx= 32 ! no pixels per sub voxel in x in reg 1
nopsvly= 32 ! no pixels per sub voxel in y in reg 1
nopsvlz= 1 ! no pixels per sub voxel in z in reg 1
c
voidfim= 5 ! uppermost grayscale of void
c
lunglim= 20 ! uppermost grayscale of lung
fatlim= 120 ! uppermost grayscale of fat
muslim = 250 ! uppermost grayscale of muscle
bonelim= 255
! uppermost grayscale of bone (255?)
! x pixel counter
xindex = 1
yindex = 1
! y pixel counter
zindex = 1
! z pixel counter
voxno - 0
! mcnp voxel counter
c
define the boundaries of the regions
xmin3= 97
t min pixel no in reg3 in x
x m a x 3 = 224
! m a x pixel no in reg3 in x
ymin3=129
ymax3=192
zmin3=15
zmax3=24
xmin2=33
xmax2=224
ymin2=65
ymax2=192
zmin2=ll
zmax2=32
c
define the desired tallying slices
c
this is a simplistic approach applicable only when the
c
z voxelling parameters are 1
tlyslcl = 17
tlyslc2 = 18
tlyslc3 = 19
tlyslc4 = 20
tlyslc5 = 27
tlysto6 = 28
tlyslc7 = 29
c
the following are counters for the tally voxels of
c
given material type (no tallying in void)
lungoeli = 0
musceli = 0
fatceli = 0
bonceli = 0
c
image input from dir a, mcnp model images in dir b
SECTION 2
n = ichar('O') Iget the correct ASCII representation
c
write(6,5)n
do 10 k = l,zmax
if (k .It. 10) then
nf=n + k
c ensure 3:3 here, otherwise char lands in pos 1, affecting all subsequent uses
c of "filename" string:
flnmun(3:3) = char(nf)
open(unit=12,file = flnmun, access = 'direct', form =
S'unformatted', reel = 1, action = 'read')
read(12,rec=l) voxel_pix
close(12)
elseif (k It. 100) then
Ichar value of units column
nf = n + mod(k,10)
flnmtn(4:4) = char(nf)
nl = n + int(k/10)
Ichar value of tens column
if (nl .gt. n) flnmtn(3:3) = char(nl) idon't replace blank

255

c

5

6
c
8
10

open(unit=12,file = flnmtn, access = 'direct', form =
S'unformatted', reel = 1, action = 'read')
read(12,rec=l) voxel _pix
close(12)
elseif (k .It. 1000) then
n f = n + mod(k,10)
flnmhd(5:5)=char(nf)
n6 = int(k/10)
nl = n + mod(n6,10)
if (nl .gt. n) flnmhd(4:4) = char(nl) Idon't replace blank
flnmhd(4:4) = char(nl)
n2 = n + int(k/100)
if (n2 .gt. n) flnmhd(3:3) = char(n2)
open(unit=12,file = flnmhd, access = 'direct', form =
S'unformatted', reel = 1, action = 'read')
read(12,rec=l) voxel_pix
close(I2)
endif
write(6,5)k
format('reading done for slice',i4)
i3=0
do 8 j=l,ymax !do 10,8,6 open the required z slice files
do 6 i=l,xmax
i3=i3+l
voxel_pixel(ij,k)=voxel_pix(i3)
continue
write(6,15)kj
continue
continue

c

c
the series of I D slicefilesis n o w
c
in a 3 D array
c
c
c
the ct data has n o w been read in
15 format('line:',i2)
c
c
open(ll,file-mcmoder,status='new',
$form='unformatted',action='write')
do 9000 while (zindex.le.zmax)
write(6,15) zindex
yindex=l
do 8000 while (yindex.Ie.ymax) !y major voxel
c
write(6,17) zindex, yindex
17
format('line', i3,lx,i3)
xindex=l
do 7000 while (xindex. le.xmax) !x major voxel
c
write(6,18) zindex, yindex, xindex
18
format('zindex',i3,lx,'yindex',i3,lx,'xindex',i3)
if (xindex.lt.xmin3) then Ido 7000,8000,9000 jumps
go to 20
! through each major voxel
elseif (xindex.gt.xmax3) then
go to 20 ! this set of elseifs determines if the
elseif (yindex.lt.ymin3) then Imajor voxel is in
go to 20 ! region 3- subvoxelling parameters are set
elseif (yindex.gt.ymax3) then 'accordingly if so
go to 20
else if (zindex.It.zmin3) then

SECTION 3

go to 20
else if (zindex. gt.zmax3) then
go to 20
else
xstep=subv3x !the index pixel of the major voxel
ystep=subv3y lis insideregion3 and the sub-voxelling
zstep=subv3z (parameters are thus set
nopsvx= nopsv3x !(the index pixel is the closest to
nopsvy=nopsv3y ! the origin)
nopsvz=nopsv3z
go to 100
end if
20
if (xindex.lt.xmin2) then
go to 30 lif you have reached this point you are
elseif (xindex.gt.xmax2) then !not in region 3
go to 30 ! this set of elseifs determines if
elseif (yindex.lt.ymin2) then !you are in region 2
go to 30 (subvoxelling parameters are set accordingly
else if (yindex.gt.ymax2) then ! if so
go to 30
else if (zindex.lt.zmin2) then
go to 30
else if (zindex.gt.zmax2) then
go to 30
else
xstep=subv2x 'index pixel inreg.2
ystep=subv2y ! and the sub-voxelling parameters
zstep=subv2z ! are thus set
nopsvx= nopsv2x
nopsvy=nopsv2y
nopsvz=nopsv2z
go to 100
end if
30
xstep=subvlx (index pixel in reg. 1
ystep=subvly ! sub-voxelling parameters
zstep=subvlz ! are thus set
nopsvx* nopsvlx
nopsvy=nopsvly
nopsvz=nopsvlz
100 continue
xmajmin=xindex
ymajmin=yindex
zmajmin=zindex
c
! The next set of 3 do loops jumps
(through the sub voxels within a
c
! major voxel
do 6000 kc=l,zstep Izstep = no. minor voxel steps per
c
(major voxel.
do 5000 jb=l,yStep Inopsvx = no. pixels per minor voxel in
'
! x direction
do 4000 ia=l, xstep
xvoxmin = xindex (planes of corresponding index are
xvoxmax = xindex + nopsvx -1 ! index pixels from the
yvoxmin = yindex ! origin
yvoxmax = yindex + nopsvy -I
zvoxmin = zindex (eg xindex =l,nopsvx = 8, thus bounding
zvoxmax = zindex + nopsvz -1 (planes are 0 and 8
void=0 (re initialize material type tallies
lung=0 ! M O D F I N D I N G

fat=0
muscle=0
bone=0
voxno=voxno+l (do 3000,2000,1000 jump through the pixels
do 3000 kl= zindex, zindex + nopsvz -1 ! in each sub voxel
do 2000 jl= yindex, yindex + nopsvy -1 land find the most
do 1000 il= xindex, xindex + nopsvx -1 (common grey scale range
voxel_byte(4) = voxel_pixel(il jl.kl)
voxel(il jl,kl) = voxel_word
if (voxel(iljl,kl).lt.voidlim) then
c
if (voxel(iljl.kl).eq.l) then
void =void +1 !no. of pixels in subvoxel in void range
c
elseif (voxel(il jl,kl).lt.lunglim) then
elseif (voxel(iljl,kl).eq.O) then
lung= lung +1
elseif (voxel(il,jl,kl).lt.fatlim) then
fat=fat + 1
elseif (voxel(iljl,kl).lt.muslim) then
muscle = muscle + 1
else
bone = bone + 1
endif
1000 continue
2000 continue
3000 continue
m o d e = void
matno = 0
if (lung.gt.void) then
mode = lung
matno=l
density = -0.1
endif
(this set of ifsfindsthe most
if (fat.gt.mode) then (common grey scale range in the
mode = fat
(subvoxel
matno = 2
density = -0.92
endif
if (muscle.gt.mode) then
m o d e = muscle
matno = 3
density = -1.05
endif
if (bone. gt. mode) then
m o d e = bone
matno = 4
density = -1.6
endif
c
the following set of ifs up to line 3 500 determine if w e
SECTION 5
c
want to tally in a given voxel and its material for
c
kerma purposes
c
this is only applicable to simple voxelling where the
c
z parameters = 1
if (zindex.eq.tlyslcl) go to 3400
if (zindex.eq.tlyslc2) go to 3400
if (zindex.eq.tlyslc3) go to 3400
if (zindex.eq.tlyslc4) go to 3400
if (zindex.eq.tlyslc5) go to 3400
if (zindex.eq.tlysfc6) go to 3400
if (zindex.eq.tlyslc7) then

go to 3400
else
go to 3500
endif
3400 if (mode.eq.void) go to 3 500
if (mode.eq. lung) then
lungceli=lungceli+1
lungcel(lungceli) = voxno
elseif (mode.eq.fat) then
fatceli=fatceli+l
fatcel(fatceli) = voxno
elseif(mode.eq.muscle) then
musceli = musceli + 1
muscel(musceli) = voxno
elseif(mode.eq.bone) then
bonceli = bonceli + 1
boncelfbonceli) = voxno
endif
3500 continue
xplmin=xvoxmin-1+1000
xplmax=-xvoxmax-1000
yplmin=yvoxmin-1 +2000
yplmax=-yvoxmax-2000
zplmin=zvoxmin-1 +3000
zplmax=-zvoxmax-3000
if<matno.eq.O) then
write( 11,9100) voxno, matno, xplmin, xplmax,
Syplmin, yplmax, zplmin, zplmax ( M C N P subvoxel
else
write(ll,9110) voxno, matno, density, xplmin, xplmax,
Syplmin, yplmax, zplmin, zplmax ( M C N P subvoxel
endif
do 3900 k2= zvoxmin, zvoxmin + nopsvz-1
do 3800 j2=yvoxmin, yvoxmin + nopsvy - 1
do 3700 i2= xvoxmin, xvoxmin + nopsvx - 1
mcnp(i2 J2,k2) = matno
3700 continue
3800 continue
3900 continue
xindex = xvoxmin (put x,y,z index back to where
yindex = yvoxmin (started at beginning of modfinding
zindex = zvoxmin (END M O D F I N D I N G
xindex= xindex + nopsvx
4000 continue !x minor voxel
xindex=xmajmin
yindex=yindex + nopsvy
5000 continue !y minor voxel
xindex=xmajmin
yindex=ymaj min
zindex = zindex + nopsvz
6000 continue !z minor voxel
xindex=xmajmin
yindex=ymajmin
zindex=zmajmin
xindex = xindex + nopsvlx
7000 continue !x major voxel
yindex = yindex + nopsvly
8000 continue !y major voxel
zindex= zindex + nopsvlz

SECTION 6

SECTION 7

SECTION 8
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9000
continue !z major voxel
9100 format(i5,",i2,",i5,",i5,",i5,",
$i5,' ',15,' \i5)
9110 format(i5,' \i2,",f6.3,",
Si5,",i5,",i5,",
Si5,' ',i5,' \i5)
c
c
n o w write out the mcnp planes
c
xpl = 0
xmin2p = xmin2 -1
xmin3p = xmin3 -1
9115 if(xpl.gt.xmax)goto9135
if (xpl.lt.xmin2p.or.xpl.ge.xmax2) then
xplane = xpl* 0.193 !0.193cm/pix
xpla = xpl + 1000
write( 11,9120)xpla,xplane
9120 format(i4,' 2 px \f7.3)
xpl = xpl + nopsvlx
go to 9115
elseif (xpl.ge.xmin3p.and.xpl.lt.xmax3) then
xplane = xpl* 0.193 !0.193cm/pix
xpla = xpl + 1000
write(ll,9120)xpia, xplane
xpl = xpl + nopsv3x
go to 9115
else
xplane = xpl* 0.193 !0.193cm/pix
xpla = xpl + 1000
write(ll,9120)xpla, xplane
xpl = xpl + nopsv2x
go to 9115
endif
9135 continue
ypl = 0
ymin2p = ymin2 -1
ymin3p = ymin3 -1
9145 if (ypl.gt.ymax) go to 9165
if(ypl.lt.ymin2p.or.ypl.ge.ymax2) then
yplane = ypl* 0.193 (0.193cm/pix
ypla = ypl + 2000
write( 11,9150)ypla,yplane
9150 format(i4,' 2 py',f7.3)
ypl = ypl + nopsvly
go to 9145
elseif (ypl.ge.ymin3p.and.ypl.lt.ymax3) then
yplane = ypl* 0.193 !0.193cm/pix
ypla = ypl + 2000
write(ll,9150)ypla, yplane
ypl = ypl + nopsv3y
go to 9145
else
yplane = ypl* 0.193 10.193cm/pix
ypla = ypl + 2000
write(ll,9150)ypla, yplane
ypl = ypl + nopsv2y
go to 9145
endif
9165 continue

SECTION 9
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9175

9180

zpl = 0
zmin2p = zmin2 - 1
zmin3p = zmin3 -1
if(zpl.gt.zmax)goto9l95
if (zpl.lt.zmin2p.or.zpl.ge.zmax2) then
zplane = zpl* 1.0 ll.Ocm/pix
zpla = zpl + 3000
write(l l,9180)zpla,zplane
format(i4,' 2 pz',f7.3)
zpl = zpl + nopsvlz
go to 9175
elseif (zpi.ge.zmin3p.and.zpl.lt.zmax3) then
zplane = zpl* 1.0 ll.Ocm/pix
zpla = zpl + 3000
write( 11,9180)zpla, zplane
zpl = zpl + nopsv3z
go to 9175
else
zplane = zpl* 1.0 ll.Ocm/pix
zpla = zpl + 3000
write(ll,9180)zpla, zplane
zpl = zpl + nopsv2z
go to 9175
endif
continue

9195
c
c
n o w write out the mcnp tally voxelsfup to line 9280)
c
taltot = lungceli+fatceli+musceli+bonceli
write(ll,9200)taltot
write(6,9200)taKot
9200 format('c
total no of tally voxels =',i5)
9210 formatfc
tally voxels of lung material')

9220 formate

9230
9233
9236
9240

9250
9253
9256
9260

9265
9267
9269
9270

',i5)

if (lungceli.eq.0) go to 9240
write(ll,9210)
do 9230 i 1 0 = l.iungceli
write(l 1,9220) lungcel(ilO)
continue
format(*c
tally voxels of fat material')
formatC ',i5)
if (fatceli.eq.O) go to 9260
write(11,9233)
do9250 ill = l,fatceli
write(l 1,9236) fatcei(i 11)
continue
format('c
tally voxels of muscle material1)
formatC ',i5)
if (musceli.eq.0) go to 9270
write(l 1,9253)
do 9265 il2= l.musceli
write( 11,9256) muscel(il2)
continue
format('c
tally voxels of bone material')
formatC ',i5)
if (bonceii.eq.O) go to 9280
write(l 1,9267)
do 9275 i 13 = 1,bonceli
write(l 1,9269) bonceli

S E C T I O N 10

9275
9280
c
c
c
c
c
c
c

continue
continue
n o w write out the m c n p model images

S E C T I O N 11

n o w do the image processing for m c n p output
convert back to a I D array for each slice

do 9400 ka=l,zmax
i7=0
do9300ja=l,ymax
do 9290 ia=l,xmax
i7=i7+l
mcnp_word=50*mcnp(iaja,ka)
mcnp_pix(i7)=mcnp_byte(4) (scaling for nice model images
9290
continue
9300
continue
if (ka.lt. 10) then
n f = n + ka
c ensure 3:3 here, otherwise char lands in pos 1, affecting all subsequent uses
c of "filename" string:
mcnpun(3:3) = char(nf)
open(unit=13,file = mcnpun, access = 'direct', form =
S'formatted',reel= 1, action = 'write',status = 'new')
write(13,rec=l) mcnp_pix
close(13)
elseif (ka.lt. 100) then
nf = n + mod(ka, 10)
(char value of units column
mcnptn(4:4) = char(nf)
nl = n + int(ka/10)
(char value of tens column
if (nl .gt. n) mcnptn(3:3) = char<nl) (don't replace blank
open(unit=13,file = menptn, access = 'direct', form =
S'formatted', reel = 1, action = 'write',status = 'new')
write(13,rec=l) mcnp_pix
close(13)
elseif (ka.lt. 1000) then
n f = n + mod(ka,10)
mcnphd(5:5) = char(nf)
n6 = int(ka/10)
n l = n + mod(n6,10)
c
if (nl .gt. n) mcnphd(4:4) = char(nl) (don't replace blank
mcnphd(4:4) = char(nl)
n2 = n + int(ka/100)
if (n2 .gt. n) mcnphd(3:3) = char(n2)
open(unit=13,file = menphd, access = 'direct', form =
S'formatted', reel = 1, action = 'write',status = 'new')
write(13,rec=l) mcnp_pix
close(13)
endif
9400 continue
close(ll)
close(9)
stop
end
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A P P E N D I X IV

DOSE RECONSTRUCTION PROGRAM

program dracon2 SECTION 1
c
reconstructs M C N P output into 3 D binary array with spatial location
equivalent to the original medical images
logical* 1 voxel_byte(4), voxel_pixel(300,300,200),
$mcnp_byte(4),
$voxeljpix(65536),mcnp_pix(65536)
integer*4 voxel(300,300,200), mcnp(300,300,200),
Smcnpword,
$voxel_word, xmax, ymax, zmax, subvlx,
Ssubvly, subvlz, subv2x, subv2y, subv2z, subv3x, subv3y,
Ssubv3z, nopsv3x, nopsv3y, nopsv3z, nopsv2x, nopsv2y,
Snopsv2z, nopsvlx, nopsvly, nopsvlz,
Sfatlim, muslim, bonelim, xindex, yindex, zindex, voxno,
Sxmin3, xmax3, ymin3, ymax3, zmin3, zmax3, xmin2, xmax2,
Symin2, ymax2, zmin2, zmax2, xstep, ystep, zstep, nopsvx,
Snopsvy, nopsvz, xvoxmin, xvoxmax, yvoxmin,
Syvoxmax, zvoxmin, zvoxmax, void, lung, fat, muscle,
Sbone, mode, matno, xplmin, xplmax, yplmin, yplmax,
Szplmin, zplmax, xmajmin, ymajmin, zmajmin,
Stlyslcl,tlyslc2,tlyslc3,tlyslc4,lungceli,fatceli,
Stlyslc5, tlyslc6, tlyslc7,
$musceli,bonoeli,lungcel( 100000),museel( 100000),taltot,
Stalvoxno,
$fatcel(100000),boncel(100000), xpl.xpla, xmin2p, xmin3p,
Sypl, ypla, ymin2p, ymin3p, zpl, zpla, zmin2p, zmin3p
c Svoidlim, lunglim,
real*8 density, xplane, yplane, zplane,
Sbig, bigerr, dose( 100000), el, vl
c Sv2,e2,v3,e3 ! ,v4,e4
character*5 flnmhd
data flnmhd/'a/ 7
character*4 flnmtn
dataflnmtn/'a/7
character*3 flnrnun
data flnmun/'a/ 7
character* 5 mcnphd
data mcnphd/'c/ 7
character*4 mcnptn
data mcnptn/'c/ 7
character*3 mcnpun
data mcnpun/'c/ 7
equivalence(voxel_word,voxel_byte)
equivalence(mcnp_word, mcnp_byte)
open( 14,file='sidam.dat', status='old',
Sform = 'unformatted', action = 'read')
big = 0.0
voxno = 30064
do 2 il7= l,voxno
dose(voxno) = 0
2
continue
taltot = 6601
do3i!8=l,taltot
read(14,*) talvoxno,vl,el
if(vl.gt.big)then
big = vl
bigerr = el
endif
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c
c

c

c
c
c

c
c

dose(talvoxno) = vl
continue
write(6,4) big,bigerr
formatCbig=',gl2.5,' error=',f7.5)
x m a x = 256
(no. pixels in x
y m a x = 256
zmax = 46
subvlx = 1
! no div per major voxel in x in reg 1
subvly = 1
subvlz = 1
subv2x= 4 !! no divisions per major voxel in x in reg 2
subv2y= 4 ! no divisions per major voxel in y in reg 2
subv2z =1 ! no divisions per major voxel in z in reg 2
subv3x = 16 ! no divisions per major voxel in x in reg 3
subv3y= 16 ! no divisions per major voxel in y in reg 3
subv3z= 1 ! no divisions per major voxel in z in reg 3
nopsv3x= 2 ! no pixels per sub voxel in x in reg 3
nopsv3y= 2 ! no pixels per sub voxel in y in reg 3
nopsv3z= 1 ! no pixels per sub voxel in z in reg 3
nopsv2x= 8 ! no pixels per sub voxel in x in reg 2
nopsv2y= 8 ! no pixels per sub voxel in y in reg 2
nopsv2z= 1 ! no pixels per sub voxel in z in reg 2
nopsvlx= 32 ( no pixels per sub voxel in x in reg 1
nopsvly= 32 ! no pixels per sub voxel in y in reg 1
! no pixels per sub voxel in z in reg 1
nopsvlz= 1
voidlim= 5 ! uppermost grayscale of void
lunglim= 20 ! uppermost grayscale of lung
fatlim= 120 ! uppermost grayscale of fat
muslim = 250 ! uppermost grayscale of muscle
bonelim= 255 ! uppermost grayscale of bone (255?)
xindex = 1 ! x pixel counter
yindex = 1 ! y pixel counter
zindex = 1 ! z pixel counter
voxno = 0
! m c n p voxel counter
define the boundaries of the regions
( min pixel no in reg3 in x
xmin3= 97
! m a x pixel no in reg3 in x
x m a x 3 = 224
ymin3=129
ymax3=192
zmin3=15
zmax3=24
xmin2=33
xmax2=224
ymin2=65
ymax2=192
zmin2=ll
zmax2=32
define the desired tallying slices
this is a simplistic: approach applicable only when the
z voxelling parameters are 1
tlyslcl = 17
tlyslc2 = 18
tlyslc3 = 19
tlyslc4 = 20
tlyslc5 = 27
tlyslc6 - 28
tlyslc7 = 29
the following are counters for the tally voxels of
given material type (no tallying in void)

lungceli = 0
musceli = 0
fatceli = 0
bonceli = 0
c
image input from dir a, m c n p dose images in dir c
SECTION 2
n = ichar('O') (get the correct ASCII representation
c
write(6,5)n
do 10 k = l,zmax
if (k .It. 10) then
nf=n + k
c ensure 3:3 here, otherwise char lands in pos 1, affecting all subsequent uses
c of "filename" string:
flnmun(3:3) = char(nf)
open(unit=12,file = flnmun, access = 'direct', form =
S'unformatted', reel = 1, action = 'read')
read(12,rec=l) voxeljjix
close(12)
elseif (k .It. 100) then
nf = n + mod(k, 10)
! char value of units column
flnmtn(4:4) = char(nf)
nl = n + int(k/10)
(char value oftenscolumn
if(nl .gt. n) flnmtn(3:3) = char(nl) (don't replace blank
open(unit=12,file = flnmtn, access = 'direct', form =
S'unformatted', reel = 1, action = 'read')
read(12,rec=l) voxel_pix
close(12)
elseif (k .It. 1000) then
n f = n + mod(k,10)
flnmhd(5:5)=char(nf)
n6 = int(k/10)
nl = n + mod(n6,10)
c
if(nl .gt. n) flnmhd(4:4) = char(nl) (don't replace blank
flnmhd{4:4)=char(nl)
n2 = n + int(k/100)
if (n2 .gt. n) flnmhd(3:3) = char(n2)
open(unit=12,file = flnmhd, access = 'direct', form =
S'unformatted', reel = 1, action = 'read')
read(12,rec=l) voxel_pix
close(12)
endif
write(6,5)k
5
format('reading done for slice',i4)
i3=0
do 8 j=l,ymax (do 10,8,6 open the required z slice files
do 6 i=l,xmax
i3=i3+l
voxel_pixel(ij,k)=voxel_pix(i3)
6
continue
c
write(6,15)kj
8
continue
10
continue
c
c
the series of ID slicefilesis now
c
in a 3 D array
c
c
SECTION 3
c
the ct data has n o w been read in
15
format('line:',i2)
c

c
c

c
17

c
18

20

30

open( 1 l,file-mcmodel',status-new',
$form='unformatted,,«:tion='write')
do 9000 while (zindex. le.zmax)
write(6,15) zindex
yindex=l
do 8000 while (yindex.le.ymax) !y major voxel
write(6,17) zindex, yindex
format('line', i3,lx,i3)
xindex=l
do 7000 while (xindex. le.xmax) !x major voxel
write(6,18) zindex, yindex, xindex
format('zindex',i3, lx,'yindex',i3, lx,'xindex',i3)
if (xindex.lt.xmin3) then (do 7000,8000,9000 jumps
go to 20
(through each major voxel
elseif (xindex.gt.xmax3) then
go to 20 ! this set of elseifs determines if the
elseif (yindex.lt.ymin3) then (major voxel is in
go to 20 ! region 3- subvoxel ling parameters are set
elseif (yindex.gt.yma.\3) then (accordingly if so
go to 20
else if (zindex.lt.zmin3) then
go to 20
else if (zindex.gt.zmax3) then
go to 20
else
xstep=subv3x (the index pixel of the major voxel
ystep=subv3y (is inside region 3 and the sub-voxelling
zstep=subv3z (parameters are thus set
nopsvx= nopsv3x ((the index pixel is the closest to
nopsvy=nopsv3y (the origin)
nopsvz=nopsv3z
go to 100
endif
if (xindex.k.xmin2) then
go to 30 (if you have reached this point you are
elseif(xindex.gt.xmax2) then (not in region 3
go to 30 ! this set of elseifs determines if
elseif (yindex.lt.ymin2) then (you are in region 2
go to 30 Isubvoxelling parameters are set accordingly
elseif (yindex.gt.yma.\2) then ! if so
go to 30
else if (zindex. It.zmin2) then
go to 30
else if (zindex.gt.zmax2) then
go to 30
else
xstep=subv2x (index pixel in reg. 2
ystep=subv2y ! and the sub-voxelling parameters
zstep=subv2z ! are thus set
nopsvx= nopsv2x
nopsvy=nopsv2y
nopsvz=nopsv2z
go to 100
endif
xstep=subvlx (index pixel inreg.1
ystep=subvly ! sub-voxelling parameters
zstep=subvlz ! are thus set
nopsvx=nopsvlx
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nopsvy=nopsvly
nopsvz=nopsvlz
100 continue
xmajmin=xindex
ymajmin=yindex
zmajmin=zindex
! The next set of 3 do loops jumps
c
c
(through the sub voxels within a
c
(major voxel
do 6000 kc=l,zstep Izstep = no. minor voxel steps per
c
(major voxel.
do 5000 jb=l,ystep (nopsvx = no. pixels per minor voxel in
c
! x direction
do 4000 ia=l, xstep
xvoxmin = xindex (planes of corresponding index are
xvoxmax = xindex + nopsvx -1 ! index pixels from the
yvoxmin = yindex ! origin
yvoxmax = yindex + nopsvy -1
zvoxmin = zindex (eg xindex =1,nopsvx = 8, thus bounding
zvoxmax = zindex + nopsvz -1 (planes are 0 and 8
void=0 (re initialize material type tallies
lung=0 ! M O D F I N D I N G
fat=0
muscle=0
bone=0
voxno=voxno+l (do 3000,2000,1000 jump through the pixels
do 3000 kl= zindex, zindex + nopsvz -1 ! in each sub voxel
do 2000 jl= yindex, yindex + nopsvy -1 (andfindthe most
do 1000 il= xindex, xindex + nopsvx -1 (common grey scale range
voxel_byte(4) = voxel_pixel(il,jl,kl)
voxel(il,jl,kl) = voxel_word
c
if (voxel(il,jl,kl).lt.voidlim) then
if (voxel(i 1 j 1 ,k 1 ).eq. 1) then
void =void +1 (no. of pixels in subvoxel in void range
c
elseif (voxel(il,jl,kl).lt.lunglim) then
elseif (voxel(il,jl,kl).eq.O) then
lung= lung +1
elseif (voxel(il,jl,kl).lt.fatlim) then
fat=fat + 1
elseif (voxel(il,jl,kl).lt.muslim) then
muscle = muscle + 1
else
bone = bone + 1
endif
1000 continue
2000 continue
3000 continue
m o d e = void
matno = 0
if (lung.gt.void) then
m o d e = lung
matno=l
density = -0.1
endif
(this set of ifsfindsthe most
if (fat.gt.mode) then (common grey scale range in the
m o d e = fat
(subvoxel
matno = 2
density - -0.92
endif

SECTION 4
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if (muscle, gt. mode) then
mode = muscle
matno = 3
density = -1.05
endif
if (bone.gt.mode) then
mode = bone
matno = 4
density = -1.6
endif
c
the following set of ifs up to line 3 500 determine if w e
c
want to tally in a given voxel and its material for
c
kerma purposes
c
this is only applicable to simple voxelling where the
c
z parameters = 1
if (zindex.eq.tlyslcl) go to 3400
if (zindex.eq.tlyslc2) go to 3400
if (zindex.eq.tlyslc3) go to 3400
if (zindex.eq.tlyslc4) go to 3400
if (zindex.eq.tlyslc5) go to 3400
if (zindex.eq.tlyslc6) go to 3400
if (zindex.eq.tlyslc7) then
go to 3400
else
go to 3500
endif
3400 if(mode.eq.void) go to 3500
if (mode.eq.lung) then
lungceli=lungceli+1
lungcel(lungceli) = voxno
elseif (mode.eq.fat) then
fatceli=fatceli+l
fatceKfatceli) = voxno
elseif(mode.eq. muscle) then
musceli = musceli + 1
muscei(musceli) = voxno
elseif(mode.eq.bone) then
bonceli = bonceli + 1
boncel(bonceli) = voxno
endif
3500 continue
xplmin=xvoxmin-l+1000
xplmax=-xvoxmax-1000
yplmin=yvoxmin-1+2000
yplmax=-yvoxmax-2000
zplmin=zvoxmin-1+3000
zplmax=-zvoxmax-3000
if (matno.eq.0) then
c
c
write(l 1,9100) voxno, matno, xplmin, xplmax,
c Syplmin, yplmax, zplmin, zplmax ( M C N P subvoxel
c
else
c
write(l 1,9110) voxno, matno, density, xplmin, xplmax,
c Syplmin, yplmax, zplmin, zplmax ( M C N P subvoxel
c
endif
do 3900 k2= zvoxmin, zvoxmin + nopsvz-1
do 3800 j2=yvoxmin, yvoxmin + nopsvy - 1
do 3700 i2= xvoxmin, xvoxmin + nopsvx -1
mcnp(i2,j2,k2) = int(dose(voxno)/big*255)
3700 continue

SECTION 5

SECTION 6

SECTION 7
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3800
3900

continue
continue
xindex = xvoxmin (put x,y,z index back to where
yindex = yvoxmin (started at beginning of modfinding
zindex = zvoxmin ( E N D M O D F I N D I N G
xindex= xindex + nopsvx
4000 continue !x minor voxel
xindex=xmajmin
yindex=yindex + nopsvy
5000 continue !y minor voxel
xindex=xmajmin
yindex=ymajmin
zindex = zindex + nopsvz
6000 continue !z minor voxel
xindex=xmaj min
yindex=ymajmin
zindex=zmajmin
xindex = xindex + nopsvlx
7000 continue !x major voxel
yindex = yindex + nopsvly
8000 continue !y major voxel
zindex= zindex + nopsvlz
9000
continue !z major voxel
9100 format(i5,",i2,",i5,",i5,",i5,",
Si5,' ',i5,' ',15)
9110 format(i5,",i2,",f6.3,",
Si5,' ',i5,' ',i5,'',
Si5,' ',15,' ',15)
c
c
n o w write out the m c n p planes
c
xpl = 0
xmin2p = xmin2 - 1
xmin3p = xmin3 - 1
9115 if(xpl.gt.xmax)goto9135
if (xpl.lt.xmin2p.or.xpl.ge.xmax2) then
xplane = xpl* 0.193 !0.193cm/pix
xpla = xpl + 1000
c
write(ll,9120)xpla,xplane
9120 format(i4,' 2 px',f7.3)
xpl = xpl + nopsvlx
go to 9115
elseif (xpl.ge.xmin3p.and.xpl.lt.xmax3) then
xplane = xpl* 0.193 !0.193cm/pix
xpla = xpl + 1000
c
write(ll,9120)xpla, xplane
xpl = xpl + nopsv3x
go to 9115
else
xplane = xpl* 0.193 !0.193cm/pix
xpla = xpl + 1000
c
write(l 1,9120)xpla, xplane
xpl = xpl + nopsv2x
go to 9115
endif
9135 continue
ypl = 0
ymin2p = ymin2 - 1
ymin3p = ymin3 -1

SECTION 8

SECTION 9
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9145

if (ypl.gt.ymax) go to 9165
if (ypl.lt.ymin2p.or.ypl.ge.ymax2) then
yplane = ypl* 0.193 !0.193cm/pix
ypla = ypl + 2000
c
write(ll,9150)ypla,yplane
9150 format(i4,' 2 py',f7.3)
ypl = ypl + nopsvly
go to 9145
elseif (ypl.ge.ymin3p.and.ypl.lt.ymax3) then
yplane = ypl* 0.193 (0.193cm/pix
ypla = ypl + 2000
c
write( 11,9150)ypla, yplane
ypl = ypl + nopsv3y
go to 9145
else
yplane = ypl* 0.193 (0.193cm/pix
ypla = ypl + 2000
c
write(ll,9150)ypla, yplane
ypl = ypl + nopsv2y
go to 9145
endif
9165 continue
zpl = 0
zmin2p = zmin2 - 1
zmin3p = zmin3 -1
9175 if <zpl.gt.zmax) go to 9195
if<zpl.ltzmin2p.or.zpl.ge.zmax2) then
zplane = zpl* 1.0 !1.0cm/pix
zpla = zpl + 3000
c
write( 11,9180)zpla,zplane
9180 format(i4,' 2 pz',f7.3)
zpl = zpl + nopsvlz
goto 9175
elseif (zpl.ge.zmin3p.and.zpl.lt.zma.\3) then
zplane = zpl* 1.0 ! l.Ocm/pix
zpla = zpl + 3000
c
write(ll,9180)zpla, zplane
zpl = zpl + nopsv3z
go to 9175
else
zplane = zpl* 1.0 !1.0cm/pix
zpla = zpl + 3000
c
write( 11,9180)zpla, zplane
zpl = zpl + nopsv2z
go to 9175
endif
9195 continue
c
c
n o w write out the m c n p tally voxels(up to line 9280)
c
taltot = lungceli+fatceli+musceli+bonceli
c
write(ll,92O0)taltot
c
write(6,9200)taltot
9200 format('c total no of tally voxels =',i5)
9210 format('c
tally voxels of lung material')
9220 formatC
\i5)
if (lungceli.eq.O) go to 9240
c
write(l 1,9210)
do 9230 i 1 0 = l,lungceli

S E C T I O N 10

c
9230
9233
9236
9240
c
c
9250
9253
9256
9260
c
c
9265
9267
9269
9270
c

write(l 1,9220) lungcei(ilO)
continue
format('c tally voxels of fat material')
formatC *,i5)
if (fatceli.eq.O) go to 9260
write( 11,9233)
do9250ill = l,fatceli
write(l 1,9236) fatcel(i 11)
continue
format('c tally voxels of muscle material')
formatC \iS)
if (musceli.eq.O) go to 9270
write(l 1,9253)
do 9265 il2 = l,musceli
write(l 1,9256) muscel(i 12)
continue
format('c tally voxels of bone material1)
formatC \i5)
if (bonceli.eq.O) go to 9280
write( 11,9267)
do 9275 i 13 = 1,bonceli
write( 11,9269) bonceli
continue
continue

c
9275
9280
c
c
n o w write out the m c n p model images
S E C T I O N 11
c
c
c
n o w do the image processing for mcnp output
c
convert back to a ID array for each slice
c
do 9400 ka=l,zmax
i7=0
do 9300 ja=l,ymax
do 9290 ia=l,xmax
i7=i7+l
mcnp_word=mcnp(ia,ja,ka) ! just to check recon
mcnp_pix(i7)=mcnp_byte(4) (scaling for nice model images
9290 continue
9300 continue
iffka.lt. 10) then
nf= n + ka
c ensure 3:3 here, otherwise char lands in pos 1, affecting all subsequent uses
c of "filename" string:
mcnpun(3:3) = char(nf)
open(unit=13,file = mcnpun, access = 'direct', form =
S'formatted', reel = 1, action = 'write',status = 'new')
write(13,rec=l) mcnp_pix
close(13)
elseif (ka.lt. 100) then
nf = n + mod(ka, 10)
(char value of units column
mcnptn(4:4) = char(nf)
nl = n + int(ka/10)
(char value of tens column
if (nl .gt. n) mcnptn(3:3) = char(nl) (don't replace blank
open(unit=13,file = menptn, access = 'direct', form =
S'formatted', reel = 1, action = 'writ^status = 'new')
write(13,rec=l) mcnp_pix
close(13)
elseif (ka .It. 1000) then
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n f = n + mod(ka,10)
mcnphd(5:5) = char(nf)
n6 = int(ka/10)
nl = n + mod(n6,10)
if (nl .gt. n) mcnphd(4:4) = char(nl) (don't replace blank
c
mcnphd(4:4) = char(nl)
n2 = n + int(ka/100)
if (n2 .gt. n) mcnphd(3:3) = char(n2)
open(unit=13,file = mcnphd, access = 'direct', form =
S'formatted', reel = 1, action = 'write',status = 'new')
write(13,rec=l) mcnp_pix
close(13)
endif
9400 continue
close(ll)
close(9)
stop
end
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APPENDIX V - I M A G E PROCESSING P R O G R A M S

C T images used in this project were acquired using a Varian treatment simulator in C T
imaging mode, courtesy of the St. George Cancer Care Centre. Images are output in the
following format:
Varian CT - HEADER format (variable are type cast according to ansi -c programming
conventions)
. The header forms thefirst1024 bytes.After this header is a 2 dimensional array of size 512x2
long integers
, 1 long integer = 4 bytes, ie 2048 bytes in total. So complete header is 3072 bytes. Image data
starts at the end of the 3072 byte header, and is a continuous stream of image pixels.

The two dimensional array forms the 'mask' for the image data
0 0 - line 1
0 0
0 0
0 0
22 232 -first scan line (line5)#pix = (232-22+1)
32 201- ending line (435)
0 0 line 436

0

0 line 512

This format ensures that only pixels within the mask aperture have to be stored. To reconstru
the 512x512 array, the program 'flxp7' was written (file expand). Several parameters have to be
altered depending upon the mask used - these are indicated ***'. This program also converts the
data to lbyte per pixel and 2x2 averages to output images in the user friendly 256x256xlbyte
format.

c
c
c
c
c
c
c

program flxp7
logical* 1 line_byte(2), imgin(236272), !** 236272=size of original imagefile(b)
$immhd(233200), !**233200=size of original imagefileminus 3072 b header
$immhd_byte(2), image_byte(2), image_pixel(600,600),
$image_ld(65536), image_256(3O0,300) ! 65536 = 256*256
integer*2 line(2,600), line_word, image(600,600),
$immhd_word, immhd_int(200000), big, image_word, sum
image=2D array of integers
imgin=original bytes including header
immhd=original bytes reversed minus header
image_pixel=512*512 2 D array of bytes
image_pixld=512*512 ID array of bytes
immhd_int=array of 2b integers with no. greater than
original no. of bytes

3
4
c

5

7
6
c
c
c

c
8
c
c

equivalence(line_word,line_byte)
equivalence(immhd_byte,immhd_word)
equivalence(image_byte, image_word)
open(unit=12,file= ctO09_00.img', form = 'unformatted',
Saction = 'read', access = 'direct', reel = I)
read(12,rec=l) imgin
close(12)
open(unit=13,file = 'torso, w/30'
$, access = 'direct', form =
S'formatted', reel = 1, action = 'write',status = 'new')
do4j20=l,512
do3i20=l,512
image(i20 j20) = 0
continue
continue
initialize array, just a precaution
m 1 = 236272 ! **totalfilesize
do 5 m 2 = 1, 233200 !**totalfileminus header
immhd(m2) = imgin(ml)
ml=ml-l
continue
m5 = 0
big = 0
do 7 m 3 = 1, 116600 !**no of integers in image (233200/2)
m5 = m5 + 1
immhd_byte(l)= immhd(m5)
m5 = m5 + 1
immhd_byte(2) = immhd(m5)
immhd_int<m3) = immhd_word
if (immhd_int(m3).gt.big) then
big = immhd_int(m3)
else
big = big
endif
continue
write(6,6)big
formatCbig = ',ilO)
image data now as 2 byte integers in ID array immhd_int()
the following do loop is the one to modify to get
correct grey scale, upper and lower limits may be changed
do 8 m 6 = 1, 116600
! ** no. of integers in image (233200/2)
if (immhd_int(m6).gt.l535) then !** 1535 - upper limit
immhd_int(m6) = 255
elseif (immhd_int(m6).lt.512) then !** 512 = lower limit
immhd_int(m6) = 0
else
immhd_int(m6) = int((immhd_int(m6) - 512)/4) (4= (u.l. - l.l.)/256
endif
immhd_int(m6)= int(immhd_int(m6)/big*255)
continue
k5 = 0
image data now as 2 byte integers normalized to 255
now find the line limits
i3 = 3072
d o 2 0 m = l ,512
do 10 n = 1, 2
line_byte(l) = imgin(i3)
i3 = i3 - 1
line_byte<2) = imgin(i3)
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line(n,m) = line_word
i3= i3 - 1
10
continue
if(line(l,m).eq.O)then
do 15 i = 1, 512
image(i,m)=0
15
continue
else
do 17 i5 = line(2,m), line(l,m)
k5=k5+l
image(i5,m) = immhd_int(k5)
17
continue
endif
20
continue
c
the image is now a 2 D array (image(i j)) of 2 byte
c
integers normalised to 25 5 max.
do 40 j = 1,512
do 30 i = 1,512
image_word = image(i j)
image_pixeKi,j) = image_byte(2)
30
continue
40
continue
image_word=0
c
the following averages to a 256*256 array
do 450jll = 1,256
do 400 ill = 1,256
jl2 = (jll-l)*2 + l
il2=(ill-l)*2+l
il3 = il2+l
jl3=jl2+ 1
sum = 0
do325jl5=jl2J13
do320i!5=il2,il3
image_byte(2) = image_pixel(il5jl5)
sum = sum + image_word
320 continue
325 continue
image_word = int(sum/4)
image_256(il l,jl 1) = image_byte(2)
c
note equivalence between image_word and image_byte
400 continue
450 continue
write(6,500)(image_256(i,129),i=60,89)
500 formatCline 129 *,30(z2))
m9 = 0
do 600 jl0= 1,256
do 550 il0= 1,256
m9 = m9 + 1
image_ld(m9) = image_256(ilO,jlO)
550 continue
600 continue
write(13,rec=l) image_ld
close(13)
stop
end

In the M C N P modelling program 'automat4.f, it can be seen that materials are designated
depending upon their grayscale value. This does not enable the distinction of different materials
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that give the same C T imageresponse,for example lung tissue and exterior voids. The program
seedl was written to take 256x256xlbyte image input and mathematically distinguish grayscale
identical but spatially seperate regions. For the C T images of the whole body phantom, both the
lungs and exterior void have an image value of zero. The user may select a 'seed* pixel, and all
connected pixels with the same value (or within tolerance limits) may be altered to distinguish
them from equal value pixels not connected to the seed pixel. In this example, both lung and
exterior pixels equal 0. A seed is chosen in the exterior region and all exterior pixels are
changed to 1, thus distinguishing them from the lung pixels. If tolerance limits were used
instead, one region m a y be given odd values whilst the other even.
program seedl
integer*2 image_word, imagei_2d(256,256), xactive(512),
$yactive(512), xwave(512),ywave(512), xindex, yindex,
Sxindex2,yindex2
equivalence(image_word, image_byte)
open(unit=12,file= 'torso.w/30', form = 'unformatted',
Saction = 'read', access = 'direct', reel = 1)
open(unit=13,file= 'a/30', form = 'unformatted',
Saction = 'write', access = 'direct', reel = 1,status-new')
read(12,rec=l) imagel_ld
close(12)
ml0 = 0
do 6jl0 = 1,256
d o 6 i l 0 = 1,256
ml0 = m l 0 + 1
image_byte(2) = imagel_ld(mlO)
imagei_2d(il0,jl0) = image_word
6
continue
c
the Id array of 65536 single byte pixels is n o w a 256*256 array of 2 byte integers
imagei_2d(l,l)= 1
xwave(l) = 1 !** the x coordinate of the seed pixel (the 2nd number) is chosen as T .
ywave(l) = 1 !** the y coordinate of the seed pixel<the 2nd number) is chosen as '1'.
m l = 1 ! m 1 is equal to the no of active
c
pixels in the next iteration
10
if (ml.eq.O) go to 1000 ! you have no active pixels
20
do30i=l,512
if (i.le.ml) then
xactive(i) = xwave(i)
yactive(i) = ywave(i)
else
xactive(i) = 0
yactive(i) = 0
endif
30
continue
ml=0
il = 0 (active pixel counter in the current iteration
50
continue
il = il + l
xindex = xactive(il)
yindex = yactive(i 1)
if (xindex.eq.0) then
go to 10 (end of currently active pixels
endif
xindex2 = xindex + 1
if (xindex.gt.256) go to 200
yindex2 = yindex
if (imagei_2d(xindex2,yindex2).eq.0) then
imagei_2d(xindex2,yindex2) = 1

ml =ml + 1
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xwave(ml) = xindex2
ywave(ml) = yindex2
endif
200
xindex2 = xindex
yindex2 = yindex + 1
if (yindex2.gt.256) go to 400
if (imagei_2d(xindex2,yindex2).eq.O) then
imagei_2d(xindex2,yindex2) = 1
ml = ml + 1
xwave(ml) = xindex2
ywave(ml) = yindex2
endif
400
xindex2 = xindex - 1
if(xindex.lt.l)goto600
yindex2 = yindex
if(imagei_2d(xindex2,yindex2).eq.O) then
imagei_2d(xindex2,yindex2) = 1 !** if a connected voxel =0, it is changed to 1
ml=ml+l
xwave(ml) = xindex2
ywave(m 1) = yindex2
endif
600
xindex2 = xindex
yindexZ = yindex - 1
if (yindex2.lt. 1) go to 50
if (imagei_2d(xindex2,yindex2).eq.O) then
imagei_2d(xindex2,yindex2) = 1
ml=ml+l
xwave(ml) = xindex2
ywave(ml) = yindex2
endif
800
go to 50
1000
mll=0
doll00jll = 1,256
do 1100 ill = 1,256
mll=mll + l
image_word = imagei_2d(i 1 l,j 11)
imagel_ld(ml 1) = image_byte(2)
1100 continue
write(6,1200)(imagel_ld(i),i=32679,32708)
1200 formatCline 129 ',30(z2))
write(13,rec=l) imagel_ld
close(13)
stop
end
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PHILOSOPHICAL REFLECTIONS

You don't toil through a decade of tertiary education without collecting a few personal
"empirical laws" that get you through the times when you can no longer see that light at
the end of the tunnel. They become even more special to you when you realise that
you were not thefirstto discover them. Here is a very small sample of s o m e of m y
empirical laws that have been worded perfectly by others.
"The gumption-filling process occurs when one is quiet long enough to see and
hear and feel the real universe, not just one's own stale opinions about it. But
it's nothing exotic. That's why I like the word.
You see it often in people who return from long, quiet fishing trips. Often
they're a little defensive about having put so much time to "no account"
because there's no intellectual justification for what they've been doing. But the
returned fisherman usually has a peculiar abundance of gumption, usually for
the very s a m e things he w a s sick to death of a few weeks before. H e hasn't
been wasting time. It's only our limited cultural viewpoint that makes it seem
so.
If you're going to repair a motorcycle, an adequate supply of gumption is the
first and most important tool. If you haven't got that you might as well gather
up all the other tools and put them away, because they won't do you any good.
Gumption is the psychic gasoline that keeps the whole thing going. If you
haven't got it there's no way the motorcycle can possibly be fixed. But if you
have got it and know how to keep it there's absolutely no way in this whole
world that the motorcycle can keep from getting fixed. It's bound to happen.
Therefore the thing that must be monitored at all times and preserved before
anything else is the gumption."
Robert M. Pirsig, Zen and the Art of Motorcycle Maintenance

"My father used to say a walk in the mountains was equivalent to church
going."

Aldous Huxley
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And while were at it - what about s o m e comments from a few of history's most
remarkable travellers:

"....we had slept in our clothes, where we could seldom or ever change them.
W e had halted among mud, waded through rivers, tumbled among snow, and
for the last few days been sunned by heat. These are but the petty
inconveniences of a traveller; which sink into insignificance, when compared
with the pleasure of seeing new m e n and countries, strange manners and
customs, and being able to temper the prejudices of one's country, by
observing those of other nations"
Alexander Bumes, Travels into Bokhara, 1839.

"At last, just as the sun set, we reached the glacier at the foot of the pass. We
were in safety once more. The tension of six crucial hours was over, and the
last and greatest obstacle in m y journey had been successfully surmounted.
Those moments when I stood at the foot of the pass are long to be
remembered by m e - moments of intense relief, of glowing pride and of deep
gratitude for the success that had been granted. But such feelings as mine
were cannot be described in words; they are known only to those who have
had their heart set on one great object and have accomplished it."
Francis Edward Younghusband, Over the Karakorams, 1887.

And what about a tribute to Ekai Kawaguchi who, in contrast to the large scale
expeditions of the time, won the race to Lhasa - the capital of Tibet - in 1900 with a
party consisting of"

himself and two sheep."

Finally a comment from one of the greatest philosophers of all time. His words are
starkly relevant to the ultimate challenge science and humankind faces in the 21st
century in light of the blindingly rapid technological advancements of the 20th.
"Man must rise above the earth - above the atmosphere and beyond, for only
then will he truly understand the world in which he lives"

Socrates, 450 BO
The time to open our eyes is now.
Steven Wallace; June 24,1996.
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